<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>biospecifics10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Biospecifics Technologies Corp - Form 10-K - Filed by newsfilecorp.com</TITLE>

</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=center><B><font size="5">UNITED STATES <BR>SECURITIES AND EXCHANGE COMMISSION
<BR></font></B>Washington, D.C. 20549 </P>
<P align=center><B><font size="5">FORM 10-K</font></B><font size="5"> </font> </P>
<P align=center>(Mark One) </P>
<P align=center>[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 </P>
<P align=center>For the fiscal year ended December 31, 2010 </P>
<P align=center>[&nbsp; ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 </P>
<P align=center>For the transition period from __________________to
__________________<BR></P>
<P align=center>Commission File Number: <B>001-34236 </B></P>
<P align=center><B><font size="5">BIOSPECIFICS TECHNOLOGIES CORP. <BR></font></B>(Exact name of
registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap
      align=center><B>Delaware</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="50%"><B>11-3054851</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=center>(State or other jurisdiction of </TD>
    <TD noWrap align=center width="50%">(I.R.S. Employer </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=center>incorporation or organization) </TD>
    <TD noWrap align=center width="50%">Identification No.) </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center><B>35
      Wilbur Street, Lynbrook, NY</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="50%"><B>11563</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=center>(Address of principal executive offices) </TD>
    <TD noWrap align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code:
<B>516.593.7000</B> </P>
<P align=center>Securities registered under Section 12(b) of the Exchange
Act:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=center>Title of each class </TD>
    <TD noWrap align=center width="50%">Name of each exchange on which
      registered </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=center><B>Common Stock</B> </TD>
    <TD noWrap align=center width="50%"><B>The Nasdaq Global Market</B>
  </TD></TR></TABLE>
<P align=justify>Securities registered under Section 12(g) of the Exchange Act:
<B>NONE</B> </P>
<P align=justify>Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act.</P>
<P align=center>[&nbsp; ] Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;[X] No
</P>
<P align=justify>Indicate by check mark if the registrant is not required to
file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. </P>
<P align=center>[&nbsp; ] Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;[X] No
</P>
<P align=justify><B>Note</B> &#150; Checking the box above will not relieve any
registrant required to file reports pursuant to Section 13 or 15(d) of the
Exchange Act from their obligations under those Sections.</P>
<P align=justify>Indicate by check mark whether the registrant (1) filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. </P>
<P align=center>[X] Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;[&nbsp; ]
No&nbsp;&nbsp;</P>
<P align=justify>Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&#167;229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant's
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K. [
&nbsp;] </P>
<P align=justify>Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the
Exchange Act.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left>Large accelerated filer [&nbsp; ] </TD>
    <TD noWrap align=left width="50%">Accelerated filer&nbsp;[X] </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Non-accelerated filer [&nbsp; ]
    <font style="font-size: 9pt">(Do not check if a
      smaller reporting company) </font> </TD>
    <TD noWrap align=left width="50%">Smaller reporting company [ &nbsp;]
  </TD></TR></TABLE>
<P align=center>i </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify>Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). </P>
<P align=center>[&nbsp; ] Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [X] No </P>
<P align=justify>The aggregate market value of voting and non-voting common
stock held by non-affiliates of the Registrant as of June 30, 2010, the last
business day of the registrant&#146;s most recently completed second fiscal quarter,
was approximately $95.3 million.</P>
<P align=justify><B>Note</B> &#150; If a determination as to whether a particular
person or entity is an affiliate cannot be made without involving unreasonable
effort and expense, the aggregate market value of the common stock held by
non-affiliates may be calculated on the basis of assumptions reasonable under
the circumstances, provided that the assumptions are set forth in this Form.</P>
<P align=justify>The number of shares outstanding of the registrant&#146;s common
stock as of March 8, 2011 is 6,293,868.<B> </B></P>
<P align=center><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>
<P align=justify>Portions of the registrant&#146;s definitive proxy statement for its
2011 Annual Meeting of Stockholders scheduled to be held on June 13, 2011, which
is expected to be filed with the Securities and Exchange Commission not later
than 120 days after the end of the registrant&#146;s fiscal year ended December 31,
2010, are incorporated by reference into Part III of this annual report on Form
10-K. With the exception of the portions of the registrant&#146;s definitive proxy
statement for its 2011 Annual Meeting of Stockholders that are expressly
incorporated by reference into this annual report on Form 10-K, such proxy
statement shall not be deemed filed as part of this annual report on Form 10-K.
</P>
<P align=center>ii </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=center><B>TABLE OF CONTENTS </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">&nbsp;</TD>
    <TD noWrap align=center width="10%" valign="bottom" ><B><U>Page</U></B>
</TD></TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD align=center width="10%" valign="bottom" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">PART I </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >2 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 1. DESCRIPTION OF
    BUSINESS</TD>
    <TD noWrap align=center width="10%" valign="bottom" >2 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 1A. RISK FACTORS </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >15
</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item IB. UNRESOLVED STAFF COMMENTS </TD>
    <TD noWrap align=center width="10%" valign="bottom" >26 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 2. DESCRIPTION OF PROPERTY </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >26
</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 3. LEGAL PROCEEDINGS </TD>
    <TD noWrap align=center width="10%" valign="bottom" >26 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 4. (REMOVED AND RESERVED) </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >27
</TD></TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD align=center width="10%" valign="bottom" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">PART II </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >27
</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 5. MARKET FOR COMMON
    EQUITY, RELATED STOCKHOLDER MATTERS</TD>
    <TD noWrap align=center width="10%" valign="bottom" >27 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 6. SELECTED FINANCIAL DATA </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >29
</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 7. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OR PLAN
      OF OPERATION </TD>
    <TD noWrap align=center width="10%" valign="bottom" >30 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 7A. QUANTITATIVE AND
      QUALITATIVE DISCLOSURES ABOUT MARKET RISK </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >39
</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 8. FINANCIAL STATEMENTS </TD>
    <TD noWrap align=center width="10%" valign="bottom" >40 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 9. CHANGES IN AND DISAGREEMENTS WITH
      ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </TD>
    <TD align=center width="10%" bgColor=#eeeeee valign="bottom" >40 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 9A. EVALUATION OF DISCLOSURE CONTROLS AND
      PROCEDURES </TD>
    <TD noWrap align=center width="10%" valign="bottom" >40 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 9B. OTHER INFORMATION </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >41
</TD></TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD align=center width="10%" valign="bottom" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">PART III </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >41
</TD></TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 10. DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND
      CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT </TD>
    <TD align=center width="10%" valign="bottom" >41 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 11. EXECUTIVE COMPENSATION </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >41
</TD></TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
      AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </TD>
    <TD align=center width="10%" valign="bottom" >41 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 13. CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</TD>
    <TD align=center width="10%" bgColor=#eeeeee valign="bottom" >41 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 14. PRINCIPAL
    ACCOUNTING FEES AND SERVICES</TD>
    <TD noWrap align=center width="10%" valign="bottom" >41 </TD></TR>
  <TR>
    <TD bgColor=#eeeeee valign="bottom">&nbsp;</TD>
    <TD align=center width="10%" bgColor=#eeeeee valign="bottom" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left valign="bottom">PART IV </TD>
    <TD noWrap align=center width="10%" valign="bottom" >41 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#eeeeee valign="bottom">
    <p style="text-indent: -35pt; margin-left: 45pt">Item 15. EXHIBITS, FINANCIAL
      STATEMENT SCHEDULES </TD>
    <TD noWrap align=center width="10%" bgColor=#eeeeee valign="bottom" >41
  </TD></TR></TABLE>
<P align=center>i </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=justify><B>Introductory Comments &#150; Terminology </B></P>
<P align=justify>Throughout this annual report on Form 10-K (this &#147;Report&#148;), the
terms &#147;BioSpecifics,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148; and &#147;us&#148; refer to BioSpecifics
Technologies Corp. and its subsidiary, Advance Biofactures Corporation
(&#147;ABC-NY&#148;). <B></B></P>
<P align=justify><B>Introductory Comments &#150; Forward-Looking Statements </B></P>
<P align=justify>This Report includes &#147;forward-looking statements&#148; within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. All statements other
than statements of historical facts are &#147;forward-looking statements&#148; for
purposes of these provisions, including any projections of earnings, revenues or
other financial items, any statements of the plans and objectives of management
for future operations, any statements concerning proposed new products or
licensing or collaborative arrangements, any statements regarding future
economic conditions or performance, and any statement of assumptions underlying
any of the foregoing. In some cases, forward-looking statements can be
identified by the use of terminology such as &#147;may,&#148; &#147;will,&#148; &#147;expects,&#148; &#147;plans,&#148;
&#147;anticipates,&#148; &#147;estimates,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative thereof
or other comparable terminology. Although we believe that the expectations
reflected in the forward-looking statements contained in this Report are
reasonable, there can be no assurance that such expectations or any of the
forward-looking statements will prove to be correct, and actual results could
differ materially from those projected or assumed in the forward-looking
statements. Our future financial condition and results of operations, as well as
any forward-looking statements, are subject to inherent risks and uncertainties,
including but not limited to the risk factors set forth in Item 1A of this
Report, and for the reasons described elsewhere in this Report. All
forward-looking statements and reasons why results may differ included in this
Report are made as of the date hereof, and we assume no obligation to update
these forward-looking statements or reasons why actual results might differ.
</P>
<P align=center>1 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_5></A>
<P align=center><B>PART I</B><B> </B></P>
<P align=justify><B>Item 1. DESCRIPTION OF BUSINESS. </B></P>
<P align=justify><B>Overview</B> </P>
<P align=justify>We are a biopharmaceutical company involved in the development
of an injectable collagenase for multiple indications. We have a development and
license agreement with Auxilium Pharmaceuticals, Inc. (&#147;Auxilium&#148;) for
injectable collagenase (which Auxilium has named XIAFLEX<SUP>&#174;</SUP>
(collagenase clostridium histolyticum)) for clinical indications in Dupuytren&#146;s
contracture, Peyronie&#146;s disease and frozen shoulder (<I>adhesive
capsulitis</I>), and Auxilium has an option to acquire additional indications
that we may pursue, including human and canine lipoma and cellulite. Auxilium
has an agreement with Pfizer, Inc. (&#147;Pfizer&#148;) pursuant to which Pfizer has the
right to market XIAFLEX for Dupuytren&#146;s contracture and Peyronie&#146;s disease in 27
member countries of the European Union and 19 other European and Eurasian
countries, and will do so under the registered trademark XIAPEX<SUP>&#174;</SUP>
(collagenase clostridium histolyticum). </P>
<P align=justify><B>Commercialization of XIAFLEX for Dupuytren&#146;s Contracture in
the United States </B></P>
<P align=justify>Auxilium announced on February 2, 2010 that it received
marketing approval from the United States Food and Drug Administration (&#147;FDA&#148;)
for XIAFLEX for the treatment of adult Dupuytren&#146;s contracture patients with a
palpable cord as further described in this Item 1 under the heading &#147;Collagenase
for Treatment of Dupuytren&#146;s Contracture.&#148; Auxilium launched XIAFLEX, the only
drug approved by the FDA for the treatment of Dupuytren&#146;s contracture, in March
2010.</P>
<P align=justify>Auxilium has announced that a new XIAFLEX-specific J-code
(J0775) became available, beginning January 1, 2011, for use in the U.S. to
identify XIAFLEX for obtaining reimbursement from Medicare, Medicaid and
commercial health plans. Auxilium has reported in its Form 10-K filed with the
SEC on March 1, 2011 (the &#147;Auxilium 10-K&#148;) that &#147;the leadership of the American
Society for Surgery of the Hands recommended a CPT code for XIAFLEX to the
American Medical Association&#146;s CPT Editorial Panel in February 2011&#148;. </P>
<P align=justify>As discussed in more detail below under the section titled
&#147;Licensing and Marketing Agreements,&#148; pursuant to our development and licensing
agreement with Auxilium, we will be entitled to low double-digit royalties for
net sales of XIAFLEX, subject to set-off for certain expenses we owe to Auxilium
relating to certain development and patent costs.</P>
<P align=justify><B>Status of Regulatory Approval of XIAFLEX for Dupuytren&#146;s
Contracture in Europe </B></P>
<P align=justify>In a press release dated February 28, 2011, Auxilium and Pfizer
announced that the European Commission granted XIAPEX marketing authorization
for the treatment of Dupuytren&#146;s contracture in adult patients with a palpable
cord. The press release also noted that XIAPEX &#147;is expected to be available for
use in some European markets later this year&#148;.</P>
<P align=justify>In the Auxilium 10-K, Auxilium stated that &#147;a total of $60
million in milestone payments will be payable to [Auxilium] by Pfizer upon
Pfizer&#146;s achievement of [the] first commercial sale of XIAPEX for Dupuytren&#146;s
[contracture] within the major markets in Europe. Of this $60 million, $30
million will be payable upon [the] first commercial sale in the first country
and a total of $30 million will be payable upon the respective first commercial
sales in each of the remaining major markets.&#148; We will receive 8.5% of any such
milestone payments from Pfizer to Auxilium. </P>
<P align=justify><B>Qualifying Therapeutic Discovery Project Program </B></P>
<P align=justify>We have received $426,000 in grant funding under the Qualifying
Therapeutic Discovery Project Program. The program, funded through the U.S.
Patient Protection and Affordable Care Act of 2010, encourages therapeutic
discovery programs. As we announced on November 3, 2010, the funding supports
the clinical development of injectable collagenase in lipoma and the development
of improved collagenases for tissue disassociation related to cellular therapy.
</P>
<P align=center>2 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_6></A>
<P align=justify><B>Research and Development of Injectable Collagenase for
Multiple Indications</B> </P>
<P align=justify>We entered into a development and license agreement with
Auxilium on June 3, 2004, as amended on May 10, 2005 and December 15, 2005,
respectively (the &#147;Prior Auxilium Agreement&#148;), pursuant to which we granted to
Auxilium an exclusive worldwide license to develop, market and sell products
containing our injectable collagenase for the treatment of Dupuytren&#146;s
contracture, Peyronie's disease and frozen shoulder, as well as an exclusive
option to develop and license the technology for use in additional indications
other than dermal formulations labeled for topical administration.</P>
<P align=justify>On December 11, 2008, the parties amended and restated, in its
entirety, the Prior Auxilium Agreement (the &#147;Auxilium Agreement&#148;), which became
effective on December 17, 2008 upon the execution and effectiveness of the
Development, Commercialization and Supply Agreement, dated December 17, 2008
(the &#147;Pfizer Agreement&#148;) between Auxilium International Holdings, Inc., a
wholly-owned subsidiary of Auxilium, and Pfizer. Under the Pfizer Agreement,
Pfizer will market XIAPEX for the treatment of Dupuytren&#146;s contracture and
Peyronie&#146;s disease in Europe and various other territories. In the Auxilium
10-K, Auxilium announced that it is seeking a partner or partners for
development and commercialization in the rest of the world. </P>
<P align=justify>The Auxilium Agreement and other licensing agreements are
discussed more fully in this Item 1, under the section titled &#147;Licensing and
Marketing Agreements.&#148;</P>
<P align=justify>In the Auxilium 10-K, Auxilium stated that it plans to
&#147;prioritize [its] development of additional indications for XIAFLEX&#148;. In the
event that Auxilium does out-license XIAFLEX in other indications, we will be
entitled to receive a certain percentage of sublicense income and milestone
payments for such indications pursuant to the terms of the Auxilium
Agreement.</P>
<P align=justify><B>Background on Collagenase </B></P>
<P align=justify>Collagenase is the only protease that can hydrolyze the triple
helical region of collagen under physiological conditions. The specific
substrate collagen comprises approximately one-third of the total protein in
mammalian organisms, and it is the main constituent of skin, tendon, and
cartilage, as well as the organic component of teeth and bone. The body relies
on endogenous collagenase production to remove dead tissue and collagenase
production is an essential biological mechanism, which regulates matrix
remodeling and the normal turnover of tissue. The <I>Clostridial</I> collagenase
produced by us has a broad specificity towards all types of collagen and is
acknowledged as much more efficient than mammalian collagenases.
<I>Clostridial</I> collagenase cleaves the collagen molecule at multiple sites
along the triple helix whereas the mammalian collagenase is only able to cleave
the molecule at a single site along the triple helix.</P>
<P align=justify>Collagenase is widely used for cell dispersion for tissue
disassociation and cell culture because it does not damage the cell membrane.
Since the main component of scar tissue is collagen, collagenase has been used
in a variety of clinical investigations to remove scar tissue without surgery.
Histological and biochemical studies have shown that the tissue responsible for
the deformities associated with Dupuytren&#146;s contracture and Peyronie&#146;s disease
is primarily composed of collagen. Surgical removal of scar tissue has the
potential to result in complications including increased scar formation. Due to
the highly specific nature of the <I>Clostridial</I> collagenase enzyme, we
consider its use to be more desirable for the removal of unwanted tissue than
the application of general proteolytic enzymes. Treatment with injectable
collagenase for removal of excessive scar tissue represents a first in class
non-invasive approach to this unmet medical need. The lead indications involving
our injectable collagenase are Dupuytren&#146;s contracture, Peyronie&#146;s disease and
frozen shoulder. New clinical indications involving the therapeutic application
of <I>Clostridial</I> collagenase to supplement the body&#146;s own natural enzymes
are continuously being proposed to us by specialists in the medical
community.</P>
<P align=justify><B>Collagenase for Treatment of Dupuytren&#146;s Contracture
</B></P>
<P align=justify>Dupuytren&#146;s contracture is a deforming condition of the hand in
which one or more fingers contract toward the palm, often resulting in physical
disability. The onset of Dupuytren&#146;s contracture is characterized by the
formation of nodules in the palm that are composed primarily of collagen. As the
disease progresses, the collagen nodules begin to form a cord causing the
patient&#146;s finger(s) to contract, making it impossible to open the hand fully.
Patients often complain about the inability to wash their hands, wear gloves, or
grasp some objects. Dupuytren&#146;s contracture has a genetic basis and it is most prevalent in individuals of
northern European ancestry. Well-known individuals with Dupuytren&#146;s contracture
include President Ronald Reagan, President George Bush, and Prime Minister
Margaret Thatcher.</P>
<P align=center>3 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_7></A>
<P align=justify>Prior to FDA approval of XIAFLEX, the only proven treatment for
Dupuytren&#146;s contracture was surgery. Recurrence rates after surgery can be as
high as 30% the first two years after surgery and 55% within ten years of
surgery. The post surgical recovery is often associated with significant pain,
delayed return to work, and extended periods of post-operative physical therapy.
Because many of the individuals with Dupuytren&#146;s contracture are older than 60,
there is considerable resistance from patients to undergo the surgical
procedure, which also involves the risk of general anesthesia. In addition, hand
surgeons note that surgery for Dupuytren&#146;s contracture is tedious, lengthy and
poorly reimbursed in the U.S. Auxilium has also stated in its presentation
materials for March 2011 that &#147;[s]urgery has been reserved for advanced disease
due to the nature of the disease, unpredictable results, complications, long
recovery time and recurrence/additional surgeries.&#148;</P>
<P align=justify>In the Auxilium 10-K, Auxilium cited the following reasons that
&#147;treatment with XIAFLEX offers benefits compared to surgery&#148;. It:<B> </B></P>
<UL>
  <LI>
  <p style="margin-bottom: 12">&#147;delivers improvement to 0 to 5 degrees of normal joint contracture
  without surgery for a majority of patients;
  <LI>
  <p style="margin-bottom: 12">safeguards patients from the complications commonly associated with
  surgery;
  <LI>
  <p style="margin-bottom: 12">simplifies treatment by offering a convenient in-office procedure
  alternative;
  <LI>
  <p style="margin-bottom: 12">streamlines recovery for a rapid return to daily activities; and
  <LI>significantly reduces costly and time-consuming physical therapy
  associated with surgery.&#148; </LI></UL>
<P align=justify>We anticipate that many of the patients who had been willing to
live with the disease at a time when the only proven treatment option was
surgery would be receptive to the XIAFLEX treatment which involves a collagenase
injection into the hand that is performed in a doctor&#146;s office. As quoted in a
February 28, 2011 joint press release of Auxilium and Pfizer, &#147;&#145;Dupuytren&#146;s
contracture can significantly impact a patient&#146;s quality of life, as the
affected finger often interferes with daily activities such as driving, washing
one&#146;s face or shaking hands so a new alternative treatment for the condition is
encouraging to those living with Dupuytren&#146;s contracture across the EU,&#146; said
Dr. J&#246;rg Witthaut, consultant hand surgeon from Sch&#246;n Klinik Vogtareuth
Handchirurgie, Vogtareuth, Germany.&#148;<B> </B></P>
<P align=justify><I>Commercialization of XIAFLEX for Dupuytren&#146;s Contracture in
the United States </I></P>
<P align=justify>In a February 2, 2010 press release, Auxilium announced that it
received marketing approval from the FDA for XIAFLEX for the treatment of adult
Dupuytren's contracture patients with a palpable cord. XIAFLEX became available
by prescription in March 2010. XIAFLEX is the only drug approved by the FDA for
the treatment of Dupuytren&#146;s contracture. The prescribing information for
XIAFLEX made available by Auxilium lists &#147;tendon rupture or other serious injury
to the injected extremity,&#148; as well as &#147;pulley rupture, ligament injury, complex
regional pain syndrome, and sensory abnormality of the hand,&#148; as reported
serious adverse reactions to XIAFLEX. The prescribing information for XIAFLEX
also states that the most frequently reported adverse drug reactions in XIAFLEX
clinical trials included swelling of the injected hand, contusion, injection
site reaction, injection site hemorrhage, and pain in the treated extremity. The
prescribing information notes that adverse reaction rates observed in clinical
trials of a drug may not reflect those observed in practice because such trials
&#147;are conducted under widely varying conditions.&#148; </P>
<P align=justify>Auxilium also stated in the Auxilium 10-K that: &#147;As a condition
of approval for XIAFLEX, [the] FDA has required a risk evaluation and mitigation
strategy (&#147;REMS&#148;) program for XIAFLEX, which consists of a communication plan
and a medication guide. This REMS program is designed (1) to evaluate and
mitigate known and potential risks and serious adverse events; (2) to inform
healthcare providers about how to properly inject XIAFLEX and perform finger
extension procedures; and, (3) to inform patients about the serious risks
associated with XIAFLEX. [Auxilium] market[s] XIAFLEX to physicians who are
experienced in injection procedures of the hand and in the treatment of
Dupuytren&#146;s, and [Auxilium] require[s] that they attest to this experience and
their completion of the REMS-required training program before they have access
to XIAFLEX.&#148;</P>
<P align=center>4 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_8></A>
<P align=justify>As discussed in more detail below under the section titled
&#147;Licensing and Marketing Agreements,&#148; we will be entitled to low double-digit
royalties for net sales of XIAFLEX pursuant to the Auxilium Agreement, subject
to set-off for certain expenses we owe to Auxilium under the Auxilium Agreement
relating to certain development and patent costs. </P>
<P align=justify>In its March 2011 presentation, Auxilium highlighted the
following as its strategy for establishing XIAFLEX as the standard of care for
Dupuytren&#146;s contracture: to &#147;[d]isseminate excellent clinical efficacy and
safety data; [f]acilitate peer to peer dialogue; [e]ducate patients on a
non-invasive option; [s]mooth the reimbursement process; [and a]ctivate a
critical mass of experienced prescribers&#148;. In furtherance of this strategy,
Auxilium has targeted 6,000 physicians including hand surgeons, plastic
surgeons, orthopedic surgeons, general surgeons and rheumatologists, is
utilizing 100 field based representatives compromised of sales representatives,
sales managers and reimbursement specialists as part of the launch, and has
medical science liaisons to help gain key opinion leader and regional opinion
leader support. </P>
<P align=justify>In the Auxilium 10-K Auxilium noted that it plans to generate
additional clinical data for Dupuytren&#146;s contracture. Specifically, it
&#147;expect[s] to provide top-line three year recurrence data from [its] long term
extension study in June 2011. In the first quarter of 2011, [it has] commenced
dosing in a phase IV study expected to evaluate the ability to inject multiple
cords in a single hand simultaneously. [Auxilium is] also planning to start a
phase IV study on recurrent contractures previously successfully treated with
XIAFLEX in 2011&#148;.</P>
<P align=justify><I>Status of Regulatory Approval of XIAFLEX for Dupuytren&#146;s
Contracture in Europe</I></P>
<P align=justify>On December 16, 2010, Pfizer and Auxilium issued a joint press
release to announce that Pfizer had received a positive opinion from the EMA&#146;s
CHMP recommending European Union approval for XIAPEX as treatment for
Dupuytren&#146;s contracture in adult patients with a palpable cord. The release
stated that the CHMP&#146;s positive recommendation will be reviewed by the European
Commission, which has authority to approve medicines for the European Union. In
addition, the release stated that Pfizer anticipates a final decision from the
European Commission by the end of the first quarter of 2011. Pfizer is
responsible for marketing XIAFLEX for Dupuytren&#146;s contracture and Peyronie&#146;s
disease in 27 member countries of the European Union and 19 other European and
Eurasian countries, and will do so under the registered trademark XIAPEX.</P>
<P align=justify><B>Collagenase for Treatment of Peyronie&#146;s Disease </B></P>
<P align=justify>Peyronie&#146;s disease is characterized by the presence of a
collagen plaque on the shaft of the penis, which can distort an erection and
make intercourse difficult or impossible in advanced cases. In some mild cases,
the plaque can resolve spontaneously without medical intervention. In severe
cases, the penis can be bent at a 90-degree angle during erection. Significant
psychological distress has been noted in patients with Peyronie&#146;s disease who
are sexually active. Frequent patient complaints include increased pain, painful
erections, palpable plaque, penile deformity, and erectile dysfunction. Patients
with Peyronie&#146;s disease have been reported to have an increased likelihood of
having Dupuytren&#146;s contracture, frozen shoulder, plantar fibromatosis, knuckle
pads, hypertension and diabetes. Peyronie&#146;s disease typically affects males in
the range of 40-70 years. The cause of Peyronie&#146;s disease is unknown, although
some investigators have proposed that it may be due to trauma or an autoimmune
component. A number of researchers have suggested that the incidence of
Peyronie&#146;s disease has increased due to the use of erectile dysfunction
drugs.</P>
<P align=justify>Surgery is the only proven treatment for Peyronie&#146;s disease and
the results are variable. Surgery often results in shortening of the penis.
Auxilium has reported that 33% of Peyronie&#146;s disease patients who undergo
surgery are subsequently dissatisfied with the results and they frequently
require a penile implant. Patients with Peyronie&#146;s disease strongly desire
therapeutic alternatives to surgery. Auxilium has reported that 90% of
urologists would use collagenase injection to delay or avoid surgery. This
finding is consistent with a survey of urologists conducted for us. In the
Auxilium 10-K, Auxilium stated its belief that &#147;there is a large unmet medical
need for a non-surgical solution to Peyronie&#146;s [disease]&#148;.</P>
<P align=justify>Histological and biochemical studies indicate that the scarring
on the penis due to Peyronie&#146;s disease is composed primarily of collagen.</P>
<P align=center>5 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_9></A>
<P align=justify><I>Development Status </I></P>
<P align=justify>On October 11, 2010, Auxilium announced that the first subject
had been dosed in the global phase III program of XIAFLEX for the treatment of
Peyronie&#146;s disease. Auxilium also stated that it anticipates reporting top-line
results in the first half of 2012. On March 9, 2011, Auxilium announced that it
had reached target enrollment for the double-blind, placebo-controlled phase III
program. </P>
<P align=justify><I>Phase IIb Trial </I></P>
<P align=justify>On December 16, 2009, Auxilium announced top-line efficacy and
safety results from a phase IIb trial of XIAFLEX for the treatment of Peyronie&#146;s
disease. According to the Auxilium 10-K, the phase IIb trial was a &#147;randomized,
double-blind, placebo-controlled study designed to assess the safety and
efficacy of XIAFLEX when administered two times a week every six weeks for up to
three treatment cycles (2 x 3) in subjects with Peyronie&#146;s. The study was
conducted at 12 sites throughout the U.S., and patients were monitored for 36
weeks following the first injection. The trial was designed to validate a
proprietary Peyronie&#146;s Disease Questionnaire (&#147;PDQ&#148;) which measures several
domains of patients&#146; sexual quality of life over a 36 week period. The four
domains measured by the PDQ are penile pain, Peyronie&#146;s bother, intercourse
discomfort and intercourse constraint. Patients had to have a penile contracture
between 30 and 90 degrees to be included in the study. Patients were stratified
by the degree of penile curvature (i.e. 30 degrees to 60 degrees versus 60 to 90
degrees) and then randomized into four treatment groups to receive either
XIAFLEX or placebo with or without modeling of the penile plaque. Modeling
refers to massaging of the plaque after the second injection of a treatment
series and is intended to maximize the enzymatic effect of the XIAFLEX injection
in the plaque. Patients were randomized in a 3:1 ratio of XIAFLEX to placebo and
a 1:1 ratio to receive penile plaque modeling or no modeling.&#148;</P>
<P align=justify>In addition, the Auxilium 10-K stated that &#147;Top-line data
demonstrated that XIAFLEX improved penile curvature when compared to placebo
with a mean improvement of 29.7% vs. 11%, respectively (P=0.001). In addition,
the PDQ domain of Peyronie&#146;s symptom bother was significantly improved in
XIAFLEX treated subjects compared to placebo. The use of modeling also
demonstrated significant improvement in XIAFLEX subjects compared to placebo,
32.4% improvement in curvature compared to a 2.5% worsening of curvature in
placebo subjects (p&lt;0.001). In the no-modeling group, XIAFLEX subjects
experienced a 27.1% mean improvement in penile curvature, which was not
statistically different from the 27.9% mean improvement for subjects receiving
the placebo. The most common adverse events reported in the phase IIb trial were
injection site bruising, injection site pain, injection site edema, contusion,
penile edema and penile pain. There was a total of five (3.4%) subjects who
experienced eight non-fatal serious adverse events, none of which were
considered to be related to XIAFLEX. [Auxilium] sought to accomplish two goals
with this study. First, [Auxilium] wanted to validate the PDQ as a tool for use
in future pivotal studies. Second, [Auxilium] aimed to establish an acceptable
primary endpoint related to the PDQ for use in pivotal phase III trials.&#148; </P>
<P align=justify><I>Phase III </I></P>
<P align=justify>In the Auxilium 10-K, Auxilium stated that &#147;[f]ollowing
discussions with the FDA where [Auxilium] achieved agreement that the PDQ was a
valid tool for use in a pivotal phase III trial and the appropriate endpoint for
such trials, [Auxilium] commenced its phase III studies.&#148; In its October 11,
2010 press release, Auxilium described these phase III studies as follows: the
&#147;late stage global development plan for XIAFLEX will consist of four clinical
studies and will be known by the acronym IMPRESS &#150; The Investigation for Maximal
Peyronie&#146;s Reduction Efficacy and Safety Studies. There will be two randomized,
double-blind, placebo-controlled phase III studies, which are expected to enroll
at least 600 patients at approximately 70 sites in the U.S. and Australia, with
a 2:1 ratio of XIAFLEX to placebo. There also will be one open label study,
which is expected to enroll at least 250 patients, at approximately 30 sites in
the U.S., EU and New Zealand, and one pharmacokinetic study, which should enroll
approximately 16 patients. XIAFLEX will be administered two times a week every
six weeks for up to four treatment cycles (2 x 4). Each treatment cycle will be
followed by a penile modeling procedure. Patients will be followed for 52 weeks
post-first injection in the double-blind studies and for 36 weeks in the open
label trial. The trials&#146; co-primary endpoints are the change from baseline in
the Peyronie&#146;s disease bother domain of the PDQ compared to placebo and percent
improvement from baseline in penile curvature compared to placebo.&#148; In addition,
the Auxilium 10-K stated that &#147;[t]he remaining domains of the PDQ will be
considered secondary endpoints. Safety measurements will include adverse event
monitoring, immunogenicity testing and clinical labs.&#148; In addition, in its
October 11, 2010 press release, Auxilium, quoting Dr. Jim Tursi, its Vice
President of Clinical Research &amp; Development, stated that it is &#147;encouraged
by the clinical profile of XIAFLEX, which emerged from [Auxilium&#146;s] earlier
phase IIb clinical trial in Peyronie&#146;s disease. XIAFLEX was well-tolerated and produced
clinically significant reductions in both penile curvature and disease bother,&#148;
and that &#147;[o]ver the last six months, [Auxilium&#146;s] team, in conjunction with the
[FDA], outside experts and men with Peyronie&#146;s disease, has spent a considerable
amount of time and effort to refine the PDQ, which has now been accepted for use
in the phase III clinical trials by the FDA&#146;s Study Endpoint and Label
Development (SEALD) Division.&#148;</P>
<P align=center>6 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_10></A>
<P align=justify><B>Collagenase For Treatment of Frozen Shoulder
(</B><B><I>Adhesive Capsulitis</I></B><B>) </B></P>
<P align=justify>Frozen shoulder is a clinical syndrome of pain and decreased
motion in the shoulder joint. It is estimated to affect 20 to 50 million people
worldwide with a slightly higher incidence in women. It is estimated that
700,000 patients visit doctors annually in the U.S. in connection with frozen
shoulder. It typically occurs between the ages of 40-70. Individuals with
insulin dependent diabetes have been reported to have a 36% higher incidence
rate and are more likely to have bilateral symptoms. One common therapy
currently available to treat frozen shoulder is manipulation, which is painful
and requires general anesthesia.<B> </B></P>
<P align=justify>We initiated, monitored and supplied requisite study drug for a
Phase II clinical trial using our injectable collagenase in the treatment of
frozen shoulder. Three different doses of injectable collagenase were compared
to placebo in this double-blind, randomized trial in 60 patients. Results of
this Phase II clinical trial were presented at the annual meeting of the
American Academy of Orthopaedic Surgeons in March 2006. Based on its prior
review of the data contained in the oral presentation, Auxilium elected to
exercise its option to develop and commercialize this additional indication for
collagenase injection in December 2005. In a press release dated December 20,
2005 and issued concurrently with the exercise of its option, Auxilium stated
its belief that &#147;the addition of a third indication for this development program
enhances the commercial potential of AA4500&#148; (now known as XIAFLEX).</P>
<P align=justify><B>Additional Clinical Indications For Collagenase</B></P>
<P align=justify><I>Human Lipoma </I></P>
<P align=justify>Lipomas are benign fatty tumors that occur as bulges under the
skin and affect humans and canines. It is estimated that lipomas are the primary
diagnosis in 575,000 patients in the U.S. annually. Based on observations made
during preclinical studies that a collagenase injection decreased the size of
fat pads in animals, we initiated, monitored and supplied the requisite study
drug for a Phase I open label clinical trial for the treatment of human lipomas
with a single injection of collagenase. Favorable initial results (10 out of 12
patients had a 50-90% reduction in the size of the lipomas) from this trial for
the treatment of lipomas were presented at a meeting of the American Society of
Plastic Surgeons. We have been developing clinical protocols for the treatment
of lipomas in humans, and this is an area that we are interested in
exploring.</P>
<P align=justify><I>Canine Lipoma</I></P>
<P align=justify>Based on the encouraging results reported in the clinical
investigations in human lipoma, we began clinical trials in canine lipoma.
Lipomas are found in 2.3% of dogs, and there may be as many as 1.7 million dogs
affected with skin lipomas in the U.S. Lipomas in older dogs are very common,
and lipomas that restrict motion in older dogs are a serious problem. The only
proven therapy for this condition is surgical excision of the lipoma, which
necessarily involves the use of general anesthesia. It has been estimated that
up to 2% of sick dogs die as a complication of general anesthesia (See Brodbelt
Vet J 2009 Dec; 182 (3): 375-6). We surveyed 77 veterinarians which included
participants from the academic field and others that are in private practice.
The participants indicated that on average they perform 25 lipoma excision
surgeries per year at an average cost of $530 for the surgical procedure. It is
conservatively estimated that 47,000 veterinarians are in active practice in the
U.S. </P>
<P align=justify>Chien-801 and Chien-802 Clinical Trials</P>
<P align=justify>Chien-801 was a pilot study conducted for the purpose of
evaluating the use of purified collagenase for the non-surgical treatment of
lipoma in six dogs. The study evaluated the appropriate dosage and frequency of
injections necessary to significantly reduce the size of the lipoma. The dose
administered ranged from 0.012 to 0.021 mg/ cm2 which was approximately &#189; to &#190;
of the dose used in previous human clinical trials. Based on this dose
escalation study the Company selected the dose for Chien-802.</P>
<P align=center>7 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_11></A>
<P align=justify>Chien-802 was designed to evaluate the efficacy of injectable
collagenase in canine lipoma in four healthy dogs with subcutaneous lipomas.
Inclusion criteria required the lipoma to be benign, superficial and easily
measureable. All dogs had a second lipoma that was untreated and used as a
control. At 90 days post injection, in the three evaluable dogs, the lipoma size
was 0%, 0% or 7% of the original size as measured by a CT scan. By contrast, the
untreated lipomas were 129%, 113% and 128% of the original size at day 90. Thus,
the treated lipomas showed a 97% reduction in the size of the lipoma and an
increase in the size of the untreated controls of 23%.</P>
<P align=justify>Chien-803 </P>
<P align=justify>Based on the positive results from Chien-802, we announced on
January 6, 2011 that we had begun enrollment in a randomized, double-blind,
placebo-controlled study designed to evaluate the efficacy of purified
collagenase for injection for the treatment of canine lipomas. </P>
<P align=justify>The trial would enroll 25 canines, each having two or more
lipomas. To meet the primary endpoint an animal must achieve at least a 50%
decrease in the drug-treated lipoma volume relative to baseline as measured by
CT scan at 3 months post injection. As further described in this Report under
&#147;Item 3 - Legal Proceedings&#148;, we have voluntarily agreed to suspend the trial
pending a resolution of our dispute with Auxilium.<B> </B></P>
<P align=justify><I>Cellulite </I></P>
<P align=justify>Cellulite is a condition characterized by dimpling of the skin
and a mattress phenomenon typically affecting the thighs and buttocks. It is due
to irregular and discontinuous subcutaneous connective tissue. An open label
study has been completed to assess whether injectable collagenase can restore
the cellulite-affected areas to a more cosmetically acceptable appearance. An
abstract of an article titled &#147;Collagenase Injection in the Treatment of
Cellulite&#148; by A. Dagum and M.Badalamente, describing the promising results of
this study was published in <I>Plastic and Reconstructive Surgery</I> on
September 15, 2006. BioSpecifics has not announced plans for any new studies in
cellulite.</P>
<P align=justify><I>Other Clinical Indications </I></P>
<P align=justify>Other clinical indications for which our collagenase injection
has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma,
herniated intervertebral discs, and as an adjunct to vitrectomy. </P>
<P align=justify><B>Total Patient Exposure to Injectable Collagenase</B></P>
<P align=justify>As discussed above, clinical investigations with our
collagenase injection have been conducted in the treatment of Dupuytren&#146;s
contracture, Peyronie&#146;s disease, frozen shoulder, lipomas, cellulite, keloids,
hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs,
and as an adjunct to vitrectomy. We have treated over 1,200 patients in our own
clinical studies. According to the prescribing information for XIAFLEX made
available by Auxilium, 1,082 patients received in excess of 2,600 injections for
the treatment of Dupuytren&#146;s contracture in trials sponsored by Auxilium.
Auxilium reported in a December 16, 2009 press release that its Phase IIb trial
for Peyronie&#146;s disease included 109 patients treated with XIAFLEX.</P>
<P align=justify><B>LICENSING AND MARKETING AGREEMENTS </B></P>
<P align=justify><I>Topical Collagenase Agreement </I></P>
<P align=justify>In connection with a March 2006 agreement (the &#147;DFB
Agreement&#148;), pursuant to which we sold our topical collagenase business to DFB
Biotech, Inc. and its affiliates (&#147;DFB&#148;), until March 2011, we received payments
for certain technical assistance and certain transition services that we
provided to DFB. Pursuant to the DFB Agreement, we continue to receive earn out
payments based on the sales of certain products. Our right to receive earn out
payments with respect to the marketed topical product sold to DFB expire in June
2013, but earn out payments for second generation collagenase products, if any,
continue indefinitely.<B> </B></P>
<P align=center>8 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_12></A>
<P align=justify>In 2010, we received $200,000 of technical assistance related
payments, and as of December 31, 2010, we have received a total of $1.4 million
in consulting fees. In addition, we have recognized $1.6 million in earn out
payments from DFB in connection with the net sales of topical collagenase in
2010. <B></B></P>
<P align=justify><I>Auxilium Agreement </I></P>
<P align=justify>Under the Auxilium Agreement, in 2010 we received $1.275
million of the $15 million paid to Auxilium by Pfizer. We also received $1
million related to milestone payments associated with FDA approval of XIAFLEX
for Dupuytren&#146;s contracture. We will receive 8.5% of the $395 million in
potential additional milestone payments that may be made by Pfizer to Auxilium
under the Pfizer Agreement. Of these additional milestones, $135 million are
tied to regulatory milestones and $260 million are based on sales milestones.
According to Auxilium in the Auxilium 2010 Earnings Call, of the $135 million
tied to regulatory milestones &#147;[a] total of $60 million in milestone payments
will be payable to Auxilium by Pfizer upon Pfizer&#146;s achievement of [the] first
commercial sale of XIAPEX for Dupuytren&#146;s contracture within the major markets
in Europe. $30 million will be payable upon [the] first commercial sale in the
first country and a total of $30 million will be payable upon the first
commercial sales in the remaining major markets.&#148;</P>
<P align=justify>Under the Auxilium Agreement, we granted to Auxilium exclusive
worldwide rights to develop, market and sell certain products containing our
injectable collagenase. Currently its licensed rights cover the indications of
Dupuytren&#146;s contracture, Peyronie&#146;s disease and frozen shoulder. Auxilium may
further expand the Auxilium Agreement, at its exclusive option, to develop and
license our injectable collagenase for use in additional indications. Under the
Pfizer Agreement, Pfizer is responsible for marketing XIAFLEX for the treatment
of both Dupuytren&#146;s contracture and Peyronie's disease in 27 member countries of
the European Union and 19 other European and Eurasian countries (the &#147;Pfizer
Territory&#148;). In addition, Pfizer will be primarily responsible for regulatory
activities for XIAFLEX in the Pfizer Territory.</P>
<P align=justify>The royalty obligations under the Auxilium Agreement extend, on
a country-by-country and product-by-product basis, for the longer of the patent
life (including pending patents), the expiration of any regulatory exclusivity
period based on orphan drug designation or foreign equivalent thereof or June 3,
2016. Auxilium may terminate the Auxilium Agreement upon 90 days prior written
notice. If Auxilium terminates the Auxilium Agreement other than because of an
uncured, material breach by us, all rights revert to us. On October 12, 2010,
Auxilium announced that the U.S. Patent &amp; Trademark Office (the &#147;USPTO&#148;)
issued a patent regarding the composition and manufacturing process for XIAFLEX,
which Auxilium expects will expire in July 2028. We claim both co-inventorship
and co-ownership of this patent, which Auxilium disputes. </P>
<P align=justify>Auxilium is generally responsible, at its own cost and expense
(excluding the third party costs for the development of the lyophilization of
the injection formulation, which are shared equally by Auxilium and us), for
developing the formulation and finished dosage form of products and arranging
for the clinical supply of products. Auxilium is responsible for all clinical
development and regulatory costs for Peyronie&#146;s disease, Dupuytren&#146;s
contracture, frozen shoulder and all additional indications for which it
exercises its options. The royalties payable by Auxilium to us are subject to
set-off for certain development and patent costs. Auxilium has sent us an
invoice for such costs; however, the amount of such costs is in dispute. </P>
<P align=justify>Under the Auxilium Agreement, we have the option, exercisable
no later than six months after FDA approval of the Biologics License Application
(&#147;BLA&#148;) with respect to XIAFLEX for an indication (in the case of Dupuytren&#146;s
contracture, by August 2, 2010), to assume the right and obligation to supply,
or arrange for the supply from a third party other than a back-up supplier
qualified by Auxilium of, a specified portion of Auxilium&#146;s commercial product
requirements in all countries and territories of the world excluding the Pfizer
Territory (the &#147;Auxilium Territory&#148;). In June 2010, we informed Auxilium that we
were not exercising this option with respect to XIAFLEX for Dupuytren&#146;s
contracture.<B> </B></P>
<P align=justify>Auxilium must pay us on a country-by-country and
product-by-product basis a low double digit royalty as a percentage of worldwide
net sales for products covered by the Auxilium Agreement. The royalty rate is
independent of sales volume, clinical indication, territory, and whether the
product is sold by Auxilium or Pfizer, but is subject to set-off for certain
expenses we owe to Auxilium relating to certain development and patent costs. In
addition, the royalty percentage may be reduced if (i) market share of a
competing product exceeds a specified threshold; or (ii) Auxilium is required to obtain a license from a third party in
order to practice our patents without infringing such third party&#146;s patent
rights, although Auxilium has confirmed to us that no license from a third party
is required. In addition, if Auxilium out-licenses to a third party, then we
will receive a specified percentage of certain payments made to Auxilium in
consideration of such out-licenses. </P>
<P align=center>9 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_13></A>
<P align=justify>On top of the payments set forth above, Auxilium must pay to us
an amount equal to a specified mark-up of the cost of goods sold for products
sold by Auxilium or Pfizer that are not manufactured by or on behalf of us.<B>
</B></P>
<P align=justify>In addition to the payments already received by us with respect
to the Dupuytren&#146;s contracture indication, Auxilium will be obligated to make
contingent milestone payments, with respect to each of the Peyronie&#146;s disease
and frozen shoulder indications, upon the acceptance of the regulatory filing
and receipt by Auxilium, its affiliate or sublicensee of regulatory approval.
Through December 31, 2010, Auxilium paid us up-front licensing and sublicensing
fees and milestone payments under the Auxilium Agreement of $17.7 million.
Auxilium could make in excess of $5 million of additional contingent milestone
payments for exercised indications under the Auxilium Agreement if all existing
conditions are met.<B> </B>Additional milestone obligations will be due if
Auxilium exercises its option to develop and license XIAFLEX for additional
medical indications.</P>
<P align=justify>In addition to the milestone payments from Auxilium, the
Company is entitled to 8.5% of all sublicense income that Auxilium receives from
Pfizer under the Pfizer Agreement, which payments are dependent on the
achievement by Pfizer of certain regulatory and sales related milestones. To the
extent Auxilium enters into an agreement or agreements related to other
territories, the percentage of sublicense income that Auxilium would pay us will
depend on the stage of development and approval of XIAFLEX for the particular
indication at the time such other agreement or agreements are executed.<B>
</B></P>
<P align=justify>In its presentation materials for March 2011, Auxilium includes
&#147;advanc[ing] XIAFLEX [for] new indication(s)&#148; as a strategic priority in 2011.
In the event that Auxilium does out-license XIAFLEX in other indications, we
will be entitled to receive a certain percentage of sublicense income and
milestone payments for such indications pursuant to the terms of the Auxilium
Agreement. </P>
<P align=justify>A copy of the Auxilium Agreement was filed on Form 8-K with the
Securities and Exchange Commission (&#147;SEC&#148;) on December 19, 2008. The foregoing
descriptions of the Auxilium Agreement do not purport to be complete and are
qualified in their entirety by reference to the full text of the Auxilium
Agreement. </P>
<P align=justify><I>In-Licensing and Royalty Agreements</I></P>
<P align=justify>We have entered into several in-licensing and royalty
agreements with various investigators, universities and other entities
throughout the years.</P>
<P align=justify style="margin-left: 5%"><I>Dupuytren&#146;s Contracture </I></P>
<P align=justify>On November 21, 2006, we entered into a license agreement (the
&#147;Dupuytren&#146;s License Agreement&#148;) with the Research Foundation of the State
University of New York at Stony Brook (the &#147;Research Foundation&#148;), pursuant to
which the Research Foundation granted to us and our affiliates an exclusive
worldwide license, with the right to sublicense to certain third parties, to
know-how owned by the Research Foundation related to the development,
manufacture, use or sale of (i) the collagenase enzyme obtained by a
fermentation and purification process (the &#147;Enzyme&#148;), and (ii) all
pharmaceutical products containing the Enzyme or injectable collagenase, in each
case to the extent it pertains to the treatment and prevention of Dupuytren&#146;s
contracture. </P>
<P align=justify>In consideration of the license granted under the Dupuytren&#146;s
License Agreement, we agreed to pay to the Research Foundation certain royalties
on net sales (if any) of pharmaceutical products containing the Enzyme or
injectable collagenase for the treatment and prevention of Dupuytren&#146;s
contracture (each a &#147;Dupuytren&#146;s Licensed Product&#148;).</P>
<P align=justify>Our obligation to pay royalties to the Research Foundation with
respect to sales by the Company, its affiliates or any sublicensee of any
Dupuytren&#146;s Licensed Product in any country (including the U.S.) arises only
upon the first commercial sale of such Dupuytren&#146;s Licensed Product on a
country-by-country basis. The royalty rate is 0.5% of net sales. Our obligation
to pay royalties to the Research Foundation will continue until the later of (i)
the expiration of the last valid claim of a patent pertaining to the Dupuytren&#146;s
Licensed Product; (ii) the expiration of the regulatory exclusivity period conveyed by the FDA&#146;s Office of Orphan
Products Development (&#147;OOPD&#148;) with respect to the Dupuytren&#146;s Licensed Product;
or (iii) June 3, 2016.</P>
<P align=center>10 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_14></A>
<P align=justify>Unless terminated earlier in accordance with its termination
provisions, the Dupuytren&#146;s License Agreement and the licenses granted under
that agreement will continue in effect until the termination of our royalty
obligations. After that, all licenses granted to us under the Dupuytren&#146;s
License Agreement will become fully paid, irrevocable exclusive licenses. </P>
<P align=justify style="margin-left: 5%"><I>Peyronie&#146;s Disease </I></P>
<P align=justify>On August 27, 2008, we entered into an agreement to improve the
deal terms related to our future royalty obligations for Peyronie&#146;s disease by
buying down our future royalty obligations with a one-time cash payment. A copy
of the agreement was filed on Form 8-K with the SEC on September 5, 2008.</P>
<P align=justify style="margin-left: 5%"><I>Frozen Shoulder </I></P>
<P align=justify>On November 21, 2006, we entered into a license agreement (the
&#147;Frozen Shoulder License Agreement&#148;) with the Research Foundation, pursuant to
which the Research Foundation granted to us and our affiliates an exclusive
worldwide license, with the right to sublicense to certain third parties, to
know-how owned by the Research Foundation related to the development,
manufacture, use or sale of (i) the Enzyme and (ii) all pharmaceutical products
containing the Enzyme or injectable collagenase, in each case to the extent it
pertains to the treatment and prevention of frozen shoulder. Additionally, the
Research Foundation granted to us an exclusive license to the patent
applications in respect of frozen shoulder. The license granted to us under the
Frozen Shoulder License Agreement is subject to the non-exclusive license (with
right to sublicense) granted to the U.S. government by the Research Foundation
in connection with the U.S. government&#146;s funding of the initial research. </P>
<P align=justify>In consideration of the license granted under the Frozen
Shoulder License Agreement, we agreed to pay to the Research Foundation certain
royalties on net sales (if any) of pharmaceutical products containing the Enzyme
or injectable collagenase for the treatment and prevention of frozen shoulder
(each a &#147;Frozen Shoulder Licensed Product&#148;). In addition, we and the Research
Foundation will share in any milestone payments and sublicense income received
by us in respect of the rights licensed under the Frozen Shoulder License
Agreement. </P>
<P align=justify>Our obligation to pay royalties to the Research Foundation with
respect to sales by us, our affiliates or any sublicensee of any Frozen Shoulder
Licensed Product in any country (including the U.S.) arises only upon the first
commercial sale of a Frozen Shoulder Licensed Product. Our obligation to pay
royalties to the Research Foundation will continue until, the later of (i) the
expiration of the last valid claim of a patent pertaining to a Frozen Shoulder
Licensed Product or (ii) June 3, 2016.</P>
<P align=justify>Unless terminated earlier in accordance with its termination
provisions, the Frozen Shoulder License Agreement and licenses granted under
that agreement will continue in effect until the termination of our royalty
obligations. After that, all licenses granted to us under the Frozen Shoulder
License Agreement will become fully paid, irrevocable exclusive licenses. </P>
<P align=justify>In connection with the execution of the Dupuytren&#146;s License
Agreement and the Frozen Shoulder License Agreement, we made certain up-front
payments to the Research Foundation and the clinical investigators working on
the Dupuytren&#146;s contracture and frozen shoulder indications for the Enzyme. </P>
<P align=justify><I>Other Indications </I></P>
<P align=justify>We have entered into certain other license and royalty
agreements with respect to other indications that we may elect to pursue.</P>
<P align=justify><B>COMPETITION </B></P>
<P align=justify>We and our licensees face worldwide competition from larger
pharmaceutical companies, specialty pharmaceutical companies and biotechnology
firms, universities and other research institutions and government agencies that
are developing and commercializing pharmaceutical products. Many of
our competitors have substantially greater financial, technical and human
resources than we have and may subsequently develop products that are more
effective, safer or less costly than any products that we have developed, are
developing or will develop, or that are generic products. Our success will
depend on our ability to acquire, develop and commercialize products and our
ability to establish and maintain markets for our products that receive
marketing approval.</P>
<P align=center>11 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_15></A>
<P align=justify><B>COST OF RESEARCH AND DEVELOPMENT ACTIVITIES</B> </P>
<P align=justify>During fiscal years 2010 and 2009, the Company invested
$1,223,931 and $488,646, respectively, in research and development
activities.</P>
<P align=justify><B>GOVERNMENT REGULATION </B></P>
<P align=justify>Any product labeled for use in humans require regulatory
approval by government agencies prior to commercialization. In particular, human
therapeutic products are subject to rigorous preclinical and clinical trials to
demonstrate safety and efficacy and other approval procedures of the FDA and
similar regulatory authorities in foreign countries. Various federal, state,
local, and foreign statutes and regulations also govern testing, manufacturing,
labeling, distribution, storage and record-keeping related to such products and
their promotion and marketing. The process of obtaining these approvals and the
compliance with federal, state, local, and foreign statutes and regulations
require the expenditure of substantial time and financial resources. In
addition, the current political environment and the current regulatory
environment at the FDA could lead to increased testing and data requirements
which could impact regulatory timelines and costs.</P>
<P align=justify>Clinical trials involve the administration of the
investigational product candidate or approved products to human subjects under
the supervision of qualified investigators. Clinical trials are conducted under
protocols detailing, among other things, the objectives of the study and the
parameters to be used in assessing the safety and the effectiveness of the drug.
Typically, clinical evaluation involves a time-consuming and costly three-phase
sequential process, but the phases may overlap. Each trial must be reviewed,
approved and conducted under the auspices of an independent institutional review
board, and each trial must include the patient&#146;s informed consent. </P>
<P align=justify>Clinical testing may not be completed successfully within any
specified time period, if at all. The FDA monitors the progress of all clinical
trials that are conducted in the U.S. and may, at its discretion, reevaluate,
alter, suspend or terminate the testing based upon the data accumulated to that
point and the FDA&#146;s assessment of the risk/benefit ratio to the patient. The FDA
can also provide specific guidance on the acceptability of protocol design for
clinical trials. The FDA, we or our partners may suspend or terminate clinical
trials at any time for various reasons, including a finding that the subjects or
patients are being exposed to an unacceptable health risk. The FDA can also
request that additional clinical trials be conducted as a condition to product
approval. During all clinical trials, physicians monitor the patients to
determine effectiveness and/or to observe and report any reactions or other
safety risks that may result from use of the drug candidate. <B></B></P>
<P align=justify>Assuming successful completion of the required clinical trials,
drug developers submit the results of preclinical studies and clinical trials,
together with other detailed information including information on the chemistry,
manufacture and control of the product, to the FDA, in the form of an NDA or
BLA, requesting approval to market the product for one or more indications. In
most cases, the NDA/BLA must be accompanied by a substantial user fee. The FDA
reviews an NDA/BLA to determine, among other things, whether a product is safe
and effective for its intended use.</P>
<P align=justify>Before approving an NDA or BLA, the FDA will inspect the
facility or facilities where the product is manufactured. The FDA will not
approve the NDA or BLA unless cGMP compliance is satisfactory. The FDA will
issue an approval letter if it determines that the NDA or BLA, manufacturing
process and manufacturing facilities are acceptable. If the FDA determines that
the NDA or BLA, manufacturing process or manufacturing facilities are not
acceptable, it will outline the deficiencies in the submission and will often
request additional testing or information. Notwithstanding the submission of any
requested additional information, the FDA ultimately may decide that the NDA or
BLA does not satisfy the regulatory criteria for approval and refuse to approve
the NDA or BLA by issuing a &#147;not approvable&#148; letter.</P>
<P align=center>12 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_16></A>
<P align=justify>The testing and approval process requires substantial time,
effort and financial resources, which may take several years to complete. The
FDA may not grant approval on a timely basis, or at all. We or our partners may
encounter difficulties or unanticipated costs in our or their efforts to
secure necessary governmental approvals, which could delay or preclude us or
them from marketing our products. Furthermore, the FDA may prevent a drug
developer from marketing a product under a label for its desired indications or
place other conditions, including restrictive labeling, on distribution as a
condition of any approvals, which may impair commercialization of the product.
After approval, some types of changes to the approved product, such as adding
new indications, manufacturing changes and additional labeling claims, are
subject to further FDA review and approval.</P>
<P align=justify>If the FDA approves the NDA or BLA, the drug can be marketed to
physicians to prescribe in the U.S. After approval, the drug developer must
comply with a number of post-approval requirements, including delivering
periodic reports to the FDA (i.e., annual reports), submitting descriptions of
any adverse reactions reported, biological product deviation reporting, and
complying with drug sampling and distribution requirements and any other
requirements set forth in the FDA&#146;s approval (such as the REMS program, which
the FDA has required for XIAFLEX and consists of a communication plan and a
medication guide). The holder of an approved NDA/BLA is required to provide
updated safety and efficacy information and to comply with requirements
concerning advertising and promotional labeling. Also, quality control and
manufacturing procedures must continue to conform to cGMP after approval. Drug
manufacturers and their subcontractors are required to register their facilities
and are subject to periodic unannounced inspections by the FDA to assess
compliance with cGMP which impose procedural and documentation requirements
relating to manufacturing, quality assurance and quality control. Accordingly,
manufacturers must continue to expend time, money and effort in the area of
production and quality control to maintain compliance with cGMP and other
regulatory requirements. The FDA may require post-market testing and
surveillance to monitor the product&#146;s safety or efficacy, including additional
studies to evaluate long-term effects.</P>
<P align=justify>In addition to studies requested by the FDA after approval, a
drug developer may conduct other trials and studies to explore use of the
approved drug for treatment of new indications, which require submission of a
supplemental or new NDA/BLA and FDA approval of the new labeling claims. The
purpose of these trials and studies is to broaden the application and use of the
drug and its acceptance in the medical community.</P>
<P align=justify>We use, and will continue to use, third party manufacturers to
produce our products in clinical quantities. Future FDA inspections may identify
compliance issues at our facilities, at the facilities of our contract
manufacturers or at those of our partners that may disrupt production or
distribution, or require substantial resources to correct. In addition,
discovery of problems with a product or the failure to comply with requirements
may result in restrictions on a product, manufacturer or holder of an approved
NDA/BLA, including withdrawal or recall of the product from the market or other
voluntary or FDA-initiated action that could delay further marketing. Newly
discovered or developed safety or effectiveness data may require changes to a
product&#146;s approved labeling, including the addition of new warnings and
contraindications. Also, new government requirements may be established that
could delay or prevent regulatory approval of our products under development.
</P>
<P align=justify><B>INTELLECTUAL PROPERTY AND RIGHTS </B></P>
<P align=justify>Our success will depend in part on our ability to protect our
existing products and the products we acquire or in-license by obtaining and
maintaining a strong proprietary position both in the U.S. and in other
countries. To develop and maintain such a position, we intend to continue
relying upon patent protection, trade secrets, know-how, continuing
technological innovations and licensing opportunities. In addition, we intend to
seek patent protection whenever available for any products or product candidates
and related technology we develop or acquire in the future.</P>
<P align=justify><I>Patents</I></P>
<P align=justify>We are the assignee or licensee of five U.S. patents, which
have received patent protection in various foreign countries. In addition, we
have licenses to other pending patent applications. Although we believe these
patent applications, if they issue as patents, will provide a competitive
advantage, the scope of the patent positions of pharmaceutical firms involves
complex legal, scientific and factual questions and, as such, is generally
uncertain. In addition, the coverage claimed in a patent application can be
significantly reduced before the patent is issued. Consequently, we do not know
whether any of our current patent applications, or the products or product
candidates we develop, acquire or license will result in the issuance of patents
or, if any patents are issued, whether they will provide significant proprietary
protection, will be of any value to us or will be challenged, circumvented or
invalidated by our competitors or otherwise.</P>
<P align=center>13 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_17></A>
<P align=justify>While we attempt to ensure that our product candidates and the
methods we employ to manufacture them do not infringe other parties&#146; patents and
proprietary rights, competitors or other parties may assert that we infringe on
their proprietary rights. Because patent applications in the U.S. and some other
jurisdictions can proceed in secrecy until patents issue, third parties may
obtain other patents without our knowledge prior to the issuance of patents
relating to our product candidates, which they could attempt to assert against
us. Also, since publication of discoveries in the scientific or patent
literature often lags behind actual discoveries, we cannot be certain of the
priority of inventions covered by pending patent applications. Moreover, we may
have to participate in interference proceedings declared by the USPTO or a
foreign patent office to determine priority of invention, or in opposition
proceedings in a foreign patent office, either of which could result in
substantial cost to us, even if the eventual outcome is favorable to us. There
can be no assurance that the patents, if issued and challenged in a court of
competent jurisdiction, would be found valid or enforceable. An adverse outcome
could subject us to significant liabilities to third parties, require disputed
rights to be licensed from third parties or require us to cease using such
technology. </P>
<P align=justify>Although we believe that our product candidates, production
methods and other activities do not currently infringe the intellectual property
rights of third parties, we cannot be certain that a third party will not
challenge our position in the future. If a third party alleges that we are
infringing its intellectual property rights, we may need to obtain a license
from that third party, but there can be no assurance that any such license will
be available on acceptable terms or at all. Any infringement claim that results
in litigation could result in substantial cost to us and the diversion of
management&#146;s attention from our core business. To enforce patents issued to us
or to determine the scope and validity of other parties&#146; proprietary rights, we
may also become involved in litigation or in interference proceedings declared
by the USPTO, which could result in substantial costs to us or an adverse
decision as to the priority of our inventions. We may be involved in
interference and/or opposition proceedings in the future. We believe there will
continue to be litigation in our industry regarding patent and other
intellectual property rights.</P>
<P align=justify>We licensed to Auxilium our injectable collagenase for the
treatment of Dupuytren&#146;s contracture, Peyronie&#146;s disease, and frozen shoulder.
We have two use patents in the U.S. covering the enzyme underlying our
injectable collagenase, one for the treatment of Dupuytren&#146;s contracture, which
issued from a reissue proceeding in December 2007, and one for the treatment of
Peyronie&#146;s disease. The Dupuytren&#146;s patent expires in 2014, and the Peyronie&#146;s
patent expires in 2019. Both the Dupuytren&#146;s and Peyronie&#146;s patents are limited
to the use of the enzyme for the treatment of Dupuytren&#146;s contracture and
Peyronie&#146;s disease within certain dose ranges. An application to extend the term
of the Dupytren&#146;s patent to August 22, 2019 based upon regulatory delay in
granting approval to sell XIAFLEX was filed in the USPTO on April 1, 2010. The
USPTO has not taken any action on the request for extension, and we cannot be
certain how much of an extension, if any, will be granted by the USPTO. In
October 2010, Auxilium was granted a patent entitled &#147;Compositions and Methods
for Treating Collagen Mediated Diseases,&#148; which will extend the royalty payments
until July 12, 2028. We have filed an application in the USPTO asserting that
the inventors named on that patent should also include inventors who have
assigned their rights to us, and thus we should be co-owners of the patent.
Auxilium has disputed that assertion. An interference might be necessary to
resolve the issue. An interference has yet to be requested, and if requested, we
cannot be certain whether the USPTO would declare an interference, and if
declared, whether we would prevail.<B> </B></P>
<P align=justify><I>Orphan Drug Designations </I></P>
<P align=justify>Two indications, Dupuytren&#146;s contracture and Peyronie&#146;s
disease, have received orphan drug designation from the OOPD. These indications
did not receive the European equivalent of orphan drug designation. </P>
<P align=justify>The OOPD administers the major provisions of the Orphan Drug
Act, an innovative program that provides incentives for sponsors to develop
products for rare diseases. <B></B>The incentives for products that qualify
under the Orphan Drug Act include seven-year exclusive marketing rights post FDA
approval (which means, with respect to Dupuytren&#146;s contracture, exclusivity
until February 2, 2017), tax credits for expenses associated with clinical
trials including a 20 year tax carry-forward, availability of FDA grants, and
advice on design of the clinical development plan. </P>
<P align=justify>The orphan drug provisions of the Federal Food, Drug, and
Cosmetic Act also provide incentives to drug and biologics suppliers to develop
and supply drugs for the treatment of rare diseases, currently defined as
diseases that affect fewer than 200,000 individuals in the U.S. or, for a
disease that affects more than 200,000 individuals in the U.S. and for which
there is no reasonable expectation that the cost of developing and making
available in the U.S. a drug for such disease or condition will be recovered from its
sales in the U.S. Under these provisions, a supplier of a designated orphan
product can seek tax benefits, and the holder of the first FDA approval of a
designated orphan product will be granted a seven-year period of marketing
exclusivity for that product for the orphan indication. It would not prevent
other drugs from being approved for the same indication.</P>
<P align=center>14 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_18></A>
<P align=justify>In the Auxilium 10-K, Auxilium stated that &#147;[w]hile XIAFLEX
does not have orphan drug status for any indication in Europe, foreign patents
cover these products in certain countries, and on approval of XIAFLEX for a
first indication in Europe, we expect the product will benefit from 10 years of
market exclusivity and 8 years of data exclusivity. We may obtain an additional
year of market exclusivity if the regulatory authorities approve an additional
indication that they determine to represent a significant clinical benefit.&#148; Our
royalty term, however, is not extended by any period of marketing exclusivity as
contrasted with any period of orphan drug status or foreign equivalent
thereof.</P>
<P align=justify><I>Trade Secrets </I></P>
<P align=justify>We also rely on trade secret protection for our confidential
and proprietary information. No assurance can be given that others will not
independently develop substantially equivalent proprietary information and
techniques or otherwise gain access to our trade secrets or disclose such
technology or that we can meaningfully protect our trade secrets.</P>
<P align=justify>It is our policy to require certain employees, consultants,
outside scientific collaborators, sponsored researchers and other advisors to
execute confidentiality agreements upon the commencement of employment or
consulting relationships with us. These agreements provide that all confidential
information developed or made known to the individual during the course of the
individual&#146;s relationship with us is to be kept confidential and not disclosed
to third parties except in specific circumstances. In the case of employees, the
agreements provide that all inventions conceived by the individual shall be our
exclusive property. There can be no assurance, however, that these agreements
will provide meaningful protection or adequate remedies for our trade secrets in
the event of unauthorized use or disclosure of such information. </P>
<P align=justify><B>EMPLOYEES </B></P>
<P align=justify>The Company currently has five employees, who are all full-time
employees.<B> </B></P>
<P align=justify><B>CORPORATE INFORMATION </B></P>
<P align=justify>BioSpecifics Technologies Corp. was incorporated in Delaware in
1990. ABC-NY was incorporated in New York in 1957. Our telephone number is
516-593-7000. Our corporate headquarters are currently located at 35 Wilbur St.,
Lynbrook, NY 11563, as further described in this Report under &#147;Item 2 -
Description of Property&#148;.<B> </B></P>
<P align=justify><B>Item 1A. </B><B>RISK FACTORS </B></P>
<P align=justify>In addition to the other information included in this Report,
the following factors should be considered in evaluating our business and future
prospects. Any of the following risks, either alone or taken together, could
materially and adversely affect our business, financial position or results of
operations. If one or more of these or other risks or uncertainties materialize
or if our underlying assumptions prove to be incorrect, our actual results may
vary materially from what we projected. There may be additional risks that we do
not presently know or that we currently believe are immaterial which could also
impair our business or financial position. </P>
<P align=justify><B><I>Risks Related to Our Limited Sources of Revenue
</I></B></P>
<P align=justify><B>Our future revenue is primarily dependent upon option,
milestone and contingent royalty payments from Auxilium and contingent earn out
payments from DFB. </B></P>
<P align=justify>Our primary sources of revenues are from (i) option, milestone
and contingent royalty<B> </B>payments from Auxilium under the Auxilium
Agreement, (ii) contingent earn out payments from DFB and (iii) the sale of
small amounts of collagenase for laboratory research.<B> </B></P>
<P align=center>15 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_19></A>
<P align=justify>As described in Item 1 above, under the Auxilium Agreement, in
exchange for the right to receive royalties and other payments, we granted to
Auxilium the right to develop, manufacture, market and sell worldwide products
(other than dermal formulations for topical administration) that contain
collagenase for the treatment of Dupuytren&#146;s contracture, Peyronie&#146;s disease and
frozen shoulder. However, we have no control over Auxilium&#146;s ability to
successfully manufacture, market and sell candidate products for the treatment
of Dupuytren&#146;s contracture, or, in the case of Peyronie&#146;s disease and frozen
shoulder, to pursue commercialization, and we may receive limited, if any,
royalty payments from Auxilium. In the Auxilium 10-K, Auxilium included as a
risk factor to its ability to successfully launch and commercialize XIAFLEX for
Dupuytren&#146;s contracture additional challenges with regard to reimbursement
&#147;including:</P>
<UL>
  <LI>
  <p style="margin-bottom: 12">unless and until a XIAFLEX-specific CPT (procedure) code is announced, the
  variability of reimbursement rates likely to be caused by the use of
  miscellaneous procedure codes may discourage physicians from providing XIAFLEX
  to certain or all patients depending on their insurance coverage;
  <LI>
  <p style="margin-bottom: 12">payor and physician confusion surrounding appropriate procedure codes to
  bill for the administration and follow up procedure related to XIAFLEX until
  such time as XIAFLEX-specific drug codes are approved could result in slow
  claims processing times and/or insufficient reimbursement to physicians and
  discourage physician use;
  <LI>
  <p style="margin-bottom: 12">physicians may have, or may believe they have, an economic incentive to
  perform Dupuytren&#146;s surgery and therefore discourage XIAFLEX use;
  <LI>
  <p style="margin-bottom: 12">continued downward pressure on reimbursement rates for services and for
  products administered incident to a physician&#146;s service may discourage uptake
  or continued usage;
  <LI>
  <p style="margin-bottom: 12">physicians may decide that managing specialty biologics such as XIAFLEX in
  their practices, including all of the requirement of the . . . REMS, is too
  complex and cumbersome for them to undertake or continue;
  <LI>
  <p style="margin-bottom: 12">an increase in insurance plans that place more of a cost share liability
  onto patients may limit patients willingness to pay for XIAFLEX and thereby
  discourage uptake;
  <LI>
  <p style="margin-bottom: 12">unforeseen changes in federal health care policy guidelines may negatively
  impact a physician practice&#146;s willingness to provide novel treatments; and
  <LI>inability, difficulty or delay in obtaining XIAFLEX-specific procedure
  billing codes resulting in underutilization.&#148; </LI></UL>
<P align=justify>In addition, there is no guarantee that a XIAFLEX-specific CPT
code will meet the expectations of physicians or significantly or quickly
increase sales of XIAFLEX. Moreover, royalty payments from Auxilium are subject
to set-off for certain expenses we owe Auxilium under the Auxilium Agreement
relating to certain development and patent costs. As a result of Auxilium&#146;s set
off of such costs, we did not receive any royalty payments from Auxilium in
2010. We have received in the past, and are entitled to receive in the future,
certain milestone payments from Auxilium in respect of its efforts to
commercialize such candidate products, but we have no control over Auxilium&#146;s
ability to achieve the milestones. Additionally, we have received in the past,
and are entitled to receive in the future, 8.5% of all sublicense income that
Auxilium receives from Pfizer under the Pfizer Agreement, which payments are
dependent on the achievement by Pfizer of certain regulatory and sales related
milestones, of which we have no control.</P>
<P align=justify>We have also granted to Auxilium an option to expand its
license and development rights to one or more additional indications for
injectable collagenase not currently licensed to Auxilium, including for the
treatment of human and canine lipoma and cellulite. If Auxilium exercises its
option with respect to an additional indication, we are entitled to receive a
one-time license fee for the rights to, as well as potential milestone, royalty
and other payments with respect to, such new indication. If Auxilium does not
exercise its option as to any additional indication, we may offer to any third
party such development rights with regard to products in the Auxilium Territory,
provided that we first offer the same terms to Auxilium, or develop the product
ourselves.<B> </B>Auxilium has no obligation to exercise its option with respect
to any such additional indication, and its decision to do so is in its complete
discretion. Clinical trials can be expensive and the results are subject to different
interpretations, therefore, there is no assurance that after conducting Phase II
clinical trials on any additional indication, and incurring the associated
expenses, Auxilium will exercise its option or we will receive any revenue from
it. Under the Auxilium Agreement, we may only offer to a third party development
rights with regard to products in the Auxilium Territory and not in the Pfizer
Territory. Auxilium&#146;s ability to develop or commercialize additional indications
in the Pfizer Territory are subject to negotiation with Pfizer under the terms
of the Pfizer Agreement. Even if Auxilium exercises its option as to any
additional indication, its obligations to develop the product for such
indication are limited to initiating Stage II Development (as defined in the
Auxilium Agreement) for such additional indication within one year of exercising
the option as to such indication. In the case of frozen shoulder, for example,
Auxilium exercised its option in 2005, but development has not progressed beyond
Stage II Development. </P>
<P align=center>16 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_20></A>
<P align=justify>As part of the sale of our topical collagenase business to DFB,
we are entitled to receive earn out payments in respect of sales of certain
products developed and manufactured by DFB that contain collagenase for topical
administration. However, our right to receive earn out payments from DFB is
dependent upon DFB&#146;s decision to pursue the manufacture and commercialization of
such products and its ability to achieve certain sales thresholds. We are aware
that DFB has certain competitive products that may adversely affect the volume
of sales of those topical collagenase products for which we are entitled to earn
out payments. </P>
<P align=justify>We also agreed to provide technical assistance to DFB&#146;s
affiliate, DPT Lakewood, for a fixed period of time in consideration for certain
payments and we are required to maintain certain scientific resources and
records in order to provide such assistance and be entitled to receive such
payments. These obligations expire during March 2011. </P>
<P align=justify><B>Our dependence upon revenue from Auxilium and DFB make us
subject to the commercialization and other risk factors affecting those two
companies over which we have limited or no control.</B></P>
<P align=justify>Auxilium has disclosed in its securities filings a number of
risk factors to consider when evaluating its business and future prospects.
Given our dependence upon revenue from Auxilium, Auxilium&#146;s operating success or
failure has a significant impact on our potential royalty stream and other
payment rights. As such, we refer you to the full text of Auxilium&#146;s disclosed
risk factors in its securities filings, which were most recently included in the
Auxilium 10-K.</P>
<P align=justify>DFB is not a publicly traded company and therefore we have
little information about its business and future prospects. Although we cannot
be certain, we presume that many of the risk factors affecting Auxilium&#146;s
business may have some bearing in evaluating DFB&#146;s ability to generate
sufficient sales of topical collagenase products to entitle us to receive any
earn out payments.</P>
<P align=justify><B>If we are unable to obtain option, milestone, earn out and
royalty payments from Auxilium or DFB or meet our needs for additional funding
from other sources, we may be required to limit, scale back or cease our
operations. </B></P>
<P align=justify>Our business strategy contains elements that we will not be
able to implement if we do not receive the anticipated option, milestone,
royalty or earn out payments from Auxilium or DFB, or secure additional funding
from other sources. We believe that our existing cash resources and interest on
these funds will be sufficient to meet our anticipated operating requirements
until at least the second half of 2012. Our future funding requirements will
depend on many factors, including:</P>
<UL>
  <LI>
  <p style="margin-bottom: 12" align="justify">DFB&#146;s ability to meet its payment obligations and to manufacture and
  commercialize topical collagenase products for which we would receive earn out
  payments until June 2013, when DFB&#146;s obligations to us terminate, absent the
  introduction of a second generation product as defined in the DFB Agreement;
  <LI>
  <p style="margin-bottom: 12" align="justify">Auxilium&#146;s ability to manufacture and commercialize XIAFLEX for which we
  would receive milestone and royalty payments;
  <LI>
  <p align="justify">Pfizer&#146;s ability to develop and commercialize the product in the Pfizer
  Territory and Auxilium&#146;s receipt of milestone payments from Pfizer under the
  Pfizer Agreement for which we would receive a percentage of sublicense income
  and royalty payments (for more information regarding Auxilium&#146;s financial
  risks associated with Pfizer under the Pfizer Agreement, we refer you to the
  full text of Auxilium&#146;s disclosed risk factors in its securities filings, which were most recently included in
  the Auxilium 10-K); </LI></UL>
<P align=center>17 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_21></A>
<UL>
  <LI>
  <p style="margin-bottom: 12" align="justify">the amount actually owed to Auxilium for certain development and patent
  costs;
  <LI>
  <p style="margin-bottom: 12" align="justify">the outcome of the litigation with Auxilium concerning our right to
  conduct clinical trials without the approval of the companies&#146; Joint
  Development Committee controlled by Auxilium;
  <LI>
  <p style="margin-bottom: 12" align="justify">the scope, rate of progress, cost and results of our clinical trials on
  additional indications, including human and canine lipoma and cellulite, for
  which Auxilium could exercise its option to acquire rights to them, and
  whether Auxilium exercises the option;
  <LI>
  <p style="margin-bottom: 12" align="justify">the terms and timing of any future collaborative, licensing, co-promotion
  and other arrangements that we may establish; and
  <LI>
  <p align="justify">the cost of filing, prosecuting, defending and enforcing any patent claims
  and other intellectual property rights or defending against any other
  litigation. </LI></UL>
<P align=justify>These factors could result in variations from our currently
projected operating requirements. If our existing resources are insufficient to
satisfy our operating requirements, we may need to limit, scale back or cease
operations or, in the alternative, borrow money. Given our operations and
history, we may not be able to borrow money on commercially reasonable terms, if
at all. If we issue any equity or debt securities, the terms of such issuance
may not be acceptable to us and would likely result in substantial dilution of
our stockholders&#146; investment. If we do not receive revenues from Auxilium or
DFB, and are unable to secure additional financing, we may be required to cease
operations. </P>
<P align=justify><B>In order to finance and to secure the rights to conduct
clinical trials for products we have licensed to Auxilium, we have granted to
third parties significant rights to share in royalty payments received by us.
</B></P>
<P align=justify>To finance and secure the rights to conduct clinical trials for
products we have licensed to Auxilium, we have granted to third parties certain
rights to share in royalty payments received by us from Auxilium under the
Auxilium Agreement. Consequently, we will be required to share a significant
portion of the payments due from Auxilium under the Auxilium Agreement.</P>
<P align=justify><B>If we breach our agreements with third parties, our business
could be materially harmed. </B></P>
<P align=justify>Our agreements with third parties impose on us various
obligations, such as those related to intellectual property rights,
non-competition, and development of products, as described throughout this Item
1A of this Report. If we fail to comply with such obligations, or a counterparty
to our agreements believes that we have failed to comply with such obligations,
we may be sued and the costs of the resulting litigation could materially harm
our business. </P>
<P align=justify><B><I>Risks Related to Clinical Trials</I></B></P>
<P align=justify><B>Our ability to conduct clinical trials may be limited by the
Auxilium Agreement.</B> </P>
<P align=justify>We have voluntarily agreed to suspend Chien-803, our clinical
trial testing the use of injectable collagenase in canine lipoma, and will not
be initiating any new trials using injectable collagenase in animals or humans
pending a resolution of our dispute with Auxilium concerning our right to
conduct clinical trials without the prior approval of the companies&#146; Joint
Development Committee. On February 15, 2011, Auxilium filed a complaint against
us in the Court of Common Pleas in Chester County, Pennsylvania. The complaint
seeks declaratory and injunctive relief, but not monetary damages. The dispute
has been sealed pending further order of the court. The outcome of the dispute
will have no effect on the amounts due to us from Auxilium for exercised
indications (Dupuytren&#146;s contracture, Peyronie&#146;s disease and Frozen Shoulder).
However, if the court rules in a manner that is detrimental to our interests or
interprets our agreement with Auxilium in a way that limits the scope of our
rights under that agreement, we may be precluded from pursuing additional
indications and, if Auxilium does not pursue such additional indications, we may
also be precluded from the opportunity to receive from Auxilium license fees for
the rights to, as well as potential milestone, royalty and other payments with
respect to, such additional indications. </P>
<P align=center>18 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_22></A>
<P align=justify><B>We have a limited supply of our own clinical material, which
may limit our ability to conduct other clinical trials and to obtain the
associated option, milestone and contingent royalty payments under the Auxilium
Agreement.</B></P>
<P align=justify>Although we currently have our own clinical material, if this
clinical material is damaged or otherwise becomes unusable because of improper
testing, storage or otherwise, then we may have insufficient clinical material
to conduct other clinical trials unless we make new material, which would entail
time and expense and delay the initiation of new clinical trials. Consequently,
the lack of availability of our own clinical material may limit our ability to
conduct other clinical trials and to obtain additional option, milestone and
royalty payments under the Auxilium Agreement.<B> </B></P>
<P align=justify><B>We may have limited access to XIAFLEX under the Auxilium
Agreement, which may limit our ability to conduct other clinical trials and to
obtain the associated option, milestone and contingent royalty payments under
the Auxilium Agreement.</B></P>
<P align=justify>Under the Auxilium Agreement, Auxilium has agreed to sell us,
at cost, XIAFLEX for pre-clinical and clinical trials approved by the joint
development committee and such other non-preclinical and non-clinical purposes
as are consistent with our rights under this Agreement. However, there is no
guaranty that Auxilium will do so. If Auxilium does not supply XIAFLEX to us
directly, we may have limited ability to acquire it through other means.
Consequently, the lack of availability of XIAFLEX may limit our ability to
conduct other clinical trials and to obtain additional option, milestone and
royalty payments under the Auxilium Agreement.</P>
<P align=justify><B>If clinical trials in humans or veterinarian trials for our
potential new indications are delayed, we may not be able to obtain option,
milestone or royalty payments under the Auxilium Agreement for new indications.
</B></P>
<P align=justify>Clinical trials that we or our investigators may conduct may
not begin on time or may need to be restructured or temporarily suspended after
they have begun. Clinical trials can be delayed or may need to be restructured
for a variety of reasons, including delays or restructuring related to: </P>
<UL>
  <LI>
  <p align="justify" style="margin-bottom: 12">changes to the regulatory approval process for product candidates;
  <LI>
  <p align="justify" style="margin-bottom: 12">obtaining regulatory approval to commence a clinical trial;
  <LI>
  <p align="justify" style="margin-bottom: 12">timing of responses required from regulatory authorities;
  <LI>
  <p align="justify" style="margin-bottom: 12">negotiating acceptable clinical trial agreement terms with prospective
  investigators or trial sites;
  <LI>
  <p align="justify" style="margin-bottom: 12">obtaining institutional review board, or equivalent, approval to conduct a
  clinical trial at a prospective site;
  <LI>
  <p align="justify" style="margin-bottom: 12">recruiting subjects to participate in a clinical trial;
  <LI>
  <p align="justify" style="margin-bottom: 12">competition in recruiting clinical investigators;
  <LI>
  <p align="justify" style="margin-bottom: 12">shortage or lack of availability of clinical trial supplies from external
  and internal sources;
  <LI>
  <p align="justify" style="margin-bottom: 12">the need to repeat clinical trials as a result of inconclusive results or
  poorly executed testing;
  <LI>
  <p align="justify" style="margin-bottom: 12">failure to validate a patient-reported outcome questionnaire;
  <LI>
  <p align="justify" style="margin-bottom: 12">the placement of a clinical hold on a study;
  <LI>
  <p align="justify" style="margin-bottom: 12">the failure of third parties conducting and overseeing the operations of
  our clinical trials to perform their contractual or regulatory obligations in
  a timely fashion; and
  <LI>
  <p align="justify">exposure of clinical trial subjects to unexpected and unacceptable health
  risks or noncompliance with regulatory requirements, which may result in
  suspension of the trial. </LI></UL>
<P align=justify><B>The process of conducting clinical trials and developing
product candidates involves a high degree of risk and may take several years,
and may ultimately not be successful. </B></P>
<P align=justify>Product candidates that appear promising in the early phases of
development may fail to reach the market for several reasons, including:</P>
<P align=center>19 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_23></A>
<UL>
  <LI>
  <p style="margin-bottom: 12">clinical trials may show product candidates to be ineffective or not as
  effective as anticipated or to have harmful side effects or any unforeseen
  result;
  <LI>
  <p style="margin-bottom: 12">product candidates may fail to receive regulatory approvals required to
  bring the products to market;
  <LI>
  <p style="margin-bottom: 12">manufacturing costs, the inability to scale up to produce supplies for
  clinical trials or other factors may make our product candidates uneconomical;
  and
  <LI>the proprietary rights of others and their competing products and
  technologies may prevent product candidates from being effectively
  commercialized or from obtaining exclusivity. </LI></UL>
<P align=justify>Success in preclinical and early clinical trials does not
ensure that large-scale clinical trials will be successful. Clinical results are
frequently susceptible to varying interpretations that may delay, limit or
prevent regulatory approvals. The length of time necessary to complete clinical
trials and to submit an application for marketing approval for a final decision
by a regulatory authority varies significantly and may be difficult to predict.
Any changes to the U.S. regulatory approval process could significantly increase
the timing or cost of regulatory approval for product candidates making further
development uneconomical or impossible. In addition, once Auxilium exercises its
option with respect to any additional indications, further clinical trials,
development, manufacturing, marketing and selling of such product is out of our
control. Our interest is limited to receiving option, milestone and royalty
payments, and the option in certain circumstances to manufacture according to
particular specifications set by Auxilium. </P>
<P align=justify><B><I>Risks Related to Our Agreements with Auxilium and DFB
</I></B><I></I></P>
<P align=justify><B>Our ability to conduct clinical trials and develop products
for injectable administration of collagenase is limited by the Auxilium
Agreement. </B></P>
<P align=justify>Under the Auxilium Agreement, we have licensed or granted
options to certain of our rights to conduct clinical trials and develop products
for injectable administration of collagenase. We agreed, for example, to certain
non-competition provisions, which may limit our clinical development
activities.</P>
<P align=justify><B>Our ability to conduct clinical trials and develop products
for topical administration of collagenase is limited by the agreement we have
signed with DFB. </B></P>
<P align=justify>Under the DFB Agreement, we have sold, licensed, or granted
options to certain of our rights to conduct clinical trials and develop products
for topical administration of collagenase. Under the terms of the DFB Agreement,
we have agreed to certain non-competition provisions, which may limit our
clinical development activities.<B> </B></P>
<P align=justify><B><I>Risks Related to Regulatory Requirements </I></B></P>
<P align=justify><B>We are subject to numerous complex regulatory requirements
and failure to comply with these regulations, or the cost of compliance with
these regulations, may harm our business. </B></P>
<P align=justify>Conducting clinical trials for human drugs and, in certain
circumstances, veterinarian trials for animal drugs, and the testing,
development and manufacturing and distribution of product candidates are subject
to regulation by numerous governmental authorities in the U.S. and other
jurisdictions, if we desire to export the resulting products to such other
jurisdictions. These regulations govern or affect the testing, manufacture,
safety, labeling, storage, record-keeping, approval, distribution, advertising
and promotion of product candidates, as well as safe working conditions.
Noncompliance with any applicable regulatory requirements can result in
suspension or termination of any ongoing clinical trials of a product candidate
or refusal of the government to approve a product candidate for
commercialization, criminal prosecution and fines, recall or seizure of
products, total or partial suspension of production, prohibitions or limitations
on the commercial sale of products or refusal to allow the entering into of
federal and state supply contracts. The FDA and comparable governmental
authorities have the authority to suspend or terminate any ongoing clinical
trials of a product candidate or withdraw product approvals that have been
previously granted. Even after a product candidate has been approved, the FDA
and comparable governmental authorities subject such product to continuing
review and regulatory requirements including, for example, requiring the
conducting and reporting of the results of certain clinical studies or trials
and commitments to voluntarily conduct additional clinical trials. In addition,
regulatory approval could impose limitations on the indicated or intended uses
for which product candidates may be marketed. With respect to its approval of
XIAFLEX for the treatment of adult Dupuytren&#146;s contracture patients with a
palpable cord, for example, the FDA has required a REMS program consisting of a
communication plan and a medication guide. Currently, there is a substantial
amount of congressional and administrative review of the FDA and the regulatory
approval process for drug candidates in the U.S. As a result, there may be
significant changes made to the regulatory approval process in the U.S. In
addition, the regulatory requirements relating to the development,
manufacturing, testing, promotion, marketing and distribution of product
candidates may change in the U.S. Such changes may increase our costs and
adversely affect our operations. </P>
<P align=center>20 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_24></A>
<P align=justify>Additionally, failure to comply with, or changes to applicable
regulatory requirements may result in a variety of consequences, including the
following:</P>
<UL>
  <LI>
  <p style="margin-bottom: 12">restrictions on our products or manufacturing processes;
  <LI>
  <p style="margin-bottom: 12">warning letters;
  <LI>
  <p style="margin-bottom: 12">withdrawal of a product from the market;
  <LI>
  <p style="margin-bottom: 12">voluntary or mandatory recall of a product;
  <LI>
  <p style="margin-bottom: 12">fines;
  <LI>
  <p style="margin-bottom: 12">suspension or withdrawal of regulatory approvals for a product;
  <LI>
  <p style="margin-bottom: 12">refusal to permit the import or export of our products;
  <LI>
  <p style="margin-bottom: 12">refusal to approve pending applications or supplements to approved
  applications that we submit;
  <LI>
  <p style="margin-bottom: 12">denial of permission to file an application or supplement in a
  jurisdiction;
  <LI>
  <p style="margin-bottom: 12">product seizure; and
  <LI>injunctions or the imposition of civil or criminal penalties against us.
  </LI></UL>
<P align=justify><B>Our corporate compliance program cannot guarantee that we
are in compliance with all potentially applicable laws and regulations and we
have incurred and will continue to incur costs relating to compliance with
applicable laws and regulations. </B></P>
<P align=justify>We are a small company and we rely heavily on third parties and
outside consultants to conduct many important functions. As a biopharmaceutical
company, we are subject to a large body of legal and regulatory requirements. In
addition, as a publicly traded company we are subject to significant
regulations, including the Sarbanes-Oxley Act of 2002 (&#147;SOX&#148;), some of which
have only recently been revised or adopted. We cannot assure you that we are or
will be in compliance with all potentially applicable laws and regulations.
Failure to comply with all potentially applicable laws and regulations could
lead to the imposition of fines, cause the value of our common stock to decline,
impede our ability to raise capital or list our securities on certain securities
exchanges. New rules could make it more difficult or more costly for us to
obtain certain types of insurance, including director and officer liability
insurance, and we may be forced to accept reduced policy limits and coverage or
incur substantially higher costs to obtain the same or similar coverage. The
impact of these events could also make it more difficult for us to attract and
retain qualified persons to serve on our board of directors, our board
committees and as executive officers. We cannot predict or estimate the amount
of the additional costs we may incur or the timing of such costs to comply with
these rules and regulations.</P>
<P align=justify><B>We may fail to maintain effective internal controls over
external financial reporting or such controls may fail or be
circumvented.</B></P>
<P align=justify>SOX requires us to report annually on our internal controls
over financial reporting, and our business and financial results could be
adversely effected if we, or our independent registered public accounting firm,
determine that these controls are not effective. In addition, any failure or
circumvention of our internal controls and procedures or failure to comply with regulations concerning controls and procedures
could have a material effect on our business, results of operation and financial
condition. The impact of these events could also make it more difficult for us
to attract and retain qualified persons to serve on our board of directors, our
board committees and as executive officers.</P>
<P align=center>21 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_25></A>
<P align=justify><B><I>Risks Related to Growth and Employees </I></B></P>
<P align=justify><B>Adverse events or lack of efficacy in clinical trials may
force us and/or our partners upon whom we are wholly dependent to stop
development of our product candidates or prevent regulatory approval of our
product candidates or significant safety issues could arise after regulatory
approval of our products, any of which could materially harm our business.
</B></P>
<P align=justify>The prescribing information for XIAFLEX for Dupuytren&#146;s
contracture made available by Auxilium lists &#147;tendon ruptures or other serious
injury to the injected extremity&#148; as a reported serious adverse reaction to
XIAFLEX and states that the most frequently reported adverse drug reactions in
XIAFLEX clinical trials included swelling of the injected hand, contusion,
injection site reaction, injection site hemorrhage, and pain in the treated
extremity. The prescribing information notes that adverse reaction rates
observed in clinical trials of a drug may not reflect those observed in practice
because such trials &#147;are conducted under widely varying conditions.&#148; </P>
<P align=justify>Auxilium reported in the Auxilium 10-K that the most common
adverse events in the Peyronie&#146;s phase IIb clinical trial were &#147;injection site
bruising, injection site pain, injection site edema, contusion, penile edema and
penile pain.&#148;</P>
<P align=justify>Adverse events or lack of efficacy may force us to stop
development of our product candidates or prevent regulatory approval of our
product candidates, which could materially harm our business. In addition, any
adverse events or lack of efficacy may force Auxilium to stop development of the
products we have licensed to it or prevent regulatory approval of such products,
which could materially impair all or a material part of the future revenue we
hope to receive from Auxilium. Even if our product candidates receive regulatory
approval, new safety issues may be reported and we or our partners may be
required to amend the conditions of use for a product.<B> </B></P>
<P align=justify><B>We and our licensees face competition in our product
development efforts from pharmaceutical and biotechnology companies,
universities and other not-for-profit institutions. </B></P>
<P align=justify>We and our licensees face competition in our product
development from entities that have substantially greater research and product
development capabilities and greater financial, scientific, marketing and human
resources. These entities include pharmaceutical and biotechnology companies, as
well as universities and not-for-profit institutions. Our and our licensees&#146;
competitors may succeed in developing products or intellectual property earlier
than we or our licensees do, entering into successful collaborations before us
or our licensees, obtaining approvals from the FDA or other regulatory agencies
for such products before us or our licensees, or developing products that are
more effective than those we or our licensees could develop. The success of any
one competitor in these or other respects will have a material adverse effect on
our business, our ability to receive option payments from Auxilium or ability to
generate revenues from third party arrangements with respect to additional
indications for which Auxilium does not exercise its option. <B></B></P>
<P align=justify><B>Because of the specialized nature of our business, the
termination of relationships with key management, consulting and scientific
personnel or the inability to recruit and retain additional personnel could
prevent us from developing our technologies, conducting clinical trials and
obtaining financing.</B><B><I> </I></B></P>
<P align=justify>The competition for qualified personnel in the biotechnology
field is intense, and we rely heavily on our ability to attract and contract
with qualified independent scientific and medical investigators, and technical
and managerial personnel. We face intense competition for qualified individuals
from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as
well as academic and other research institutions. To the extent we are unable to
attract and retain any of these individuals on favorable terms our business may
be adversely affected.</P>
<P align=justify><B>If product liability lawsuits are brought against us, we may
incur substantial liabilities. </B></P>
<P align=justify>We continue to have product liability exposure for topical
product sold by us prior to the sale of our topical business to DFB. In
addition, under the Auxilium Agreement, we are obligated to indemnify Auxilium
and its affiliates for any harm or losses they suffered relating to any personal
injury and other product liability resulting from our development, manufacture
or commercialization of any injectable collagenase product. In addition, the
clinical testing and, if approved, commercialization of our product candidates involves
significant exposure to product liability claims. We have clinical trial and
product liability insurance in the aggregate amount of $5 million dollars that
we believe is adequate in both scope and amount and has been placed with what we
believe are reputable insurers. We may not be able to maintain our clinical
trial and product liability insurance at an acceptable cost, if at all, and this
insurance may not provide adequate coverage against potential claims or losses.
If losses from product liability claims exceed our insurance coverage, we may
incur substantial liabilities that exceed our financial resources, and our
business and results of operations may be harmed. Whether or not we are
ultimately successful in product liability litigation, such litigation could
consume substantial amounts of our financial and managerial resources, and might
result in adverse publicity, all of which could impair our business.</P>
<P align=center>22 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_26></A>
<P align=justify><B>If we are unable to negotiate a new lease for our corporate
headquarters or relocate, our existing operations and our operating results
could be adversely affected. </B></P>
<P align=justify>As described in this Report under &#147;Item 2 - Description of
Property&#148;, we notified our landlord of our termination of our existing lease
effective March 31, 2011. If we are unable to negotiate a new lease for our
current premises or relocate to other premises, our existing operations and
operating results could be adversely affected. </P>
<P align=justify><B><I>Risks Related to Intellectual Property Rights
</I></B></P>
<P align=justify><B>If we breach any of the agreements under which we license
rights to products or technology from others, we could lose license rights that
are critical to our business and our business could be harmed. </B></P>
<P align=justify>We are a party to a number of license agreements by which we
have acquired rights to use the intellectual property of third parties that are
necessary for us to operate our business. If any of the parties terminates its
agreement, whether by its terms or due to our breach, our right to use the
party&#146;s intellectual property may negatively affect our licenses to Auxilium or
DFB and, in turn, their obligation to make option, milestone, contingent royalty
or other payments to us.</P>
<P align=justify><B>Our ability and the ability of our licensors, licensees and
collaborators to develop and license products based on our patents may be
impaired by the intellectual property of third parties.</B></P>
<P align=justify>Auxilium&#146;s, DFB&#146;s and our commercial success in developing and
manufacturing collagenase products based on our patents is dependent on these
products not infringing the patents or proprietary rights of third parties.
While we currently believe that we, our licensees, licensors and collaborators
have freedom to operate in the collagenase market, others may challenge that
position in the future. There has been, and we believe that there will continue
to be, significant litigation in the pharmaceutical industry regarding patent
and other intellectual property rights.</P>
<P align=justify>Third parties could bring legal actions against us, our
licensees, licensors or collaborators claiming damages and seeking to enjoin
clinical testing, manufacturing and marketing of the affected product or
products. A third party might request a court to rule that the patents we
in-licensed or licensed to others, or those we may in-license in the future, are
invalid or unenforceable. In such a case, even if the validity or enforceability
of those patents were upheld, a court might hold that the third party&#146;s actions
do not infringe the patent we in-license or license to others, which could, in
effect, limit the scope of our patent rights and those of our licensees,
licensors or collaborators. Our agreements with Auxilium and DFB require us to
indemnify them against any claims for infringement based on the use of our
technology. If we become involved in any litigation, it could consume a
substantial portion of our resources, regardless of the outcome of the
litigation. If Auxilium or DFB becomes involved in such litigation, it could
also consume a substantial portion of their resources, regardless of the outcome
of the litigation, thereby jeopardizing their ability to commercialize candidate
products and/or their ability to make option, milestone or royalty payments to
us. If any of these actions is successful, in addition to any potential
liability for damages, we could be required to obtain a license to permit
ourselves, our licensees, licensors or our collaborators to conduct clinical
trials, manufacture or market the affected product, in which case we may be
required to pay substantial royalties or grant cross-licenses to our patents.
However, there can be no assurance that any such license will be available on
acceptable terms or at all. Ultimately, we, our licensees, licensors or
collaborators could be prevented from commercializing a product, or forced to
cease some aspect of their or our business, as a result of patent infringement
claims, which could harm our business or right to receive option, milestone and
contingent royalty payments.</P>
<P align=center>23 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_27></A>
<P align=justify><B><I>Risks Related to Litigation with Auxilium </I></B></P>
<P align=justify><B>Our litigation with Auxilium could be detrimental to our
relationship and the results of our operations.</B></P>
<P align=justify>Our litigation with Auxilium may inhibit or preclude our
ability to pursue additional indications, and, if Auxilium does not pursue such
additional indications, we may be precluded from the opportunity to receive from
Auxilium license fees for the rights to, as well as potential milestone, royalty
and other payments with respect to, such additional indications. If we decided
to settle the litigation with Auxilium, the settlement could result in an
amendment to the Auxilium Agreement and change the scope of our rights under the
Auxilium Agreement.</P>
<P align=justify><B>Auxilium may obtain the relief it is seeking in its
litigation against us, which could adversely affect the results of our
operations.</B></P>
<P align=justify>The court before which the litigation with Auxilium is being
conducted could:</P>
<UL>
  <LI>
  <p style="margin-bottom: 12">grant the relief Auxilium is seeking,
  <LI>
  <p style="margin-bottom: 12">rule in a manner that is detrimental to our interests, or
  <LI>interpret the Auxilium Agreement in a manner that limits the scope of our
  rights under the Auxilium Agreement. </LI></UL>
<P align=justify>Any of the foregoing results may inhibit or preclude our
ability to conduct clinical trials in additional indications, and, if Auxilium
does not pursue such additional indications, we may be precluded from the
opportunity to receive from Auxilium license fees for the rights to, as well as
potential milestone, royalty and other payments with respect to, such additional
indications.</P>
<P align=justify><B>Our litigation with Auxilium may have an impact on our cash
flow and management priorities. </B></P>
<P align=justify>The litigation that Auxilium has initiated against us, any
related litigation and any resulting appeals could be costly and time-consuming
and could divert the attention of management and key personnel from our business
operations. These costs and diversions of management could have an adverse
effect on our business and our financial condition.</P>
<P align=justify><B><I>Risks Related to our Common Stock </I></B></P>
<P align=justify><B>Future sales of our common stock could negatively affect our
stock price. </B></P>
<P align=justify>If our common stockholders sell substantial amounts of common
stock in the public market, or the market perceives that such sales may occur,
the market price of our common stock could decline. In addition, we may need to
raise additional capital in the future to fund our operations. If we raise
additional funds by issuing equity securities, our stock price may decline and
our existing stockholders may experience dilution of their interests. Because we
historically have not declared dividends, stockholders must rely on an increase
in the stock price for any return on their investment in us. </P>
<P align=justify><B>Our stock price has, in the past, been volatile, and the
market price of our common stock may drop below the current price. </B></P>
<P align=justify>Our stock price has, at times, been volatile. Currently, our
common stock is traded on Nasdaq and is thinly traded. </P>
<P align=justify>Market prices for securities of pharmaceutical, biotechnology
and specialty pharmaceutical companies have been particularly volatile. Some of
the factors that may cause the market price of our common stock to fluctuate
include:</P>
<UL>
  <LI>
  <p style="margin-bottom: 12">results of our clinical trials;
  <LI>
  <p style="margin-bottom: 12">failure of any product candidates we have licensed to Auxilium or sold to
  DFB to achieve commercial success;
  <LI>
  <p style="margin-bottom: 12">regulatory developments in the U.S. and foreign countries;
  <LI>
  <p style="margin-bottom: 12">developments or disputes concerning patents or other proprietary rights;
  <LI>litigation involving us or our general industry, or both; </LI></UL>
<P align=center>24 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_28></A>
<UL>
  <LI>
  <p style="margin-bottom: 12">future sales of our common stock by the estate of our former Chairman and
  CEO or others;
  <LI>
  <p style="margin-bottom: 12">changes in the structure of healthcare payment systems, including
  developments in price control legislation;
  <LI>
  <p style="margin-bottom: 12">departure of key personnel;
  <LI>
  <p style="margin-bottom: 12">announcements of material events by those companies that are our
  competitors or perceived to be similar to us;
  <LI>
  <p style="margin-bottom: 12">changes in estimates of our financial results;
  <LI>
  <p style="margin-bottom: 12">investors&#146; general perception of us; and
  <LI>general economic, industry and market conditions. </LI></UL>
<P align=justify>If any of these risks occurs, or continues to occur, it could
cause our stock price to fall and may expose us to class action lawsuits that,
even if unsuccessful, could be costly to defend and a distraction to management.
In addition, purchases of our common stock pursuant to our stock repurchase
program may, depending on the timing and volume of such repurchases, result in
our stock price being higher than it would be in the absence of such
repurchases. If repurchases pursuant to the program are discontinued, our stock
price may fall.<B> </B></P>
<P align=justify><B>We may become subject to stockholder activism efforts that
could cause material disruption to our business. </B></P>
<P align=justify>Certain influential institutional investors, hedge funds and
other stockholders have taken steps to involve themselves in the governance and
strategic direction of certain companies due to governance or strategic related
disagreements between such companies and such stockholders. If we become subject
to such stockholder activism efforts, it could result in substantial costs and a
diversion of management&#146;s attention and resources, which could harm our business
and adversely affect the market price of our common stock.</P>
<P align=justify><B>We have no current plan to pay dividends on our common stock
and investors may lose the entire amount of their investment.</B></P>
<P align=justify>We have no current plans to pay dividends on our common stock.
Therefore, investors will not receive any funds absent a sale of their shares.
We cannot assure investors of a positive return on their investment when they
sell their shares nor can we assure that investors will not lose the entire
amount of their investment.</P>
<P align=justify><B>Our</B> <B>outstanding options to purchase shares of common
stock could have a possible dilutive effect. </B></P>
<P align=justify>As of December 31, 2010, options to purchase 1,346,425 shares
of common stock were outstanding. In addition, as of December 31, 2010 a total
of 269,098 options were available for grant under our stock option plans. The
issuance of common stock upon the exercise of these options could adversely
affect the market price of the common stock or result in substantial dilution to
our existing stockholders. <B></B></P>
<P align=justify><B>If securities analysts do not publish research reports about
our business or if they downgrade us or our sector, the price of our common
stock could decline.</B></P>
<P align=justify>The trading market for our common stock will depend in part on
research reports that industry or financial analysts publish about us or our
business. If analysts downgrade us or any of our licensees, or other research
analysts downgrade the industry in which we operate or the stock of any of our
competitors or licensees, the price of our common stock will probably
decline.</P>
<P align=justify><B>Provisions in our certificate of incorporation, bylaws and
stockholder rights agreement may prevent or frustrate a change in control.
</B></P>
<P align=justify>Provisions of our certificate of incorporation, bylaws (as
amended) and stockholder rights agreement may discourage, delay or prevent a
merger, acquisition or other change in control that stockholders may consider
favorable, including transactions in which you might otherwise receive a premium
for your shares. These provisions: </P>
<P align=center>25 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_29></A>
<UL>
  <LI>
  <p style="margin-bottom: 12" align="justify">provide for a classified board of directors;
  <LI>
  <p style="margin-bottom: 12" align="justify">give our Board the ability to designate the terms of and issue new series
  of preferred stock without stockholder approval, commonly referred to as
  &#147;blank check&#148; preferred stock, with rights senior to those of our common
  stock;
  <LI>
  <p style="margin-bottom: 12" align="justify">limit the ability of the stockholders to call special meetings; and
  <LI>
  <p align="justify">impose advance notice requirements on stockholders concerning the election
  of directors and other proposals to be presented at stockholder meetings.
</LI></UL>
<P align=justify>In addition, during May 2002, the Board implemented a rights
agreement (commonly known as a &#147;Poison Pill&#148;), which effectively discourages or
prevents acquisitions of more than 15% of our common stock in transactions
(mergers, consolidations, tender offer, etc.) that have not been approved by our
Board. The Board amended the Poison Pill in February 2011 to increase the
threshold from 15% to 18% and extended the expiration date of the Poison Pill
for an additional two years, to May 31, 2014. These provisions could make it
more difficult for common stockholders to replace members of the Board. Because
our Board is responsible for appointing the members of our management team,
these provisions could in turn affect any attempt to replace the current
management team.</P>
<P align=justify><B>If our principal stockholders, executive officers and
directors choose to act together, they may be able to control our operations,
acting in their own best interests and not necessarily those of other
stockholders. </B></P>
<P align=justify>As of March 8, 2011 our executive officers, directors and their
affiliates, in the aggregate, beneficially owned shares representing
approximately 30.6% of our common stock. Beneficial ownership includes shares
over which an individual or entity has investment or voting power and includes
shares that could be issued upon the exercise of options within 60 days. As a
result, if these stockholders were to choose to act together, they may be able
to control all matters submitted to our stockholders for approval, as well as
our management and affairs. For example, these individuals, if they chose to act
together, could control the election of directors and approval of any merger,
consolidation or sale of all or substantially all of our assets. This
concentration of ownership could have the effect of delaying, deferring or
preventing a change in control or impeding a merger or consolidation, takeover
or other business combination that could be favorable to other stockholders.</P>
<P align=justify>This significant concentration of share ownership may adversely
affect the trading price for our common stock because investors often perceive
disadvantages in owning stock in companies with controlling stockholders.</P>
<P align=justify><B>Item IB. UNRESOLVED STAFF COMMENTS</B></P>
<P align=justify>None.</P>
<P align=justify><B>Item 2. DESCRIPTION OF PROPERTY. </B></P>
<P align=justify>Our corporate headquarters are currently located at 35 Wilbur
St., Lynbrook, NY 11563. As previously reported, our previous lease for our
headquarters terminated on June 30, 2010. Since June 30, 2010, we have been
leasing the space from Wilbur St. Corp. on a month-to-month basis. On February
28, 2011, we notified Wilbur St. Corp. of our termination of the lease effective
March 31, 2011. We intend to negotiate a new lease for our current space at a
reduced rental or seek alternative space at a reduced rental. </P>
<P align=justify><B>Item 3. LEGAL PROCEEDINGS. </B></P>
<P align=justify>On February 15, 2011, Auxilium filed a complaint against us in
the Court of Common Pleas in Chester County, Pennsylvania. We have voluntarily
agreed to suspend Chien-803, our clinical trial testing the use of injectable
collagenase in canine lipoma, and will not be initiating any new trials using
injectable collagenase in animals or humans pending a resolution of our dispute
with Auxilium concerning our right to conduct clinical trials without the prior
approval of the companies&#146; Joint Development Committee. The complaint seeks
declaratory and injunctive relief and does not seek monetary damages. The
dispute has been sealed pending further order of the court. The outcome of the
dispute will have no effect on the amounts due to us from Auxilium for exercised
indications (Dupuytren&#146;s contracture, Peyronie&#146;s disease and Frozen
Shoulder). However, if the court rules in a manner that is detrimental to our
interests or interprets our agreement with Auxilium in a way that limits the
scope of our rights under that agreement, we may be precluded from pursuing
additional indications and, if Auxilium does not pursue such additional
indications, we may also be precluded from the opportunity to receive from
Auxilium license fees for the rights to, as well as potential milestone, royalty
and other payments with respect to, such additional indications. </P>
<P align=center>26 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_30></A>
<P align=justify><B>Item 4. (REMOVED AND RESERVED). </B></P>
<P align=center><B>PART II </B></P>
<P align=justify><B>Item 5. MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER
MATTERS. </B></P>
<P align=justify><B><I>Market Information</I></B> </P>
<P align=justify>Our common stock currently trades under the symbol BSTC on the
Nasdaq Global Market (&#147;Nasdaq&#148;). We were listed and commenced trading on Nasdaq
on January 9, 2009. From January 29, 2008 through market close on January 8,
2009, our common stock was quoted and traded on the Over-The-Counter Bulletin
Board (the &#147;OTCBB&#148;) under the symbol BSTC.OB. Prior to January 29, 2008, our
common stock was quoted on the Pink Sheets.</P>
<P align=justify>The table below sets forth the high and low closing sale prices
for our common stock for each of the quarterly periods in 2010 and 2009 as
reported by and as quoted in the OTCBB or Nasdaq, as applicable:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left style="border-bottom-style: solid; border-bottom-width: 1"><B>2010</B> </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="12%" style="border-bottom-style: solid; border-bottom-width: 1"><B>HIGH</B> </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="12%" style="border-bottom-style: solid; border-bottom-width: 1"><B>LOW</B> </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff style="border-top-style: solid; border-top-width: 1">Fourth Quarter </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-top-style: solid; border-top-width: 1">27.86 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-top-style: solid; border-top-width: 1">20.71 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Third Quarter </TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">27.36 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">18.80 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff>Second Quarter </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff>31.72 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff>19.02 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>First Quarter </TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">29.98 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">26.53 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-bottom-style: solid; border-bottom-width: 1"><B>2009</B> </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="12%" style="border-bottom-style: solid; border-bottom-width: 1"><B>HIGH</B> </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="12%" style="border-bottom-style: solid; border-bottom-width: 1"><B>LOW</B> </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff style="border-top-style: solid; border-top-width: 1">Fourth Quarter </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-top-style: solid; border-top-width: 1">33.00 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-top-style: solid; border-top-width: 1">27.86 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Third Quarter </TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">32.05 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">23.67 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff>Second Quarter </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff>24.98 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff>18.06 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>First Quarter </TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">21.50 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="12%">17.50 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=justify>These quotations reflect inter-dealer prices, without retail
mark-up, mark-down or commission and may not represent actual
transactions.<B><I> </I></B></P>
<P align=justify><B><I>Holders of Record</I></B> </P>
<P align=justify>As of March 8, 2011, there were approximately 80 holders of
record of our common stock. Because many of such shares are held by brokers and
other institutions on behalf of stockholders, we are unable to estimate the
total number of stockholders represented by these record holders.</P>
<P align=justify><B><I>Dividends</I></B> </P>
<P align=justify>It has been our policy to retain potential earnings to finance
the growth and development of our business and not pay dividends, and we have no
current plans to pay dividends. Any payment of cash dividends in the future will
depend upon our financial condition, capital requirements and earnings as well
as such other factors as our board of directors may deem relevant.</P>
<P align=justify><B><I>Securities Authorized for Issuance Under Equity
Compensation Plans </I></B></P>
<P align=justify>The following table provides information as of December 31,
2010 with respect to the shares of our common stock that may be issued under our
existing equity compensation plans:</P>
<P align=center>27 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_31></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1; border-top-style: solid; border-top-width: 1" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1; border-top-style: solid; border-top-width: 1"><B>Number of securities to</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1; border-top-style: solid; border-top-width: 1"><B>Weighted-average</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1; border-top-style: solid; border-top-width: 1"><B>Number of securities</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>be issued upon exercise</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>exercise price of</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>remaining available</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>of outstanding options,</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>outstanding options,</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>for future issuance</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>warrants and rights</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>warrants and rights</B> </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>under equity</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD noWrap align=left width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1">&nbsp; </TD>
    <TD noWrap align=left width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1">&nbsp; </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>compensation plans</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD noWrap align=left width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1">&nbsp; </TD>
    <TD noWrap align=left width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1">&nbsp; </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>(excluding securities</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD noWrap align=left width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1">&nbsp; </TD>
    <TD noWrap align=left width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1">&nbsp; </TD>
    <TD noWrap align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1"><B>reflected in column (a))</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=left
      >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=center
      width="18%"><B>(a)</B> </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=center
      width="18%"><B>(b)</B> </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=center
      width="18%"><B>(c)</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=left bgcolor="#E6EFFF"
      >
    <p style="text-indent: -9; margin-left: 14; margin-right: 5">Equity compensation plans approved by security
      holders<SUP>(1)</SUP> </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=center
      width="18%" bgcolor="#E6EFFF">1,346,425 </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=center
      width="18%" bgcolor="#E6EFFF">$7.81 </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=center
      width="18%" bgcolor="#E6EFFF">269,098 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=left
      >
    <p style="text-indent: -9; margin-left: 14; margin-right: 5">Equity compensation plans not approved by security holders
    </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=center width="18%">-
</TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=center width="18%">-
</TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" align=center width="18%">-
  </TD></TR>
  <TR>
    <TD style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" bgcolor="#E6EFFF" >
    <p style="margin-left: 4; margin-right: 5">&nbsp; </TD>
    <TD align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" bgcolor="#E6EFFF">&nbsp; </TD>
    <TD align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" bgcolor="#E6EFFF">&nbsp; </TD>
    <TD align=center width="18%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1" bgcolor="#E6EFFF">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=left bgcolor="#E6EFFF"
      >
    <p style="text-indent: -9; margin-left: 14; margin-right: 5">Total </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=center
      width="18%" bgcolor="#E6EFFF">1,346,425 </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=center
      width="18%" bgcolor="#E6EFFF">$7.81 </TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:solid; border-left-width:1; border-right-style:solid; border-right-width:1" noWrap align=center
      width="18%" bgcolor="#E6EFFF">269,098 </TD></TR></TABLE>
<P align=justify>(1) Please see Note 9, &#147;Stockholders&#146; Equity,&#148; of the notes to
the consolidated financial statements for a description of the material features
of each of our plans.</P>
<P align=justify><B><I>Recent Sales of Unregistered Securities </I></B></P>
<P align=justify>During the quarter ended December 31, 2010, we did not issue
any unregistered shares of securities.</P>
<P align=justify><B><I>Issuer Purchases of Equity Securities (1) </I></B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=center style="border-right-style: none; border-right-width: medium" >&nbsp; </TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Maximum Dollar</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=center style="border-right-style: none; border-right-width: medium" >&nbsp; </TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Total Number of</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Value of Shares</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=center style="border-right-style: none; border-right-width: medium" >&nbsp; </TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Total Number of</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Average</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Shares Purchased</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>that may yet be</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=center style="border-right-style: none; border-right-width: medium" >&nbsp; </TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Shares Purchased</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Price Paid</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>as Part of Publicly</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium"><B>Purchased</B> </TD>
    <TD noWrap align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-right-style:none; border-right-width:medium" noWrap align=left
      ><B>Month</B> </TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium" noWrap align=center
      width="12%"><B>During Month (2)</B></TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium" noWrap align=center
      width="12%"><B>Per Share (3)</B></TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium" noWrap align=center
      width="12%"><B>Announced Plan</B> </TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: 1px solid #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium" noWrap align=center
      width="12%"><B>under the Plan (4)</B></TD>
    <TD style="BORDER-BOTTOM: medium none #000000; ; border-left-style:none; border-left-width:medium; border-right-style:none; border-right-width:medium; border-top-style:none; border-top-width:medium" noWrap align=center width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff style="border-right-style: none; border-right-width: medium" >October 1 to October
      31, 2010 </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&#8722; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp;&#8722; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&#8722; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp;1,581,242.43 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left style="border-right-style: none; border-right-width: medium" >November 1 to November 30, 2010 </TD>
    <TD noWrap align=left width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=right width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">1,890 </TD>
    <TD noWrap align=left width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=left width="1%" style="border-style: none; border-width: medium" >$</TD>
    <TD noWrap align=right width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp;20.76 </TD>
    <TD noWrap align=left width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=left width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=right width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">1,890 </TD>
    <TD noWrap align=left width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD noWrap align=left width="1%" style="border-style: none; border-width: medium" >$</TD>
    <TD noWrap align=right width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp;1,541,999.23 </TD>
    <TD noWrap align=left width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff style="border-right-style: none; border-right-width: medium" >December 1 to December
      31, 2010 </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&#8722; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp;&#8722; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&#8722; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">$</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp;1,541,999.23 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD></TR>
  <TR>
    <TD style="border-right-style: none; border-right-width: medium" >&nbsp; </TD>
    <TD align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD align=center width="1%" style="border-style: none; border-width: medium" >&nbsp;</TD>
    <TD align=center width="12%" style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD align=center width="2%" style="border-style: none; border-width: medium" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff style="border-right-style: none; border-right-width: medium" >Total </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=right width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">1,890 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=center width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=center width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=center width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=center width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=center width="1%"  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD>
    <TD noWrap align=center width="12%" bgColor=#e6efff style="border-left-style: none; border-left-width: medium; border-right-style: none; border-right-width: medium">&nbsp; </TD>
    <TD noWrap align=center width="2%"
  bgColor=#e6efff style="border-style: none; border-width: medium">&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>On June 4, 2010, we announced that our board of directors
      authorized a stock repurchase program under Rule 10b-18 of the Securities
      Exchange Act of 1934, as amended, of up to $2.0 million of our outstanding
      common stock over a period of 12 months. The above table provides
      information regarding our stock repurchases in the quarter ended December
      31, 2010. This program expires on June 4, 2011 and may be suspended or
      discontinued at any time. We have no obligation to repurchase stock under
      this program. </P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>The purchases were made in open-market transactions.
    </P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(3) </TD>
    <TD>
      <P align=justify>Includes commissions paid, if any, related to the stock
      repurchase transactions. </P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(4) </TD>
    <TD>
      <P align=justify>Represents the difference between the $2,000,000 of stock
      repurchases authorized by our board of directors and the value of the
      stock repurchased from June 4, 2010 through the indicated month.
  </P></TD></TR></TABLE>
<P align=justify><B><I>Performance Graph </I></B></P>
<P align=justify>The graph below compares the cumulative total stockholder
return on our common stock with the cumulative total stockholder return of (i)
the NASDAQ Biotechnology Index, and (ii) the NASDAQ Composite Index, assuming an
investment of $100 on December 31, 2005, in each of our common stock; the stocks
comprising the NASDAQ Composite Index; and the stocks comprising the NASDAQ
Biotechnology Index.</P>
<P align=center>28 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_32></A>
<P align=justify><B>Comparison of Cumulative Total Return* Among BioSpecifics
Technologies Corp., the NASDAQ Biotechnology Index and the NASDAQ Composite
Index </B></P>
<P align=center>
<img border="0" src="biospe1.jpg" width="742" height="386"> </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=center >&nbsp; </TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>12/30/2005</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>12/31/2006</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>12/31/2007</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>12/31/2008</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>12/31/2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>12/31/2010</B> </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff ><B>BioSpecifics
      Technologies Corp.</B> </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;100.00 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;463.41 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;1,219.51 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;2,609.76 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;3,579.27 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;3,121.95 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left ><B>Nasdaq Biotechnology Index</B> </TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="9%">&nbsp;100.00 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="9%">&nbsp;101.02 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="9%">&nbsp;105.65 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="9%">&nbsp;92.31 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="9%">&nbsp;106.71 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >$</TD>
    <TD noWrap align=right width="9%">&nbsp;122.76 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff ><B>Nasdaq Composite
      Index</B> </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;100.00 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;109.52 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;120.27 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;71.51 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;102.89 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;120.29 </TD>
    <TD noWrap align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=justify>*Total return assumes $100 invested on December 31, 2005 in our
common stock, the NASDAQ Composite Index, and the NASDAQ Biotechnology Index and
reinvestment of dividends through fiscal year ended December 31, 2010.
<I></I></P>
<P align=justify><B>Item 6. SELECTED FINANCIAL DATA </B></P>
<P align=justify>The following selected consolidated financial data should be
read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and our consolidated financial statements
and the related notes appearing elsewhere in this Report. The consolidated
statements of operations data for the years ended December 31, 2010, 2009 and
2008 and the consolidated balance sheet data as of December 31, 2010 and 2009
have been derived from our audited consolidated financial statements and related
notes, which are included elsewhere in this Report. The consolidated statement
of operations data for the years ended December 31, 2007 and 2006 and the
consolidated balance sheet data as of December 31, 2008, 2007 and 2006 have been
derived from audited financial statements which do not appear in this Report.
The historical results presented are not necessarily indicative of results to be
expected in any future period.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left >&nbsp; </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="33%"
    colSpan=7><B>Years Ended December 31,</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%">&nbsp; </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left ><B>Consolidated Statement of
      Operations Data</B> </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2010</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2008</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2007</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2006 (1)</B></TD>
    <TD noWrap align=center width="2%" ></TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff >Net revenues </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;5,661,348 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;3,155,757 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;8,411,780 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;1,514,334 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;1,916,918 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff ><B>Operating
      expenses:</B> </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >&nbsp; &nbsp;Research and development
    </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">1,223,931 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">488,646 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">439,919 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">2,489,122 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">1,217,306 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff >&nbsp; &nbsp;General
      and administrative </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>6,470,449 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>4,832,019 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>4,191,052 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>3,516,716 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>4,002,519 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff >Total operating
      expenses </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>7,694,380 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>5,320,665 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>4,630,971 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>6,005,838 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>5,219,825 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff ><B>Operating income
      (loss)</B> </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff><B>(2,033,032</B></TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff><B>)</B>
</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff><B>(2,164,908</B></TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff><B>)</B>
</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff><B>3,780,809</B> </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff><B>(4,491,504</B></TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff><B>)</B>
</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff><B>(3,302,907</B></TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff><B>)</B>
  </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff ><B>Other income
      (expense):</B> </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >&nbsp; &nbsp;Interest income </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">86,310 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">55,693 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">107,552 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">126,821 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">220,608 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff >&nbsp; &nbsp;Interest
      expense </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>- </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>(39</TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>46,529 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>(781</TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>(63,133</TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >&nbsp; &nbsp;Other </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">13,130 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">(8,863</TD>
    <TD noWrap align=left width="2%" >) </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">108,730 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">(125,000</TD>
    <TD noWrap align=left width="2%" >) </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">(70,399</TD>
    <TD noWrap align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff >&nbsp;
      &nbsp;Qualifying Therapeutic Credit </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>426,403 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>- </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>- </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>- </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right width="9%"
    bgColor=#e6efff>- </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >&nbsp; </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">525,843 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">46,791 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">262,811 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">1,040 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">87,076 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR></TABLE>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff>Income (loss) before income tax </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>(1,507,189</TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>) </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>(2,118,117</TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>) </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>4,043,620 </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>(4,490,464</TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>) </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>(3,215,831</TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>&nbsp;&nbsp; Income tax benefit (expense) </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">(1,351</TD>
    <TD noWrap align=left width="2%">) </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">161,574 </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">(299,212</TD>
    <TD noWrap align=left width="2%">) </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">(53,865</TD>
    <TD noWrap align=left width="2%">) </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=right
      width="9%">(147,480</TD>
    <TD noWrap align=left width="2%">) </TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left><B>Net income (loss)</B> </TD>
    <TD noWrap align=left width="1%"><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right
      width="9%"><B>&nbsp;(1,508,540</B></TD>
    <TD noWrap align=left width="2%"><B>)</B> </TD>
    <TD noWrap align=left width="1%"><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right
      width="9%"><B>&nbsp;(1,956,543</B></TD>
    <TD noWrap align=left width="2%"><B>)</B> </TD>
    <TD noWrap align=left width="1%"><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right
      width="9%"><B>&nbsp;3,744,408</B> </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right
      width="9%"><B>&nbsp;(4,544,329</B></TD>
    <TD noWrap align=left width="2%"><B>)</B> </TD>
    <TD noWrap align=left width="1%"><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right
      width="9%"><B>(3,363,311</B></TD>
    <TD noWrap align=left width="2%"><B>)</B> </TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff><B>Basic net income (loss) per
      share</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.24</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.32</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;0.64</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.86</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.64</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff><B>Diluted net income (loss) per
      share</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.24</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.32</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;0.55</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.86</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(0.64</B></TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff><B>)</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="9%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left><B>Shares used in computation of basic net
      income</B> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff><B>(loss) per share</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>6,261,214</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>6,065,939</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>5,854,836</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>5,291,506</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>5,219,908</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left><B>Shares used in computation of diluted net
      income</B> </TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="9%">&nbsp; </TD>
    <TD noWrap align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff><B>(loss) per share</B> </TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>6,261,214</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>6,065,939</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>6,836,911</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>5,291,506</B> </TD>
    <TD noWrap align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" noWrap align=right width="9%"
    bgColor=#e6efff><B>5,219,908</B> </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=center>29 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_33></A><BR>
<P align=justify>(1) In March 2006, we sold our topical collagenase business to
DFB, including all rights to the exclusive license agreement and we were
released of any obligations thereunder. For the year-ended December 31, 2006
operating results of ABC-Curacao and certain operations of ABC-NY were
classified as discontinued operations in our 2006 consolidated financial
statements and are excluded in the table above. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left >&nbsp; </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="57%"
    colSpan=13><B>Years Ended December 31,</B> </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left ><B>Consolidated Balance Sheet
      Data:</B> </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2010</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2008</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2007</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>2006</B> </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff >Cash and cash
      equivalents </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;2,470,852 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;3,950,389 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;3,494,150 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;68,564 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>&nbsp;4,367,178 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >Short-term investments </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">5,360,970 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">4,548,541 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">900,000 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">975,000 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">- </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left bgColor=#e6efff >Total assets </TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>11,518,701 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>11,748,478 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>12,831,361 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>1,261,211 </TD>
    <TD noWrap align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD noWrap align=right width="9%" bgColor=#e6efff>4,530,538 </TD>
    <TD noWrap align=left width="2%"
bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >Total stockholders&#146; equity (deficit)
    </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">6,700,723 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">6,092,107 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">6,178,539 </TD>
    <TD noWrap align=left width="2%" >&nbsp;</TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">(6,735,658</TD>
    <TD noWrap align=left width="2%" >) </TD>
    <TD noWrap align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=right width="9%">(3,268,799</TD>
    <TD noWrap align=left width="2%" >) </TD></TR></TABLE>
<P align=justify><B>Item 7. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OR PLAN OF
OPERATION</B></P>
<P align=justify>This Report includes &#147;forward-looking statements&#148; within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. All statements other
than statements of historical facts are &#147;forward-looking statements&#148; for
purposes of these provisions, including any projections of earnings, revenues or
other financial items, any statements of the plans and objectives of management
for future operations, any statements concerning proposed new products or
licensing or collaborative arrangements, any statements regarding future
economic conditions or performance, and any statement of assumptions underlying
any of the foregoing. In some cases, forward-looking statements can be
identified by the use of terminology such as &#147;may,&#148; &#147;will,&#148; &#147;expects,&#148; &#147;plans,&#148;
&#147;anticipates,&#148; estimates,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative thereof or
other comparable terminology. Although we believe that the expectations
reflected in the forward-looking statements contained in this Report are
reasonable, there can be no assurance that such expectations or any of the
forward-looking statements will prove to be correct, and actual results could
differ materially from those projected or assumed in the forward-looking
statements. Our future financial condition and results of operations, as well as
any forward-looking statements, are subject to inherent risks and uncertainties,
including but not limited to the risk factors set forth in Item 1A above, and
for the reasons described elsewhere in this Report. All forward-looking
statements and reasons why results may differ included in this Report are made
as of the date hereof, and we assume no obligation to update these
forward-looking statements or reasons why actual results might differ.</P>
<P align=justify><B><I>Overview</I></B> </P>
<P align=justify>We are a biopharmaceutical company involved in the development
of an injectable collagenase for multiple indications. We have a development and
license agreement with Auxilium for injectable collagenase (which Auxilium has
named XIAFLEX (collagenase clostridium histolyticum)) for clinical indications
in Dupuytren&#146;s contracture, Peyronie&#146;s disease and frozen shoulder (<I>adhesive
capsulitis</I>), and Auxilium has an option to acquire additional indications
that we may pursue, including human and canine lipoma and cellulite. Auxilium
has an agreement with Pfizer pursuant to which Pfizer has the right to market
XIAFLEX for Dupuytren&#146;s contracture and Peyronie&#146;s disease in 27 member
countries of the European Union and 19 other European and Eurasian countries,
and will do so under the registered trademark XIAPEX (collagenase clostridium
histolyticum). </P>
<P align=center>30 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_34></A>
<P align=justify>In connection with the DFB Agreement, until March 2011, we
received payments for certain technical assistance and certain transition
services that we provided to DFB. Under the DFB Agreement, we continue to
receive earn out payments based on the sales of certain products. Our right to
receive earn out payments with respect to the marketed topical product sold to
DFB expire in June 2013, but earn out payments for second generation collagenase
products, if any, continue indefinitely. </P>
<P align=justify><I>Operational Highlights </I></P>
<P align=justify>On February 28, 2011, Auxilium and Pfizer announced that the
European Commission granted XIAPEX marketing authorization for the treatment of
Dupuytren&#146;s contracture in adult patients with a palpable cord. Auxilium and
Pfizer also announced that XIAPEX &#147;is expected to be available for use in some
European markets later this year&#148;. </P>
<P align=justify>On January 6, 2011, we announced promising results from our
study Chien-802 showing reductions in canine lipoma following injections with
purified injectable collagenase. These results build upon an earlier dose
escalation study from which the Company selected the dose for Chien-802.
<B></B></P>
<P align=justify>Chien-802 was designed to evaluate the efficacy of injectable
collagenase in canine lipoma in four healthy dogs with subcutaneous lipomas.
Inclusion criteria required the lipomas to be benign, superficial and easily
measureable. All dogs had a second lipoma that was untreated and used as a
control. At 90 days post injection, in the three evaluable dogs, the lipoma size
was 0%, 0% or 7% of the original size as measured by a computed tomography
(&#147;CT&#148;) scan. By contrast, the untreated lipomas were 129%, 113% and 128% of the
original size at day 90. Thus, the treated lipomas showed a 97% reduction in the
size of the lipoma and an increase in the size of the untreated controls of 23%.
Based on the positive results from Chien-802, we announced on January 6, 2011
the initiation of a larger clinical trial, Chien-803, for the same indication.
We have voluntarily agreed to suspend this trial and will not be initiating any
new trials using injectable collagenase in animals or humans pending a
resolution of our dispute with Auxilium concerning our right to conduct clinical
trials without the prior approval of the companies&#146; Joint Development Committee.
This dispute is described in this Report in &#147;Item 3 - Legal Proceedings&#148;.</P>
<P align=justify>On November 3, 2010, we announced that we had been awarded
$426,000 in grant funding under the Qualifying Therapeutic Discovery Project
Program. The program, funded through the U.S. Patient Protection and Affordable
Care Act of 2010, encourages therapeutic discovery programs. The grant funding
supports the clinical development of injectable collagenase in human lipoma and
the development of improved collagenases for tissue disassociation related to
cellular therapy.</P>
<P align=justify>On October 11, 2010, Auxilium announced that the first subject
had been dosed in the global Phase III program of XIAFLEX for the treatment of
Peyronie's disease. In its announcement, Auxilium described that the &#147;late stage
global development plan for XIAFLEX will consist of four clinical studies and
will be known by the acronym IMPRESS - The Investigation for Maximal Peyronie's
Reduction Efficacy and Safety Studies. There will be two randomized,
double-blind, placebo-controlled phase III studies, which are expected to enroll
at least 600 patients at approximately 70 sites in the U.S. and Australia, with
a 2:1 ratio of XIAFLEX to placebo. There also will be one open label study,
which should enroll at least 250 patients, at approximately 30 sites in the
U.S., EU and New Zealand, and one pharmacokinetic study, which it expected to
enroll approximately 16 patients.&#148; </P>
<P align=justify>On June 4, 2010, we announced that our board of directors
authorized the repurchase of up to $2 million of our outstanding common stock,
reflecting our continued commitment to increasing value for our stockholders and
our confidence that we will achieve our goals. </P>
<P align=justify>On February 2, 2010, Auxilium announced that it received
marketing approval from the FDA for XIAFLEX for the treatment of adult
Dupuytren&#146;s contracture patients with a palpable cord. XIAFLEX, the only drug
approved by the FDA for the treatment of Dupuytren&#146;s contracture, became
available by prescription for such treatment in March 2010. </P>
<P align=justify>The Auxilium Agreement and other licensing agreements are
discussed more fully in Item 1 of this Report under the section titled
&#147;Licensing and Marketing Agreements.&#148;</P>
<P align=center>31 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_35></A>
<P align=justify><B>Outlook </B></P>
<P align=justify>Currently, we generate revenue from two primary sources: in
connection with the DFB Agreement and in connection with the Auxilium Agreement.
Under the DFB Agreement, until March 2011, we received revenue related to
certain technical assistance and certain transition services that we provided to
DFB. Under the DFB Agreement, we continue to receive earn-out payments from DFB
based on the sales of certain products. Under the Auxilium Agreement, we receive
royalties, milestones and mark-up on cost of goods sold payments related to the
sale and approval of XIAFLEX. We will receive 8.5% of the $395 million in
potential additional milestone payments that may be made by Pfizer to Auxilium
under the Pfizer Agreement. In addition to the payments already received by us
with respect to the Dupuytren&#146;s contracture indication, Auxilium will be
obligated to make contingent milestone payments, with respect to each of the
Peyronie&#146;s disease and frozen shoulder indications, upon the acceptance of the
regulatory filing and receipt by Auxilium, its affiliate or sublicensee of
regulatory approval.</P>
<P align=justify>Based on our current business model, we expect to have adequate
cash reserves until at least the second half of 2012. As a significant portion
of our revenues is tied directly to the success of Auxilium in commercializing
XIAFLEX, we cannot reasonably forecast our financial condition beyond this time.
</P>
<P align=justify><B>Significant Risks </B></P>
<P align=justify>In recent history we have had operating losses and may not
achieve sustained profitability. As of December 31, 2010, we had an accumulated
deficit from continuing operations of approximately $9.9 million.</P>
<P align=justify>We are dependent to a significant extent on third parties, and
our principal licensee, Auxilium, may not be able to successfully commercialize
XIAFLEX for Dupuytren&#146;s contracture, successfully develop XIAFLEX for additional
indications, obtain required regulatory approvals, manufacture XIAFLEX at an
acceptable cost, in a timely manner and with appropriate quality, or
successfully market products or maintain desired margins for products sold, and
as a result we may not achieve sustained profitable operations. </P>
<P align=justify><B>Critical Accounting Policies, Estimates and Assumptions
</B></P>
<P align=justify>The preparation of consolidated financial statements in
conformity with U.S. generally accepted accounting principles requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the consolidated financial statements and the reported amounts of
revenues and expenses during the reporting period. These estimates are based on
historical experience and on various other assumptions that we believe are
reasonable under the circumstances. Actual results could differ from those
estimates. While our significant accounting policies are described in more
detail in the notes to our consolidated financial statements, we believe the
following accounting policies to be critical to the judgments and estimates used
in the preparation of our consolidated financial statements.</P>
<P align=justify><B><I>Revenue Recognition</I></B><I>.</I> We recognize revenues
from product sales when there is persuasive evidence that an arrangement exists,
title passes, the price is fixed and determinable, and payment is reasonably
assured. We currently recognize revenues resulting from the licensing,
sublicensing and use of our technology and from services we sometimes perform in
connection with the licensed technology. </P>
<P align=justify>We enter into product development licenses, and collaboration
agreements that may contain multiple elements, such as upfront license and
sublicense fees, milestones related to the achievement of particular stages in
product development and royalties. As a result, significant contract
interpretation is sometimes required to determine the appropriate accounting,
including whether the deliverables specified in a multiple-element arrangement
should be treated as separate units of accounting for revenue recognition
purposes, and if so, how the aggregate contract value should be allocated among
the deliverable elements and when to recognize revenue for each element. </P>
<P align=justify>We recognize revenue for delivered elements only when the fair
values of undelivered elements are known, when the associated earnings process
is complete and, to the extent the milestone amount relates to our performance
obligation, when our licensee confirms that we have met the requirements under
the terms of the agreement, and when payment is reasonably assured. Changes in
the allocation of the contract value between various deliverable elements might
impact the timing of revenue recognition, but in any event, would not change the
total revenue recognized on the contract. For example, nonrefundable upfront
product license fees, for product candidates for which we are providing
continuing services related to product development, are deferred and
recognized as revenue over the development period. </P>
<P align=center>32 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_36></A>
<P align=justify>Milestones, in the form of additional license fees, typically
represent nonrefundable payments to be received in conjunction with the
achievement of a specific event identified in a contract, such as completion of
specified clinical development activities and/or regulatory submissions and/or
approvals. We believe that a milestone represents the culmination of a distinct
earnings process when it is not associated with ongoing research, development or
other performance on our part. We recognize such milestones as revenue when they
become due and payment is reasonably assured. When a milestone does not
represent the culmination of a distinct earnings process, we recognize revenue
in a manner similar to that of an upfront product license fee. </P>
<P align=justify><B><I>Royalty/ Mark-up on Cost of Goods Sold / Earn-Out Revenue
</I></B></P>
<P align=justify>For those arrangements for which royalty, mark-up on cost of
goods sold or earn-out payment information becomes available and collectability
is reasonably assured, we recognize revenue during the applicable period earned.
For interim quarterly reporting purposes, when collectability is reasonably
assured but a reasonable estimate of royalty, mark-up on cost of goods sold or
earn-out payment revenues cannot be made, the royalty, mark-up on cost of goods
sold or earn-out payment revenues are generally recognized in the quarter that
the applicable licensee provides the written report and related information to
us. </P>
<P align=justify>Under the Auxilium Agreement, we do not participate in the
selling, marketing or manufacturing of products for which we receive royalties
and a mark-up of the cost of goods sold revenues, The royalty, mark-up on cost
of goods sold revenues will generally be recognized in the quarter that Auxilium
provides the written reports and related information to us, that is, royalty and
mark up on cost of goods sold revenues are generally recognized one quarter
following the quarter in which sales by Auxilium occurred.<B> </B>The royalties
payable by Auxilium to us are subject to set-off for certain third party
development and patent costs.</P>
<P align=justify>Under the DFB Agreement, pursuant to which we sold our topical
collagenase business to DFB, we have the right to receive earn-out payments in
the future based on sales of certain products. Generally, under the DFB
Agreement we would receive payments and a report within ninety (90) days from
the end of each calendar year after DFB has sold the royalty-bearing product.
Currently, DFB is providing us earn-out reports on a quarterly basis. </P>
<P align=justify><B><I>Consulting and Technical Assistance Services.</I></B> We
recognize revenues from consulting and technical assistance contracts primarily
as a result of the DFB Agreement. Consulting revenues are recognized ratably
over the term of the contract. The consulting and technical assistance
obligations to DFB expire during March 2011. </P>
<P align=justify><B><I>Reimbursable Third Party Development Costs.</I></B> We
accrue expenses for research and development and capitalize certain patent costs
related to estimated third party development costs that are reimbursable under
the Auxilium Agreement. Estimates are based on contractual terms, historical
development costs, reviewing third party data and expectations regarding future
development for certain products. Further, we monitor the activities and
clinical trials of our development partners. <B><I></I></B></P>
<P align=justify>If conditions or other circumstances change, we may take
actions to revise our reimbursable third party development cost estimates. These
revisions could result in an incremental increase or decrease in research and
development costs. For example, the Auxilium Agreement provides that we will
share equally with Auxilium in third party costs for the development of the
lyophilization of the injection formulation and certain patent expenses which
are creditable against future royalty revenues.</P>
<P align=justify>In January 2011, we received a credit memo from Auxilium
reducing by $227,000 the amount Auxilium claims we owe for our portion of the
lyophilization expenses through December 31, 2010. Any amount ultimately agreed
as being owed by us to Auxilium for lyophilization expenses and patent expenses
are creditable against future royalties payable by Auxilium on net sales of
XIAFLEX. In 2010, we recognized approximately $0.7 million related to royalty
revenue from the sale of XIAFLEX. Based upon the updated information and the
royalty revenue reported to us, we reduced our estimates for reimbursable third
party development and certain patent costs to approximately $2.6 million. </P>
<P align=justify>Based on our preliminary review, we believe that only a portion
of the amounts invoiced actually relates to the development of the
lyophilization of the injection formulation and certain patent expenses may
increase based upon a resolution of certain patent matters, and therefore, we
reserve all rights related to this matter, including but not limited </P>
<P align=center>33 </P>


<!--$$/page=--><A name=page_1></A>
<P align=justify>to our right to contest the amount charged by Auxilium. We have
classified accrued third party development costs as current liabilities on our
balance sheet as of December 31, 2010. </P>
<P align=justify>Actual results have differed in the past, and may differ in the
future, from our estimates and could impact our earnings in any period during
which an adjustment is made.</P>
<P align=justify><B><I>Receivables and Deferred Revenue.</I></B> Under the DFB
Agreement, we agreed to provide certain technical assistance and transitional
services in consideration of fees and costs totaling over $1.4 million. At the
closing of the DFB Agreement, DFB made a partial payment to us of $400,000 in
respect of the technical assistance to be provided by us. To date, we have
received a total of $1.4 million in payments from DFB. The consulting and
technical assistance obligations expire during March 2011.</P>
<P align=justify><B><I>Royalty Buy-Down</I></B><B>.</B> In August 2008, we
signed an agreement to significantly improve the deal terms related to our
future royalty obligations for Peyronie&#146;s disease by buying down our future
royalty obligations with a one-time cash payment. We modified our agreement to
lower future royalties payable on net sales of injectable collagenase, XIAFLEX,
for Peyronie&#146;s disease. In addition, we agreed to pay certain development
milestones, if achieved. </P>
<P align=justify>As of December 31, 2010, we capitalized $1,250,000 which will
be amortized over approximately five years beginning on the date of the first
commercial sale of XIAFLEX, for Peyronie&#146;s disease, which represents the period
estimated to be benefited, using the straight-line method. In accordance with
Accounting Standards Codification 350,<I> Intangibles, Goodwill and Other</I>,
the Company amortizes intangible assets with finite lives in a manner that
reflects the pattern in which the economic benefits of the assets are consumed
or otherwise used up. If that pattern cannot be reliably determined, the assets
are amortized using the straight-line method. </P>
<P align=justify><B><I>Stock Based Compensation</I></B><B>.</B> Under ASC 718,
we estimate the fair value of our employee stock awards at the date of grant
using the Black-Scholes option-pricing model, which requires the use of certain
subjective assumptions. The most significant assumptions are our estimates of
the expected volatility of the market price of our stock and the expected term
of an award. Expected volatility is based on the historical volatility of our
common stock. When establishing an estimate of the expected term of an award, we
consider the vesting period for the award, our historical experience of employee
stock option exercises (including forfeitures) and the expected volatility. As
required under the accounting rules, we review our valuation assumptions at each
grant date and, as a result, we are likely to change our valuation assumptions
used to value future employee stock-based awards granted, to the extent any such
awards are granted. </P>
<P align=justify>Further, ASC 718 requires that employee stock-based
compensation costs to be recognized over the requisite service period, or the
vesting period, in a manner similar to all other forms of compensation paid to
employees. The allocation of employee stock-based compensation costs to each
operating expense line are estimated based on specific employee headcount
information at each grant date and estimated stock option forfeiture rates and
revised, if necessary, in future periods if actual employee headcount
information or forfeitures differ materially from those estimates. As a result,
the amount of employee stock-based compensation costs we recognize in each
operating expense category in future periods may differ significantly from what
we have recorded in the current period. </P>
<P align=justify><B>RESULTS OF OPERATIONS </B></P>
<P align=justify><B>YEAR ENDED DECEMBER 31, 2010 COMPARED WITH YEAR ENDED
DECEMBER 31, 2009 </B></P>
<P align=justify><I>Net revenues</I></P>
<P align=justify>Net revenues for the two years ended December 31, 2010 and 2009
comprise the following: <B></B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="23%"
    colSpan=4><B>Year Ended December 31</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%">&nbsp; </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2010</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>Change</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>% Change</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net sales </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;34,508 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;39,035 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(4,527</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(12%</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Royalties </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">2,320,729 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,271,597 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,049,132 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">83% </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Licensing revenue </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>3,026,111 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,565,125 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,460,986 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>93% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">280,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">280,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD align=left  bgColor=#e6efff><B>Total net revenues</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$ </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
     bgColor=#e6efff> <B>5,661,348</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$ </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
     bgColor=#e6efff> <B>3,155,757</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><B>$ </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
     bgColor=#e6efff><B>2,505,591</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
     bgColor=#e6efff><B>79%</B> </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=center>34 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A><BR>
<P align=justify><I>Product Revenues, net </I></P>
<P align=justify>Product revenues include the sales of the collagenase for
laboratory use recognized at the time it is shipped to customers. We had a small
amount of revenue from the sale of collagenase for laboratory use. For the
calendar years ended 2010 and 2009 product revenues were $34,508 and $39,035,
respectively. This decrease of $4,527 or 12% was primarily related to the amount
of material required to perform testing and additional research by our
customers. </P>
<P align=justify><I>Royalties </I></P>
<P align=justify>Royalties consist of royalties and the mark-up on cost of goods
sold under our agreement with Auxilium and earn-out revenues associated with the
DFB Agreement. Total royalty and earn-out revenues for year ended December 31,
2010 were $2,320,729 as compared to $1,271,597 in the 2009 period, an increase
of $1,049,132 or 83%. We receive royalty revenues from DFB under the earn-out
payment provision of the DFB Agreement, after certain net sales levels are
achieved. Royalty revenues recognized under the DFB Agreement for the year ended
December 31, 2010 were $1,610,548 and $1,271,597 for the same period in 2009.
This increase of $338,950 or 27% is mainly related to the increase in net sales
during the 2010 period reported to us by DFB.</P>
<P align=justify>In 2010, we began to recognize royalties and the mark-up on
cost of goods sold due to us under the terms of the Auxilium Agreement. Under
the Auxilium Agreement, royalties to which we are entitled are subject to
set-off for certain expenses we owe to Auxilium relating to certain development
and patent costs. Royalty and cost of goods sold revenues recognized under the
Auxilium Agreement for the 2010 period were $682,160 and zero in the comparable
period of 2009. The increase was due to the net sales of XIAFLEX during 2010
reported to us by Auxilium. Auxilium launched XIAFLEX in March 2010. </P>
<P align=justify><I>Licensing Revenue</I> </P>
<P align=justify>Licensing revenue consist of licensing fees, sublicensing fees
and milestones. For the year ended December 31, 2010 and 2009, we recognized
total licensing and milestone revenue of $3,026,111 and $1,565,125, an increase
of $1,490,986 or 93%, respectively. Licensing revenues recognized are related to
the cash payments received under the Auxilium Agreement in prior years and
amortized over the expected development period. Licensing revenue recognized for
the year ended December 31, 2010 and 2009 were $751,111 and $1,065,125,
respectively. The decrease of $314,014, or 29%, was mainly due to the completed
recognition of licensing revenue associated with the Dupuytren&#146;s contracture
indication during the first quarter of 2010. </P>
<P align=justify>Milestone revenue recognized for the year ended December 31,
2010 and 2009 was $2.275 million and $0.5 million, respectively. In the 2010
period, we received and recognized $1.275 million of the $15 million paid to
Auxilium by Pfizer for the scientific/technical review procedure of the
Marketing Authorization Application for XIAFLEX for Dupuytren&#146;s contracture in
Europe. We also received and recognized a milestone of $1.0 million related to
the FDA&#146;s approval of XIAFLEX for Dupuytren&#146;s contracture in February 2010 and
in connection with our notification in June 2010 to Auxilium of our election not
to commercially manufacture XIAFLEX. In the comparable 2009 period, we
recognized $500,000 related to a milestone received under the Auxilium Agreement
for the filing and acceptance of a new drug application for Dupuytren&#146;s
contracture. </P>
<P align=justify>Under current accounting guidance, nonrefundable upfront
license fees for product candidates for which we are providing continuing
services related to product development are deferred and recognized as revenue
over the development period. The remaining balance will be recognized over the
respective development periods or when we determine that we have no ongoing
performance obligations. </P>
<P align=justify><I>Consulting Services </I></P>
<P align=justify>We recognize revenues from consulting and technical assistance
contracts primarily as a result of the DFB Agreement. We recognize consulting
revenues ratably over the term of the contract. The consulting and technical
assistance obligations under the DFB Agreement expire during March 2011. For
calendar years 2010 and 2009 we recognized $280,000 in each period in consulting
revenue. </P>
<P align=center>35 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=justify><I>Research and Development Activities </I></P>
<P align=justify>Our research and development expenses consist of salaries and
expenses for our research personnel; supplies, payments to consultants,
investigators clinical trials and overhead costs. Research and development
expenses were $1,223,931 and $488,646, respectively, for calendar years 2010 and
2009, representing an increase in 2010 of $735,285, or 150%. This increase in
research and development expenses was primarily due to third party development
costs that are reimbursable under the Auxilium Agreement. </P>
<P align=justify><I>General and Administrative Expenses </I></P>
<P align=justify>General and administrative expenses consist primarily of
salaries and other related costs for personnel, consultant costs, legal fees,
investor relations, professional fees and overhead costs. General and
administrative expenses were $6,470,449 and $4,832,019 for calendar years 2010
and 2009, respectively, an increase of $1,638,430, or 34%, from 2009. The
increase in general and administrative expenses was due to legal fees, stock
based compensation and services related to investor relations partially offset
by lower patent costs. </P>
<P align=justify><I>Other Income and expense </I></P>
<P align=justify>Other income for calendar year 2010 was $525,843 compared to
$46,791 for calendar year 2009. Other income during 2010 was due to interest of
$83,310 earned on our investments compared to $55,693 in the 2009 period. Other
income during 2010 was due to a reversal of accrued tax penalties of $13,130
associated with our delinquent tax filings in previous years.</P>
<P align=justify><I>Qualifying Therapeutic Discovery Project Program
</I><I></I></P>
<P align=justify>In November 2010, we were notified that we had been awarded a
total cash grant of approximately $426,000 under the Qualifying Therapeutic
Discovery Project program administered under section 48D of the Internal Revenue
Code, of which approximately $102,000 relates to qualifying expenses we had
previously incurred during the 2009 fiscal year which was received during the
fourth quarter of fiscal 2010. The remainder of the grant of approximately
$324,000 was received in February 2011 based on qualifying expenses that we
incurred during the 2010 fiscal year. We recognized the full $426,000 of the
grant as of the date of notification since we had already incurred all of the
qualifying expenses. Since this program is non-recurring, we elected to classify
this payment as other income in the Consolidated Statement of Operations for the
year ended December 31, 2010. </P>
<P align=justify><I>Income Taxes</I> </P>
<P align=justify>The income tax expense for 2010 was $1,351 as compared to an
income tax benefit of $161,574 for 2009. The income tax expense for 2010 was the
result of minimum New York State taxes. In 2009, the Company utilized its
current federal NOL to carry-back to the 2008 tax year to claim a refund of
taxes paid of $198,239 which were partially offset by 2009 state tax of $1,784
and a $34,881 tax adjustment related to prior years&#146; tax returns.</P>
<P align=justify><B>YEAR ENDED DECEMBER 31, 2009 COMPARED WITH YEAR ENDED
DECEMBER 31, 2008 </B></P>
<P align=justify><I>Net revenues</I></P>
<P align=justify>Net revenues for the two years ended December 31, 2009 and 2008
comprise the following: <B></B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="23%"
    colSpan=4><B>Year Ended December 31</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%">&nbsp; </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2008</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>Change</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>% Change</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net sales </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;39,035 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;37,343 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;1,692 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>5% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Royalties </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,271,597 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">510,127 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">761,470 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">149% </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Licensing revenue </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,565,125 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>7,440,125 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(5,875,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(79%</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">280,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">424,185 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(144,185</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="10%">(34%</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp;<B>Total
      revenues</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;<B>3,155,757</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;8,411,780</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;(5,256,023</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff><B>(62%</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B>
  </TD></TR></TABLE>
<P align=center>36 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=justify><I>Product Revenues, net </I></P>
<P align=justify>Product revenues include the sales of the collagenase for
laboratory use recognized at the time it is shipped to customers. We had a small
amount of revenue from the sale of collagenase for laboratory use. For the
calendar years ended 2009 and 2008 product revenues were $39,035 and $37,343,
respectively. This increase of $1,692 or 5% was primarily related to the amount
of material required to perform testing and additional research by our
customers. </P>
<P align=justify><I>Royalties </I></P>
<P align=justify>All of the royalty revenues we received in 2009 are from DFB
under the earn-out payment provision of the DFB Agreement. Total royalty
revenues recognized under that agreement were $1,271,597 and $510,126 for
calendar years 2009 and 2008, respectively. The increase of $761,470, or 149%,
from calendar year 2008 to 2009 was due to certain sales levels achieved by DFB
in connection with the sale of topical collagenase. </P>
<P align=justify><I>Licensing Revenue </I></P>
<P align=justify>Licensing revenue consist of licensing fees, sublicensing fees
and milestones. We recognized as licensing, sublicensing and milestone revenue
$1,565,125 and $7,440,125 in calendar years 2009 and 2008, respectively. The
decrease of $5,875,000, or 79%, from 2008 to 2009 was due to a sublicense fee of
$6,375,000 recognized in 2008 partially offset by a $500,000 milestone received
in 2009 in connection with the Auxilium Agreement. </P>
<P align=justify><I>Consulting Services </I></P>
<P align=justify>We recognize revenues from consulting and technical assistance
contracts primarily as a result of the DFB Agreement and a consulting agreement
signed in October 2007 with Auxilium. We recognize consulting revenues ratably
over the term of the contract. The consulting and technical obligations under
the DFB Agreement expire during March 2011. For calendar years 2009 and 2008 we
recognized $280,000 and $424,185, respectively, in consulting revenue. The
decrease of $144,185 or 34% from 2008 to 2009 was primarily due to the
recognition in 2008 of revenues earned in connection with the October 2007
consulting agreement with Auxilium. </P>
<P align=justify><I>Research and Development Activities </I></P>
<P align=justify>Research and development expenses were $488,646 and $439,919
respectively, for calendar years 2009 and 2008, representing an increase from
2008 to 2009 of $48,727, or 11%. This increase was primarily due to certain
employee costs which were reimbursable under the DFB Agreement until October
2008 and stock-based compensation expense partially offset by decreases in
external study development costs. </P>
<P align=justify><I>General and Administrative Expenses </I></P>
<P align=justify>General and administrative expenses were $4,832,019 and
$4,191,052 for calendar years 2009 and 2008, respectively, an increase of
$640,967, or 15%, from 2008 to 2009. This increase was primarily due to outside
consulting services, certain facility costs which were reimbursable under the
DFB Agreement until October 2008, employee costs, legal fees and board member
service partially offset by a decrease in patent related fees and stock-based
compensation expense.<B> </B></P>
<P align=justify><I>Other Income and expense </I></P>
<P align=justify>Other income for calendar year 2009 was $46,791 compared to
$262,811 for calendar year 2008. Other income during 2009 was due to interest of
$55,693 earned on our investments and other consisting of tax penalties of
$9,463 which was partially offset by a $600 gain related to an asset sale. Other
income during 2008 was due to interest earned of $107,552 on our investments, a
reversal of interest expense penalty of $80,409 associated with our delinquent
tax filings partially offset by an interest expense tax payment of $33,880 after
finalizing our delinquent tax returns, a reversal of accrued tax penalties of
$103,203 and a small gain from the sale of an asset of $5,527. </P>
<P align=justify><I>Income Taxes</I><B><I> </I></B></P>
<P align=center>37 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_5></A>
<P align=justify>The income tax benefit for 2009 was $161,574 as compared to an
income tax expense of $299,212 for 2008. In 2009 the Company utilized its
current federal NOL to carryback to the 2008 tax year to claim a refund of taxes
paid of $198,239 which were partially offset by 2009 state tax of $1,784 and a
$34,881 tax adjustment related to prior years&#146; tax returns. In 2008, we accrued
approximately $494,234 associated with federal and state taxes based on our net
income in 2008 which was partially offset by a tax benefit related to the
exercise of stock options of $314,648 and we recognized a $195,022 tax benefit
in connection with our 2007 net operating loss. </P>
<P align=justify><B>Liquidity and Capital Resources</B> </P>
<P align=justify>To date, we have financed our operations primarily through
product sales, debt instruments, licensing revenues and royalties under
agreements with third parties and sales of our common stock. At December 31,
2010, 2009 and 2008, we had cash and cash equivalents and short-term investments
in the aggregate of approximately $7.8 million, $8.5 million and $4.4 million,
respectively.<B> </B></P>
<P align=justify><B>Sources and Uses of Cash</B><B><I> </I></B></P>
<P align=justify><I>Net Cash provided by (Used In) Operating Activities </I></P>
<P align=justify>Net cash provided by (used in) operating activities was $(0.9)
million, $3.7 million and $(3.1) million for 2010, 2009 and 2008. Cash used in
operations for 2010 resulted primarily from operating losses, net of stock
compensation expenses and other non-cash charges. At December 31, 2010, accounts
receivable increased by $0.4 million, compared to December 31, 2009 primarily
due to a higher receivable balance related to the DFB Agreement. Our deferred
revenue at December 31, 2010 decreased by $0.8 million compared to December 31,
2009 primarily due to the amortization of previously received license payments
under the Auxilium Agreement.</P>
<P align=justify>At December 31, 2009, accounts receivable decreased by $5.2
million, compared to December 31, 2008, primarily due to a receipt of a $6.375
million sublicense payment under the Auxilium Agreement which was earned in 2008
partially offset by an increase in earn-out royalties under the DFB Agreement.
Our deferred revenue at December 31, 2009 decreased by $1.1 million compared to
December 31, 2008 primarily due to the amortization of previously received
license payments under the Auxilium Agreement. </P>
<P align=justify>The majority of our cash expenditures in 2010, 2009, and 2008
were to fund research and development and our business activities. </P>
<P align=justify><I>Net Cash Used in Investing Activities </I></P>
<P align=justify>Net cash used in investing activities was $0.8 million in 2010,
compared to $3.6 million in 2009 and $1.2 million in 2008. In 2010, purchases of
marketable securities exceeded maturities by $0.8 million. In 2009, purchases of
marketable securities exceeded maturities by $3.6 million. In 2008, maturities
of marketable securities exceeded purchases by $75,000 and reflects a one-time
cash payment related to the buy down of future royalty obligations for
Peyronie's disease of $1,250,000. </P>
<P align=justify><I>Net Cash provided by Financing Activities </I></P>
<P align=justify>Net cash provided by financing activities was $0.2 million,
$0.4 million and $7.7 million for 2010, 2009 and 2008, respectively. Net cash
provided by financing activities in 2010 was from proceeds from stock option
exercises partly offset by the repurchase of our common stock under our 2010
Stock Repurchase Program. Net cash provided by financing activities in 2009 was
from proceeds received from stock option exercises. Net cash provided by
financing activities for 2008 consisted of proceeds from the sale of our common
stock of $6.0 million, repayment of an outstanding loan from our former Chairman
and CEO of $1.1 million, $0.3 million related to excess tax benefits from
share-based payment arrangements and proceeds received from stock option
exercises of $0.3 million. </P>
<P align=justify><B>Contractual Commitments </B></P>
<P align=justify>We are involved with licensing of products which are generally
associated with payments to third parties from whom we have licensed the
product. Such payments may take the form of an up-front payment, milestone
payments which are paid when certain parts of the overall development program
are accomplished; payments upon certain regulatory events, such as the filing of an IND, an NDA or BLA, approval
of an NDA or BLA, or the equivalents in other countries and payments based on a
percentage of sales. </P>
<P align=center>38 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_6></A>
<P align=justify>We may also out-license products, for which we hold the rights,
to other companies for commercialization in other territories, or at times, for
other uses. When this happens, the payments to us would also take the same form
as described above.</P>
<P align=justify><I>Operating Leases </I></P>
<P align=justify>Our operating leases are principally for facilities and
equipment. We currently lease approximately 15,000 square feet of space at our
headquarters in Lynbrook, New York on a month to month basis. Additionally, we
lease certain vehicle and certain office equipment which generally expire in
2011 and 2014. </P>
<P align=justify>Future minimum annual payments required under non-cancelable
operating leases are approximated as follows: </P>
<P align=justify>Year ending December 31, </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>2011 </TD>
    <TD align=left width="50%" bgColor=#e6efff>$5,000 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#ffffff>2012 </TD>
    <TD align=left width="50%" bgColor=#ffffff>$3,500 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>2013 </TD>
    <TD align=left width="50%" bgColor=#e6efff>$3,500 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#ffffff>2014 </TD>
    <TD align=left width="50%" bgColor=#ffffff>$1,700
</TD></TR></TABLE></DIV>
<P align=justify><B>Off-Balance Sheet Arrangements </B></P>
<P align=justify>We do not have any off-balance sheet arrangements as defined in
Item 303(a)(4) of Regulation S-K.</P>
<P align=justify><B>Future Impact of Recently Issued Accounting Standards</B>
</P>
<P align=justify>In March 2010, the Financial Accounting Standards Board
(&#147;FASB&#148;) amended its authoritative guidance on the milestone method of revenue
recognition. The milestone method of revenue recognition has now been codified
as an acceptable revenue recognition model when a milestone is deemed to be
substantive. This guidance may be applied retrospectively to all arrangements or
prospectively for milestones achieved after the adoption of the guidance. We
will adopt this amended guidance for the fiscal year beginning January 1, 2011.
We do not anticipate that the adoption of this guidance will have a material
impact on our financial statements. </P>
<P align=justify>In February 2010, the FASB issued update No. 2010-09,<I>
Subsequent Events (Topic 855): Amendments to Certain Recognition and Disclosure
Requirements. </I>This update provides amendments to Subtopic 855-10 for an
entity that is an SEC filer and is required to evaluate subsequent events
through the date that the financial statements are issued. An entity that is an
SEC filer is not required to disclose the date through which subsequent events
have been evaluated. The adoption of this update on February 24, 2010 did not
have any impact on the consolidated financial statements. </P>
<P align=justify>In January 2010, the FASB issued update No. 2010-06,<I> Fair
Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair
Value Measurements.</I> This update amends subtopic 820-10 to require 1) a
reporting entity to disclose separately the amounts of significant transfers in
and out of level 1 and 2 fair value measurements and to describe the reasons for
the transfers, and 2) in the reconciliation for fair value measurements using
significant unobservable inputs (level 3), a reporting entity should present
separately information about purchases, sales, issuances, and settlements on a
gross basis rather than as one net number. This update also provides
clarification about existing disclosures about the level of disaggregation and
inputs and valuation techniques. The new disclosures and clarifications of
existing disclosures are effective for interim and annual reporting periods
beginning after December 2009. The adoption of this update did not have a
material impact on the consolidated financial statements. Disclosures about
purchases, sales, issuances, and settlements in the roll forward of activity on
Level 3 fair value measurements is effective for fiscal years beginning after
December 15, 2010 and for interim periods within those fiscal years. </P>
<P align=justify><B>Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK. </B></P>
<P align=justify>We do not use derivative financial instruments or derivative
commodity instruments for trading purposes. Our financial instruments consist of cash, cash equivalents,
short-term investments, trade accounts receivable, accounts payable and
long-term obligations. We consider investments that, when purchased, have a
remaining maturity of 90 days or less to be cash equivalents.</P>
<P align=center>39 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_7></A>
<P align=justify>Our investment portfolio is subject to interest rate risk,
although limited given the nature of the investments, and will fall in value in
the event market interest rates increase. All our cash and cash equivalents at
December 31, 2010, amounting to approximately $2.5 million, were maintained in
bank demand accounts and money market accounts. Our short-term investments of
$5.4 million were maintained in certificates of deposit. We do not hedge our
interest rate risks, as we believe reasonably possible near-term changes in
interest rates would not materially affect our results of operations, financial
position or cash flows.</P>
<P align=justify><B>Item 8. FINANCIAL STATEMENTS. </B></P>
<P align=justify>For the discussion of Item 8, &#147;Financial Statements&#148; please see
the Consolidated Financial Statements, beginning on page F-1 of this Report.<B>
</B></P>
<P align=justify><B>Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE.</B></P>
<P align=justify>None.</P>
<P align=justify><B>Item 9A. EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES.
</B></P>
<P align=justify>The Company, under the supervision and with the participation
of Thomas L. Wegman, the Company&#146;s President, Principal Executive Officer,
Principal Financial Officer and Principal Accounting Officer, evaluated the
effectiveness of its disclosure controls and procedures as of the end of the
period covered by this Report. Based on that evaluation, management has
concluded that the Company&#146;s disclosure controls and procedures are effective to
ensure that information required to be disclosed in reports filed under the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), is recorded,
processed, summarized and reported within the time periods specified in the
rules and forms of the SEC, and that such information is accumulated and
communicated to the Company&#146;s management, to allow timely decisions regarding
required disclosure. Because of the inherent limitations in all control systems,
any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives,
and management necessarily is required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. Furthermore, our
controls and procedures can be circumvented by the individual acts of some
persons, by collusion of two or more people or by management override of the
control, and misstatements due to error or fraud may occur and not be detected
on a timely basis. </P>
<P align=justify><B>Management&#146;s Annual Report on Internal Control Over
Financial Reporting </B></P>
<P align=justify>Management of the Company is responsible for establishing and
maintaining adequate internal control over financial reporting for the Company
as defined in Rule 13a-15(f) under the Exchange Act. The Company&#146;s internal
control over financial reporting is designed to provide reasonable assurance to
the Company&#146;s management and board of directors regarding the preparation and
fair presentation of published financial statements and the reliability of
financial reporting.</P>
<P align=justify>Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements. Therefore, even
those systems determined to be effective can provide only reasonable assurance
with respect to financial statement preparation and presentation.</P>
<P align=justify>Management assessed the effectiveness of the Company&#146;s internal
control over financial reporting as of December 31, 2010. In making this
assessment, management used the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission in <I>Internal Control &#150;
Integrated Framework</I>. We believe that, as of December 31, 2010, the
Company&#146;s internal control over financial reporting was effective based on this
criteria. </P>
<P align=justify>Tabriztchi &amp; Co, the independent registered public
accounting firm that audited our Consolidated Financial Statements included in
this Report, audited the effectiveness of our internal control over financial
reporting as of December 31, 2010, as stated in their report which is included
in Part IV, Item 15 of this Report.</P>
<P align=center>40 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_8></A>
<P align=justify><B>Changes in Internal Control Over Financial Reporting</B></P>
<P align=justify>There were no changes in our internal control over financial
reporting identified in connection with the evaluation of our controls performed
during the year ended December 31, 2010 that have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.</P>
<P align=justify><B>Item 9B. OTHER INFORMATION </B></P>
<P align=justify>Not applicable. </P>
<P align=center><B>PART III </B></P>
<P align=justify><B>Item 10. DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND
CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT </B></P>
<P align=justify>The information required by this item is incorporated herein by
reference to the sections captioned &#147;Directors and Executive Officers,&#148;
&#147;Committees of the Board of Directors,&#148; and &#147;Section 16(a) Beneficial Ownership
Reporting Compliance&#148; in our definitive Proxy Statement relating to our 2011
Annual Meeting of Stockholders.</P>
<P align=justify><B>Item 11. EXECUTIVE COMPENSATION. </B></P>
<P align=justify>The information required by this item is incorporated herein by
reference to the section captioned &#147;Executive Compensation&#148; in our definitive
Proxy Statement relating to our 2011 Annual Meeting of Stockholders. </P>
<P align=justify><B>Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</B></P>
<P align=justify>The information required by this item is incorporated herein by
reference to the sections captioned &#147;Security Ownership of Certain Beneficial
Owners and Management&#148; and &#147;Equity Compensation Plan Information&#148; in our
definitive Proxy Statement relating to our 2011 Annual Meeting of Stockholders.
</P>
<P align=justify><B>Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE. </B></P>
<P align=justify>The information required by this item is incorporated herein by
reference to the section captioned &#147;Certain Relationships and Related
Transactions&#148; in our definitive Proxy Statement relating to our 2011 Annual
Meeting of Stockholders.</P>
<P align=justify><B>Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES. </B></P>
<P align=justify>The information required by this item is incorporated herein by
reference to the section captioned &#147;Ratification of Selection of Independent
Registered Public Accounting Firm&#148; in our definitive Proxy Statement relating to
our 2011 Annual Meeting of Stockholders.<B> </B></P>
<P align=center><B>PART IV </B></P>
<P align=justify><B>Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>The following documents are filed as part of this Report:
      </P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Consolidated Financial Statements (See Index to
      Consolidated Financial Statements on page F-1) </P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>Financial Statement Schedules </P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>All schedules to the consolidated financial statements
      are omitted as the required information is either inapplicable or
      presented in the consolidated financial statements.</P></TD></TR></TABLE>
<P align=center>41 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_9></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(3) </TD>
    <TD>
      <P align=justify>Exhibits </P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The information required by this Item is set forth in the
      Exhibit Index hereto which is incorporated herein by reference.
  </P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>Exhibits </P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>
      <P align=justify>&nbsp;</P></TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The information required by this Item is set forth in the
      Exhibit Index hereto which is incorporated herein by reference.
  </P></TD></TR></TABLE>
<P align=center>42 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_10></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=center><B>BIOSPECIFICS TECHNOLOGIES CORP.</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE
      YEAR</B> </TD></TR>
  <TR vAlign=bottom>
    <TD align=center><B>ENDED DECEMBER 31, 2010</B> </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="10%" ><B>Page</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>Report of Independent Registered Public
      Accounting Firm </TD>
    <TD align=center width="10%" bgColor=#eeeeee >F-2 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Consolidated Balance Sheets </TD>
    <TD align=center width="10%" >F-5 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>Consolidated Statements of Operations </TD>
    <TD align=center width="10%" bgColor=#eeeeee >F-6 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Consolidated Statements of Cash Flows </TD>
    <TD align=center width="10%" >F-7 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>Consolidated Statements of Stockholders&#146;
      Deficit </TD>
    <TD align=center width="10%" bgColor=#eeeeee >F-8 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Notes to Consolidated Financial Statements </TD>
    <TD align=center width="10%" >F-9 </TD></TR></TABLE>
<P align=center>F-1 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=-->
<p align="center"><A name=page_11></A>
<IMG
src="part2x11x1.jpg" border=0 width="632" height="64"> <BR>
</p>
<P align=center>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P align=justify>To the Board of Directors and <BR>Stockholders of
<BR>BioSpecifics Technologies Corp. </P>
<P align=justify>We have audited the accompanying consolidated balance sheets of
BioSpecifics Technologies Corp. as of December 31, 2010 and 2009, and the
related consolidated statements of income, stockholders' equity and cash flows
for each of the three-years in the period ended December 31, 2010. BioSpecifics
Technologies Corp.'s management is responsible for these financial statements.
Our responsibility is to express an opinion on these financial statements based
on our audits. </P>
<P align=justify>We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion. </P>
<P align=justify>In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial position of
BioSpecifics Technologies Corp. as of December 31, 2010 and 2009, and the
results of its operations and its cash flows for each of the three years in the
period ended December 31, 2010 in conformity with accounting principles
generally accepted in the United States of America. </P>
<P align=justify>We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), BioSpecifics
Technologies Corp.'s internal control over financial reporting as of December
31, 2010, based on criteria established in <I>Internal Control&#151;Integrated
Framework</I> issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO), and our report dated March 14, 2011 expressed an
unqualified opinion. </P>
<P align=justify>/s/ Tabriztchi &amp; Co., CPA, P.C. </P>
<P align=justify>Garden City, NY <BR>March 14, 2011 </P>
<p align="center">
<IMG src="part2x11x2.jpg"
border=0 width="598" height="55"> <BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_12></A>
<P align=center><IMG src="part2x12x1.jpg" border=0 width="636" height="69"> </P>
<P align=center>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P align=justify>To the Board of Directors and <BR>Stockholders of
<BR>BioSpecifics Technologies Corp. </P>
<P align=justify>We have audited BioSpecifics Technologies Corp.'s internal
control over financial reporting as of December 31, 2010 based on criteria
established in <I>Internal Control&#151;Integrated Framework</I> issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO).
BioSpecifics Technologies Corp's management is responsible for maintaining
effective internal control over financial reporting and for its assessment of
the effectiveness of internal control over financial reporting included in the
accompanying Management&#146;s Annual Report on Internal Control over Financial
Reporting. Our responsibility is to express an opinion on the company's internal
control over financial reporting based on our audit. </P>
<P align=justify>We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about
whether effective internal control over financial reporting was maintained in
all material respects. Our audit of internal control over financial reporting
included obtaining an understanding of internal control over financial
reporting, assessing the risk that a material weakness exists, and testing and
evaluating the design and operating effectiveness of internal control based on
the assessed risk. Our audit also included performing such other procedures as
we considered necessary in the circumstances. We believe that our audit provides
a reasonable basis for our opinion. </P>
<P align=justify>A company's internal control over financial reporting is a
process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles. A
company's internal control over financial reporting includes those policies and
procedures that (1) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the
assets of the company; (2) provide reasonable assurance that transactions are
recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with
authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company's assets that could have a
material effect on the financial statements. </P>
<P align=justify>Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk
that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate. </P>
<P align=justify>In our opinion, BioSpecifics Technologies Corp. maintained, in
all material respects, effective internal control over financial reporting as of
December 31, 2010, based on criteria established in Internal Control&#151;Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </P>
<P align=center><IMG src="part2x12x2.jpg" border=0 width="602" height="59"> </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_13></A>
<P align=justify>We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the balance sheets as
of December 31, 2010 and 2009 and the related statements of income,
stockholders' equity and comprehensive income, and cash flows of BioSpecifics
Technologies Corp. for each of the three years ended December 31, 2010, and our
report dated March 14, 2011 expressed an unqualified opinion. </P>
<P align=justify>/s/ Tabriztchi &amp; Co., CPA, P.C. </P>
<P align=justify>Garden City, NY <BR>March 14, 2011 </P>
<P align=center>F-4 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_14></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B>BioSpecifics Technologies Corp.</B> </TD></TR>
  <TR vAlign=top>
    <TD align=center><B>Consolidated Balance Sheet</B> </TD></TR>
  <TR vAlign=bottom>
    <TD align=center><B>December 31,</B> </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%"><B>2010</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%"><B>2009</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Assets</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Current assets:</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Cash and cash equivalents </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;2,470,852 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;3,950,389 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Short term investments </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">5,360,970 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">4,548,541 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Accounts receivable, net </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,986,125 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,295,399 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Income tax receivable </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">185,386 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">416,821 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Prepaid expenses and other
      current assets </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>91,925 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>63,260 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Total current assets</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%"><B>10,095,258</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%"><B>10,274,410</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Deferred royalty buy-down </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,250,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,250,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Property, plant and equipment,
      net </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>610 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;&nbsp;&nbsp;Patent costs, net </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">173,443 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">223,458 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<STRONG>Total
      assets</STRONG> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%"><B>11,518,701</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%"><B>11,748,478</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Liabilities and Stockholders' Equity</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Current liabilities: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Accounts payable and accrued expenses </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">893,083 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">584,509 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Accrued third party
      development expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>2,649,369 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>2,965,225 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Deferred revenue </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">483,769 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">877,778 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Accrued liabilities of
      discontinued operations </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>78,138 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>78,138 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Total current liabilities</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%"><B>4,104,359</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%"><B>4,505,650</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Deferred revenue - license fees </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">713,619 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,150,721 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Stockholders' equity:</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;&nbsp;&nbsp;Series A Preferred stock,
      $.50 par value, 700,000 shares
      authorized;&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;none outstanding
    </TD>
    <TD align=left width="1%"  bgColor=#e6efff><BR></TD>
    <TD align=right width="12%" bgColor=#e6efff><BR>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff><BR></TD>
    <TD align=left width="1%"  bgColor=#e6efff><BR></TD>
    <TD align=right width="12%" bgColor=#e6efff><BR>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;&nbsp;&nbsp;Common stock, $.001 par value; 10,000,000
      shares
      authorized;&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6,445,743and
      6,327,318 shares issued at December 31,
      2010&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and 2009, respectively
    </TD>
    <TD align=left width="1%" ><BR><BR></TD>
    <TD align=right width="12%"><BR><BR>6,446 </TD>
    <TD align=left width="2%" ><BR><BR></TD>
    <TD align=left width="1%" ><BR><BR></TD>
    <TD align=right width="12%"><BR><BR>6,327 </TD>
    <TD align=left width="2%" ><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Additional paid-in capital </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>17,739,765 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>15,164,727 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Accumulated deficit </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(9,893,530</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(8,384,990</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;&nbsp;&nbsp;Treasury stock, 151,875
      and 131,267 shares at cost as of December
      31,&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2010 and 2009 </TD>
    <TD align=left width="1%"  bgColor=#e6efff><BR></TD>
    <TD align=right width="12%" bgColor=#e6efff><BR>(1,151,958</TD>
    <TD align=left width="2%"  bgColor=#e6efff><BR>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff><BR></TD>
    <TD align=right width="12%" bgColor=#e6efff><BR>(693,957</TD>
    <TD align=left width="2%"  bgColor=#e6efff><BR>) </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Total stockholders' equity</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%"><B>6,700,723</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%"><B>6,092,107</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<STRONG>Total
      liabilities and stockholders&#146; equity</STRONG> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%"><B>&nbsp;11,518,701</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%"><B>11,748,478</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=center>F-5 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_15></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B>BioSpecifics Technologies Corp.</B> </TD></TR>
  <TR vAlign=top>
    <TD align=center><B>Consolidated Statements of Operations</B> </TD></TR>
  <TR vAlign=bottom>
    <TD align=center><B>Years Ended December 31,</B> </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2010</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2009</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Revenues:</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net sales </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;34,508 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;39,035 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;37,343 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Royalties </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>2,320,729 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,271,597 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>510,127 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Licensing revenue </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">3,026,111 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,565,125 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">7,440,125 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Consulting fees </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>280,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>280,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>424,185 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Total revenues </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>5,661,348</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>3,155,757</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>8,411,780</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Costs and expenses:</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Research and development </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,223,931 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>488,646 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>439,919 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;General and administrative </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">6,470,449 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">4,832,019 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">4,191,052 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Total costs and expenses </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>7,694,380 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>5,320,665 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>4,630,971 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Operating income (loss)</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>(2,033,032</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>(2,164,908</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>3,780,809</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Other income (expense):</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Interest income </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>86,310 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>55,693 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>107,552 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Interest expense </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(39</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">46,529 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Other </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>13,130 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(8,863</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>108,730 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Qualifying Therapeutic Discovery Grant </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">426,403 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>525,843 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>46,791 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>262,811 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Income (loss) before benefit (expense) for
      income tax </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(1,507,189</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(2,118,117</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>4,043,620 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Income tax benefit (expense) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="10%">(1,351</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">161,574 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(299,212</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Net income (loss)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff><B>&nbsp;(1,508,540</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff><B>&nbsp;(1,956,543</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff><B>&nbsp;3,744,408</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Basic net income (loss) per share</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;(0.24</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;(0.32</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;0.64</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Diluted net income (loss) per share</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;(0.24</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;(0.32</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;0.55</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Shares used in computation of basic net income (loss)
      per share</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>6,261,214</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>6,065,939</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>5,854,836</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Shares used in computation of diluted
      net income (loss) per share</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff><B>6,261,214</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff><B>6,065,939</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff><B>6,836,911</B> </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=center>F-6 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_16></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B>BioSpecifics Technologies Corp.</B> </TD></TR>
  <TR vAlign=top>
    <TD align=center><B>Consolidated Statements of Cash Flows</B> </TD></TR>
  <TR vAlign=bottom>
    <TD align=center><B>Years Ended December 31,</B> </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Cash flows from operating activities:</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2010</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2009</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Net income (loss) </TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;(1,508,540</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;(1,956,543</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;3,744,408</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income
      (loss) to net cash used&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
      operating activities: </TD>
    <TD align=left width="1%" ><BR></TD>
    <TD align=left width="10%"><BR></TD>
    <TD align=left width="2%" ><BR></TD>
    <TD align=left width="1%" ><BR></TD>
    <TD align=left width="10%"><BR></TD>
    <TD align=left width="2%" ><BR></TD>
    <TD align=left width="1%" ><BR></TD>
    <TD align=left width="10%"><BR></TD>
    <TD align=left width="2%" ><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left
      bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
      and amortization </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>18,949 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>35,669 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>55,774 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain
      on disposal of fixed assets </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(5,535</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left
      bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based
      compensation expense </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,901,781 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,490,083 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>1,476,148 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Changes in operating assets and
      liabilities: </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left
      bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts
      receivable </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(459,291</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>5,616,601 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(6,843,974</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid
      expenses and other current assets </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(28,664</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(371,592</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">5,449 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left
      bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts
      payable and accrued expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>24,394 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>55,658 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(388,200</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
      revenue </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(831,111</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(1,145,125</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(1,145,125</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Net cash provided by (used in) operating
      activities from continuing operations</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff><B>(882,482</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff><B>3,724,751</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff><B>(3,101,055</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Cash flows from investing
      activities:</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Maturities of marketable securities </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">4,548,541 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">2,799,754 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">2,075,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Purchases of marketable
      securities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(5,360,970</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(6,448,295</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(2,000,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Payment for royalty buy down </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(1,250,000</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Proceeds from sale of fixed
      asset </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>8,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Net cash used in investing activities from continuing
      operations</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>(812,429</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>(3,648,541</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>(1,167,000</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Cash flows from financing activities:</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Proceeds from issuance of
      capital stock </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>6,007,047 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;&nbsp;&nbsp;Proceeds from stock option exercises </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">673,375 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">380,029 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">255,388 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Repurchases of common stock
</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(458,001</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Excess tax benefits from share-based payment
      arrangements </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">314,648 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;&nbsp;&nbsp;Proceeds from pay-off of
      notes receivable from former CEO and Chairman </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>1,116,558 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Net cash provided by financing activities from
      continuing operations</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>215,374</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>380,029</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>7,693,641</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Increase (decrease) in cash and cash equivalents </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(1,479,537</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">456,239 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">3,425,586 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash and cash equivalents at beginning of
      year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>3,950,389 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>3,494,150 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>68,564 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Cash and cash equivalents at end of year</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;2,470,852</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B><U>$</U></B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B><U>&nbsp;3,950,389</U></B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%"><B>&nbsp;3,494,150</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Supplemental disclosures of cash flow information:</B>
    </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash paid during the year for: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Interest </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;33,880 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Taxes </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;9,851 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;214,467 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;225,824 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=justify><B>Supplemental disclosures of non-cash transactions:</B> </P>
<P align=justify>Under our agreement with Auxilium certain patent costs paid by
Auxilium on behalf of the Company are creditable against future royalties. As of
December 31, 2010 we accrued $250,621 related to this issue of which $36,041,
$33,983 and $24,856 was amortized in the 2010, 2009 and 2008 periods,
respectively. The net patent amortization expense for 2010 was $18,339 due to a
reduction of reimbursable patents fees under our agreement with Auxilium from
prior periods.</P>
<P align=center><B>See accompanying notes to consolidated financial
statements</B> </P>
<P align=center>F-7 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_17></A>
<P align=justify><B>BioSpecifics Technologies Corp. Consolidated Statement of
Stockholders' Equity (Deficit</B>)<B> </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="8%">&nbsp; </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="8%">&nbsp; </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="8%"><B>Additional Paid</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="8%"><B>Accumulated</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="8%"><B>Shares</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="8%"><B>Amount</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="8%"><B>in Capital</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="8%"><B>Deficit</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Balances - December 31, 2007</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff><B>5,480,768</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff><B>&nbsp;5,481</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff><B>&nbsp;4,751,447 </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff>&nbsp;<STRONG>(10,172,855</STRONG></TD>
    <TD align=left width="2%"  bgColor=#e6efff><STRONG>)</STRONG>
    </TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock at $10.50 to a private investor,
      net of issuance costs </TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">200,000 </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">200 </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">2,093,450 </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" ></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Issuance of common stock at $13.00 to a
      private investor, net of issuance costs </TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>100,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>100 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>1,299,900 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock at $15.00 to a private investor,
      net of issuance costs </TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">100,000 </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">100 </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">1,488,929 </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" ></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Issuance of common stock at $22.50 to a
      private investor, net of issuance costs </TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>50,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>50 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>1,124,318 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock under stock option plans </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">209,300 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">209 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">255,178 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Tax benefit from exercised stock options
</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>314,648 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Stock compensation expense </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">1,476,149 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Payment from former CEO and Chairman loan
      principal and interest </TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>490,784 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD></TR>
  <TR vAlign=top>
    <TD align=left>Net income </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="8%">3,744,408 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Balances - December 31, 2008</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff><B>6,140,068</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff><B>&nbsp;6,140</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff><B>&nbsp;13,294,803 </B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff>&nbsp;<STRONG>(6,428,447</STRONG></TD>
    <TD align=left width="2%"  bgColor=#e6efff><STRONG>)</STRONG>
    </TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock under stock option plans </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">187,250 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">187 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">379,841 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Stock compensation expense </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>1,490,083 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Net loss </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="8%">(1,956,543</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Balances - December 31, 2009</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff><B>6,327,318</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff><B>&nbsp;6,327</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff><B>&nbsp;15,164,727</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="8%"
    bgColor=#e6efff><B>(8,384,990</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock under stock option plans </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">118,425 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">119 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">673,257 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Stock compensation expense </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>1,901,781 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="8%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Repurchases of common stock </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="8%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net loss </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="8%"
    bgColor=#e6efff>(1,508,540</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Balances - December 31, 2010</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="8%"><B>6,445,743</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="8%"><B>&nbsp;6,446</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="8%"><B>&nbsp;17,739,765</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="8%">&nbsp;<STRONG>(9,893,530</STRONG></TD>
    <TD align=left width="2%" ><STRONG>)</STRONG>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%">&nbsp; </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%"><B>Due from</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%">&nbsp; </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%"><B>former</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%"
      ><STRONG>Shareholder</STRONG> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%"><B>Treasury</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%" ><STRONG>Chairman
      and</STRONG>&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="9%" ><STRONG>Equity
      (Deficit</STRONG>)&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>Stock</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>CEO</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="9%"><B>Total</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Balances - December 31, 2007</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="9%"
    bgColor=#e6efff><B>(693,957</B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="9%"
    bgColor=#e6efff>&nbsp;<STRONG>(625,774</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="9%"
    bgColor=#e6efff>&nbsp;<STRONG>(6,735,658</STRONG></TD>
    <TD align=left width="2%"  bgColor=#e6efff><STRONG>)</STRONG>
    </TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock at $10.50 to a private investor,
      net of issuance costs </TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="9%">2,093,650 </TD>
    <TD align=left width="2%" ></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Issuance of common stock at $13.00 to a
      private investor, net of issuance costs </TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff>1,300,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock at $15.00 to a private investor,
      net of issuance costs </TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" ></TD>
    <TD align=left width="1%" ></TD>
    <TD align=right width="9%">1,489,029 </TD>
    <TD align=left width="2%" ></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Issuance of common stock at $22.50 to a
      private investor, net of issuance costs </TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff>1,124,368 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock under stock option plans </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">255,387 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Tax benefit of exercised stock options </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff>314,648 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Stock compensation expense </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%"><B>-</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">1,476,149 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Payment from former CEO and Chairman loan
      principal and interest </TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff>625,774 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD>
    <TD align=left width="1%"  bgColor=#e6efff></TD>
    <TD align=right width="9%" bgColor=#e6efff>1,116,558 </TD>
    <TD align=left width="2%"  bgColor=#e6efff></TD></TR>
  <TR vAlign=top>
    <TD align=left>Net income </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="9%"><B>-</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="9%"><B>-</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="9%">3,744,408 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Balances - December 31, 2008</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(693,957</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="9%"
    bgColor=#e6efff>&nbsp;<STRONG>-</STRONG> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="9%"
    bgColor=#e6efff>&nbsp;<STRONG>6,178,539</STRONG> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock under stock option plans </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">380,028 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Stock compensation expense </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff>1,490,083 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Net loss </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="9%"><B>-</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="9%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="9%">(1,956,543</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Balances - December 31, 2009</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="9%"
    bgColor=#e6efff><B>&nbsp;(693,957</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="9%"
    bgColor=#e6efff>&nbsp;<STRONG>-</STRONG> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="9%"
    bgColor=#e6efff>&nbsp;<STRONG>6,092,107</STRONG> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common stock under stock option plans </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">673,376 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Stock compensation expense </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="9%" bgColor=#e6efff>1,901,781 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Repurchases of common stock </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">(458,001</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="9%">(458,001</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net loss </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="9%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="9%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="9%"
    bgColor=#e6efff>(1,508,540</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Balances - December 31, 2010</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="9%"><B>&nbsp;(1,151,958</B></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    ><B>)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="9%">&nbsp;<STRONG>-</STRONG> </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    ><STRONG>$</STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="9%">&nbsp;<STRONG>6,700,723</STRONG> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=center>F-8 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_18></A>
<P align=center><B>BIOSPECIFICS TECHNOLOGIES CORP. </B></P>
<P align=center><B>Notes to Consolidated Financial Statements <BR>December 31,
2010, 2009 and 2008 </B></P>
<P align=justify><B>1. ORGANIZATION AND DESCRIPTION OF BUSINESS </B></P>
<P align=justify>We are a biopharmaceutical company involved in the development
of an injectable collagenase for multiple indications. We have a development and
license agreement (the &#147;Auxilium Agreement&#148;) with Auxilium Pharmaceuticals, Inc.
(&#147;Auxilium&#148;) for injectable collagenase (which Auxilium has named
XIAFLEX<SUP>&#174;</SUP> (collagenase clostridium histolyticum)) for clinical
indications in Dupuytren&#146;s contracture, Peyronie&#146;s disease and frozen shoulder
(<I>adhesive capsulitis</I>), and Auxilium has an option to acquire additional
indications that we may pursue, including human and canine lipoma and cellulite.
Auxilium has an agreement with Pfizer, Inc. (&#147;Pfizer&#148;) pursuant to which Pfizer
has the right to market XIAFLEX for Dupuytren&#146;s contracture and Peyronie&#146;s
disease in 27 member countries of the European Union and 19 other European and
Eurasian countries, and will do so under the registered trademark
XIAPEX<SUP>&#174;</SUP> (collagenase clostridium histolyticum). </P>
<P align=justify><B>DISCONTINUED OPERATIONS</B></P>
<P align=justify>Prior to March 2006, we were a party to an exclusive license
agreement with Abbott Laboratories, Inc. and its subsidiaries, for the
production of the active pharmaceutical ingredient for topical collagenase. In
March 2006 we sold our topical collagenase business to DFB Biotech, Inc. and its
affiliates (&#147;DFB&#148;), including all rights to the exclusive license agreement and
we were released of any obligations thereunder (the &#147;DFB Agreement&#148;).</P>
<P align=justify>As consideration for the purchased assets we received $8
million in cash, DFB&#146;s assumption of certain liabilities, and the right to
receive earn out payments in the future based on sales of certain products. In
connection with the closing of the DFB Agreement, we agreed to provide certain
technical assistance and certain transition services to DFB in consideration of
fees and costs totaling over $1.4 million. At the closing, DFB paid to us a
partial payment of $400,000 in respect of the technical assistance to be
provided by us. As of December 31, 2010, we have received a total of $1.4
million in payments from DFB. The consulting and technical assistance
obligations expire during March 2011. </P>
<P align=justify><B>2</B>. <B>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
</B></P>
<P align=justify><B>Principles of Consolidation </B></P>
<P align=justify>The audited consolidated financial statements include the
accounts of the Company and its subsidiary, Advance Biofactures Corp.
(&#147;ABC-NY&#148;).</P>
<P align=justify><B>Use of Estimates</B></P>
<P align=justify>The preparation of consolidated financial statements in
conformity with U.S. generally accepted accounting principles requires the use
of management&#146;s estimates and assumptions that affect the amounts reported in
the consolidated financial statements and accompanying notes. Actual results
could differ from those estimates.</P>
<P align=justify><B>Cash, Cash Equivalents and Short-term Investments </B></P>
<P align=justify>Cash, cash equivalents and short-term investments are stated at
market value. Cash equivalents include only securities having a maturity of
three months or less at the time of purchase. The Company limits its credit risk
associated with cash, cash equivalents and short-term investments by placing its
investments with banks it believes are highly creditworthy and with highly rated
money market funds, U.S. government securities, or short-term commercial
paper.</P>
<P align=justify><B>Fair Value Measurements </B></P>
<P align=justify>Management believes that the carrying amounts of the Company&#146;s
financial instruments, including cash, cash equivalents, short-term investments,
accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of those instruments. </P>
<P align=center>F-9 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_19></A>
<P align=justify><B>Revenue Recognition </B></P>
<P align=justify>We currently recognize revenues resulting from product sales,
the licensing and sublicensing of the use of our technology and from services we
sometimes perform in connection with the licensed technology under the guidance
of Accounting Standards Codification 605, <I>Revenue Recognition</I> (&#147;ASC
605&#148;). </P>
<P align=justify>If we determine that separate elements exist in a revenue
arrangement under ASC 605, we recognize revenue for delivered elements only when
the fair values of undelivered elements are known, when the associated earnings
process is complete, when payment is reasonably assured and, to the extent the
milestone amount relates to our performance obligation, when our customer
confirms that we have met the requirements under the terms of the agreement.</P>
<P align=justify>Revenues, and their respective treatment for financial
reporting purposes, are as follows:</P>
<P align=justify><B><I>Product Sales </I></B></P>
<P align=justify>We recognize revenue from product sales when there is
persuasive evidence that an arrangement exists, title passes, the price is fixed
or determinable and collectability is reasonably assured. No right of return
exists for our products except in the case of damaged goods. To date, we have
not experienced any significant returns of our products. </P>
<P align=justify>Net sales include the sales of the collagenase for laboratory
use that are recognized at the time the product is shipped to customers for
laboratory use. </P>
<P align=justify><B><I>Royalty/Earn-Out Revenue</I></B></P>
<P align=justify>Under the Auxilium Agreement, we do not participate in the
selling, marketing or manufacturing of products for which we receive royalties
and a mark-up of the cost of goods sold revenues, The royalty, mark-up on cost
of goods sold revenues will generally be recognized in the quarter that Auxilium
provides the written reports and related information to us, that is, royalty and
mark up on cost of goods sold revenues are generally recognized one quarter
following the quarter in which sales by Auxilium occurred.<B> </B>The royalties
payable by Auxilium to us are subject to set-off for certain third party
development and patent costs.</P>
<P align=justify>Under the DFB Agreement, pursuant to which we sold our topical
collagenase business to DFB, we have the right to receive earn-out payments in
the future based on sales of certain products. Generally, under the DFB
Agreement we would receive payments and a report within ninety (90) days from
the end of each calendar year after DFB has sold the royalty-bearing product.
Currently, DFB is providing us earn-out reports on a quarterly basis. </P>
<P align=justify><B><I>Licensing Revenue</I></B> </P>
<P align=justify>We include revenue recognized from upfront licensing,
sublicensing and milestone payments in &#147;License Revenues&#148; in our consolidated
statements of operations in this Report.</P>
<P align=justify><I>Upfront License and Sublicensing Fees</I></P>
<P align=justify>We generally recognize revenue from upfront licensing and
sublicensing fees when the agreement is signed, we have completed the earnings
process and we have no ongoing performance obligation with respect to the
arrangement. Nonrefundable upfront technology license for product candidates for
which we are providing continuing services related to product development are
deferred and recognized as revenue over the development period.</P>
<P align=justify><I>Milestones </I></P>
<P align=center>F-10 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_20></A>
<P align=justify>Milestones, in the form of additional license fees, typically
represent nonrefundable payments to be received in conjunction with the
achievement of a specific event identified in the contract, such as completion
of specified development activities and/or regulatory submissions and/or
approvals. We believe that a milestone represents the culmination of a distinct
earnings process when it is not associated with ongoing research, development or
other performance on our part. We recognize such milestones as revenue when they
become due and collection is reasonably assured. When a milestone does not
represent the culmination of a distinct earnings process, we recognize revenue
in a manner similar to that of an upfront license fee. </P>
<P align=justify>The timing and amount of revenue that we recognize from
licenses of technology, either from upfront fees or milestones where we are
providing continuing services related to product development, is primarily
dependent upon our estimates of the development period. We define the
development period as the point from which research activities commence up to
regulatory approval of either our, or our partners&#146; submission assuming no
further research is necessary. As product candidates move through the
development process, it is necessary to revise these estimates to consider
changes to the product development cycle, such as changes in the clinical
development plan, regulatory requirements, or various other factors, many of
which may be outside of our control. Should the FDA or other regulatory agencies
require additional data or information, we would adjust our development period
estimates accordingly. The impact on revenue of changes in our estimates and the
timing thereof is recognized prospectively over the remaining estimated product
development period. </P>
<P align=justify><B><I>Consulting and Technical Assistance Services </I></B></P>
<P align=justify>We recognize revenues from consulting and technical assistance
contracts primarily as a result of our DFB Agreement and Auxilium Agreement.
Consulting revenues are recognized ratably over the term of the contract. The
consulting and technical assistance obligations to DFB expire during March
2011.<B><I> </I></B></P>
<P align=justify><B>Accounts receivable and Allowance for Doubtful Accounts
</B></P>
<P align=justify>The Company performs ongoing credit evaluations of its
customers and maintains allowances for potential credit losses which when
realized have been within the range of management&#146;s expectations. Our policy is
to write off bad debts as uncollectible when it is determined that they cannot
be collected.</P>
<P align=justify>As of December 31, 2010, accounts receivables include
approximately $1.6 million due from DFB in accordance with the terms of the DFB
Agreement. Under the DFB Agreement, we receive royalty payments and a report
within ninety (90) days from the end of each calendar year after the licensee
has sold the royalty-bearing product.</P>
<P align=justify><B>Reimbursable Third Party Development Costs</B></P>
<P align=justify>We accrue expenses for research and development and capitalize
certain patent costs related to estimated third party development costs that are
reimbursable under the Auxilium Agreement. Estimates are based on contractual
terms, historical development costs, reviewing third party data and expectations
regarding future development for certain products. Further, we monitor the
activities and clinical trials of our development partners. <B><I></I></B></P>
<P align=justify>If conditions or other circumstances change, we may take
actions to revise our reimbursable third party development cost estimates. These
revisions could result in an incremental increase or decrease in research and
development costs. For example, the Auxilium Agreement provides that Auxilium
and BioSpecifics will share equally in third party costs for the development of
the lyophilization of the injection formulation and certain patent expenses
which are creditable against future royalty revenues.</P>
<P align=justify>In January 2011, we received a credit memo from Auxilium
reducing the amount we owed for lyophilization expenses by $227,000 to the total
amount due that Auxilium believes is owed by us through December 31, 2010 under
this provision. Any amount ultimately agreed as being owed by us to Auxilium for
lyophilization expenses and patent expenses are creditable against future
royalties payable by Auxilium on net sales of XIAFLEX. In 2010, we recognized
approximately $0.7 million related to royalty revenue from the sale of XIAFLEX.
Based upon the updated information and the royalty revenue reported to us, we
reduced our estimates for reimbursable third party development and certain
patent costs to approximately $2.6 million. </P>
<P align=center>F-11 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_21></A>
<P align=justify>Based on our preliminary review, we believe that only a portion
of the amounts invoiced actually relates to the development of the
lyophilization of the injection formulation and certain patent expenses may
increase based upon a resolution of certain patent matters, and therefore, we
reserve all rights related to this matter, including but not limited to our
right to contest the amount charged by Auxilium. We have classified accrued
third party development costs as current liabilities on our balance sheet as of
December 31, 2010. </P>
<P align=justify>Actual results have differed in the past, and may differ in the
future, from our estimates and could impact our earnings in any period during
which an adjustment is made.</P>
<P align=justify><B>Research and Development Expenses</B></P>
<P align=justify>Our research and development (&#147;R&amp;D&#148;) costs are expensed as
incurred. R&amp;D includes, but is not limited to, internal costs, such as
salaries and benefits, costs of materials, lab expense, facility costs and
overhead. R&amp;D also consists of third party costs, such as medical
professional fees, contract manufacturing costs for material used in clinical
trials, consulting fees and costs associated with clinical study R&amp;D
arrangements. We fund R&amp;D at medical research institutions under agreements
that are generally cancelable. All of these costs are charged to R&amp;D as
incurred, which may be measured by percentage of completion, contract
milestones, patient enrollment, or the passage of time. </P>
<P align=justify><B>Clinical Trial Expenses</B></P>
<P align=justify>Our cost accruals for clinical trials are based on estimates of
the services received and efforts expended pursuant to contracts with various
clinical trial centers and clinical research organizations. In the normal course
of business we contract with third parties to perform various clinical trial
activities in the ongoing development of potential drugs. The financial terms of
these agreements are subject to negotiation and vary from contract to contract
and may result in uneven payment flows. Payments under the contracts depend on
factors such as the achievement of certain events, the successful enrollment of
patients, the completion of portions of the clinical trial, or similar
conditions. The objective of our accrual policy is to match the recording of
expenses in our financial statements to the actual cost of services received and
efforts expended. As such, expenses related to each patient enrolled in a
clinical trial are recognized ratably beginning upon entry into the trial and
over the course of the patient&#146;s continued participation in the trial. In the
event of early termination of a clinical trial, we accrue an amount based on our
estimate of the remaining non-cancelable obligations associated with the winding
down of the clinical trial. Our estimates and assumptions could differ
significantly from the amounts that may actually be incurred.</P>
<P align=justify><B>Income Taxes </B></P>
<P align=justify>Deferred tax assets and liabilities are recognized based on the
expected future tax consequences, using current tax rates, of temporary
differences between the financial statement carrying amounts and the income tax
basis of assets and liabilities. A valuation allowance is applied against any
net deferred tax asset if, based on the weighted available evidence, it is more
likely than not that some or all of the deferred tax assets will not be
realized. </P>
<P align=justify>We use the asset and liability method of accounting for income
taxes, as set forth in Accounting Standards Codification 740-10-25-2. Under this
method, deferred income taxes, when required, are provided on the basis of the
difference between the financial reporting and income tax basis of assets and
liabilities at the statutory rates enacted for future periods. In accordance
with Accounting Standards Codification 740-10-45-25, <I>Income Statement
Classification of Interest and Penalties</I>, we classify interest associated
with income taxes under interest expense and tax penalties under other. </P>
<P align=justify><B>Stock Based Compensation </B></P>
<P align=justify>The Company has two stock-based compensation plans in effect
which are described more fully in Note 9. Accounting Standards Codification 718,
<I>Compensation - Stock Compensation </I>(&#147;ASC 718&#148;) requires the recognition of
compensation expense, using a fair-value based method, for costs related to all
share-based awards including stock options and common stock issued to our
employees and directors under our stock plans. It requires companies to estimate
the fair value of share-based awards on the date of grant using an
option-pricing model. The value of the portion of the award that is ultimately
expected to vest is recognized as expense on a straight-line basis over the
requisite service periods in our Consolidated Statements of Operations.</P>
<P align=center>F-12 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_22></A>
<P align=justify>Under the ASC 718, we estimate the fair value of our employee
stock awards at the date of grant using the Black-Scholes option-pricing model,
which requires the use of certain subjective assumptions. The most significant
of these assumptions are our estimates of the expected volatility of the market
price of our stock and the expected term of an award. When establishing an
estimate of the expected term of an award, we consider the vesting period for
the award, our recent historical experience of employee stock option exercises
(including forfeitures) and the expected volatility. When there is uncertainty
in the factors used to determine the expected term of an award, we use the
simplified method. As required under the accounting rules, we review our
valuation assumptions at each grant date and, as a result, our valuation
assumptions used to value employee stock-based awards granted in future periods
may change. The company did not grant stock options during the 2010 year. The
ranges of valuation assumptions used were as follows for 2009 and 2008: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="12%"><B>Year Ended</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="12%"><B>Year Ended</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="12%"><B>December 31,</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="12%"><B>December 31,</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="12%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="12%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Stock Option Plans</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Expected life, in years </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">5.0 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">5.0 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Risk free interest rate </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1.9%- 2.7% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1.9%- 2.9% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Volatility </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">41% - 69% </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">61% - 80% </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Dividend yield </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#151; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#151; </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=justify>Further, ASC 718 requires that employee stock-based
compensation costs to be recognized over the requisite service period, or the
vesting period, in a manner similar to all other forms of compensation paid to
employees. The allocation of employee stock-based compensation costs to each
operating expense line are estimated based on specific employee headcount
information at each grant date and estimated stock option forfeiture rates and
revised, if necessary, in future periods if actual employee headcount
information or forfeitures differ materially from those estimates. As a result,
the amount of employee stock-based compensation costs we recognize in each
operating expense category in future periods may differ significantly from what
we have recorded in the current period.</P>
<P align=justify>Stock-based compensation expense recognized under ASC 718 was
as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="36%"
    colSpan=7><B>December 31,</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2010</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Research and development </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;109,385 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;108,465 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;37,789 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>General and administrative </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">1,792,396 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">1,381,618 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">1,438,360 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;&nbsp;&nbsp;<STRONG>Total stock-based
      compensation</STRONG>&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<STRONG>expense</STRONG>
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><BR><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff><BR><B>1,901,781</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><BR><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff><BR><B>1,490,083</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff><BR><B>$</B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff><BR><B>1,476,149</B> </TD>
    <TD align=left width="2%"
bgColor=#e6efff><BR></TD></TR></TABLE>
<P align=justify>We account for stock options granted to persons other than
employees or directors at fair value using the Black-Scholes option-pricing
model in accordance with Accounting Standards Codification 505-50, <I>Equity
Based Payments to Non-Employees</I> (&#147;ASC 505-50&#148;). Stock options granted to
such persons and stock options that are modified and continue to vest when an
employee has a change in employment status are subject to periodic revaluation
over their vesting terms. We recognize the resulting stock-based compensation
expense during the service period over which the non-employee provides services
to us. The stock-based compensation expense related to non-employees for the
years ended December 31, 2010, 2009 and 2008 was $685,096, zero and $572,424,
respectively.</P>
<P align=justify><B>Property, Plant and Equipment </B></P>
<P align=center>F-13 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_23></A>
<P align=justify>Property, plant and equipment are stated at cost, less
accumulated depreciation. Machinery and equipment, furniture and fixtures, and
autos are depreciated on the straight-line basis over their estimated useful
lives of 5 to 10 years.</P>
<P align=justify><B>Patent Costs</B> </P>
<P align=justify>We amortize intangible assets with definite lives on a
straight-line basis over their estimated useful lives, ranging from 3 to 11
years, and review for impairment on a quarterly basis and when events or changes
in circumstances indicate that the carrying amount of such assets may not be
recoverable.</P>
<P align=justify>As of December 31, 2010, the Company&#146;s capitalized costs
related to certain patents paid by Auxilium on behalf of the Company and are
reimbursable to Auxilium under our agreement. These patent costs are creditable
against future royalty revenues. At December 31, net patent costs consisted of:
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2010</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2009</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Patents, net </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;173,443 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;223,458 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;164,424 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=justify>The amortization expense for patents was $36,041, $33,983 and
$24,856, for the years ended December 31, 2010, 2009 and 2008. The net patent
amortization expense for 2010 was $18,339 due to a reduction of reimbursable
patents fees under our agreement with Auxilium from prior periods. The estimated
aggregate amortization expense for each of the next five years is as
follows:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>2011 </TD>
    <TD align=left width="50%" bgColor=#e6efff>38,000 </TD></TR>
  <TR vAlign=top>
    <TD align=left>2012 </TD>
    <TD align=left width="50%">35,000 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>2013 </TD>
    <TD align=left width="50%" bgColor=#e6efff>33,000 </TD></TR>
  <TR vAlign=top>
    <TD align=left>2014 </TD>
    <TD align=left width="50%">26,000 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>2015 </TD>
    <TD align=left width="50%" bgColor=#e6efff>10,000
</TD></TR></TABLE></DIV>
<P align=justify><B>Income Taxes </B></P>
<P align=justify>In accordance with Accounting Standards Codification
740-10-45-25, <I>Income Statement Classification of Interest and Penalties</I>
(&#147;ASC 740-10-45-25&#148;)<B> </B>we classify interest associated with income taxes
under interest expense and tax penalties under other. </P>
<P align=justify><B>Qualifying Therapeutic Discovery Project Program</B></P>
<P align=justify>In November 2010, we were notified that we had been awarded a
total cash grant of approximately $426,000 under the Qualifying Therapeutic
Discovery Project program administered under section 48D of the Internal Revenue
Code, of which approximately $102,000 relates to qualifying expenses we had
previously incurred during the 2009 fiscal year which was received during the
fourth quarter of fiscal 2010. The remainder of the grant of approximately
$324,000 was received in February 2011 based on qualifying expenses that we
incurred during the 2010 fiscal year. We recognized the full $426,000 of the
grant as of the date of notification since we had already incurred all of the
qualifying expenses. Since this program is non-recurring, we elected to classify
this payment as other income in the Consolidated Statement of Operations for the
year ended December 31, 2010. </P>
<P align=justify><B>Future Impact of Recently Issued Accounting Standards</B>
</P>
<P align=justify>In March 2010, the Financial Accounting Standards Board
(&#147;FASB&#148;) amended its authoritative guidance on the milestone method of revenue
recognition. The milestone method of revenue recognition has now been codified
as an acceptable revenue recognition model when a milestone is deemed to be
substantive. This guidance may be applied retrospectively to all arrangements or
prospectively for milestones achieved after the adoption of the guidance. We
will adopt this amended guidance for the fiscal year beginning January 1, 2011.
We do not anticipate that the adoption of this guidance will have a material
impact on our financial statements. </P>
<P align=justify>In February 2010, the FASB issued update No. 2010-09,<I>
Subsequent Events (Topic 855): Amendments to Certain Recognition and Disclosure Requirements. </I>This update
provides amendments to Subtopic 855-10 for an entity that is an SEC filer and is
required to evaluate subsequent events through the date that the financial
statements are issued. An entity that is an SEC filer is not required to
disclose the date through which subsequent events have been evaluated. The
adoption of this update on February 24, 2010 did not have any impact on the
consolidated financial statements. </P>
<P align=center>F-14 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_24></A>
<P align=justify>In January 2010, the FASB issued update No. 2010-06,<I> Fair
Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair
Value Measurements.</I> This update amends subtopic 820-10 to require 1) a
reporting entity to disclose separately the amounts of significant transfers in
and out of level 1 and 2 fair value measurements and to describe the reasons for
the transfers, and 2) in the reconciliation for fair value measurements using
significant unobservable inputs (level 3), a reporting entity should present
separately information about purchases, sales, issuances, and settlements on a
gross basis rather than as one net number. This update also provides
clarification about existing disclosures about the level of disaggregation and
inputs and valuation techniques. The new disclosures and clarifications of
existing disclosures are effective for interim and annual reporting periods
beginning after December 2009. The adoption of this update did not have a
material impact on the consolidated financial statements. Disclosures about
purchases, sales, issuances, and settlements in the roll forward of activity on
Level 3 fair value measurements is effective for fiscal years beginning after
December 15, 2010 and for interim periods within those fiscal years. </P>
<P align=justify><B>3. FAIR VALUE MEASUREMENTS </B></P>
<P align=justify>The authoritative literature for fair value measurements
established a three-tier fair value hierarchy, which prioritizes the inputs in
measuring fair value. These tiers are as follows: Level 1, defined as observable
inputs such as quoted market prices in active markets; Level 2, defined as
inputs other than the quoted prices in active markets that are either directly
or indirectly observable; and Level 3, defined as significant unobservable
inputs (entity developed assumptions) in which little or no market data exists.
<B></B></P>
<P align=justify>As of December 31, 2010, the Company held certain investments
that are required to be measured at fair value on a recurring basis. The
following tables present the Company&#146;s fair value hierarchy for these financial
assets as of December 31, 2010, 2009 and 2008:<B> </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B><U>December 31, 2010</U></B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%"><B><U>Fair Value</U></B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%"><B><U>Level 1</U></B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%"><B><U>Level 2</U></B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD noWrap align=center width="1%" >&nbsp;</TD>
    <TD noWrap align=center width="10%"><B><U>Level 3</U></B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash and cash equivalents </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;2,470,852 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;2,470,852 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff><B>-</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Certificates of Deposit </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">5,360,970 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">5,360,970 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>-</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%"><B>-</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B><U>December 31, 2009</U></B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash and cash equivalents </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;3,950,389 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;3,950,389 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Certificates of Deposit </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">4,548,541 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">4,548,541 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B><U>December 31, 2008</U></B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash and cash equivalents </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>3,494,150 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>3,494,150 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Certificates of Deposit </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">900,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">900,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=justify><B>4. EARNINGS PER SHARE </B></P>
<P align=justify>Basic earnings per share is computed by dividing net income
(loss) by the weighted-average number of common shares outstanding during the
period. Diluted earnings per share is computed by dividing net income by the
</P>
<P align=center>F-15 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_25></A>
<P align=justify>weighted-average number of common shares outstanding during the
period increased to include all additional common shares that would have been
outstanding assuming potentially dilutive common shares, resulting from option
exercises, had been issued and any proceeds thereof used to repurchase common
stock at the average market price during the period. In periods in which there
is a net loss, potentially dilutive common shares are excluded from the
computation of diluted earnings per share as their effect would be
anti-dilutive.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="10%">2010
    </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="10%">2009
    </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="10%">2008
    </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net income (loss) for diluted computation
    </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff>&nbsp;(1,508,540</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff>&nbsp;(1,956,543</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%"
    bgColor=#e6efff>&nbsp;3,744,408 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Weighted average shares: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Basic </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">6,261,214 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">6,065,939 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">5,854,836 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Effect of dilutive securities: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Stock options </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">982,075 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Diluted </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">6,261,214 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">6,065,939 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">6,836,911 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Net income (loss) Per Share: </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Basic</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;(0.24</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;(0.32</B></TD>
    <TD align=left width="2%"  bgColor=#e6efff><B>)</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="10%" bgColor=#e6efff><B>&nbsp;0.64</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Diluted</B> </TD>
    <TD align=left width="1%" ><B>$</B></TD>
    <TD align=right width="10%"><B>&nbsp;(0.24</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD align=left width="1%" ><B>$</B></TD>
    <TD align=right width="10%"><B>&nbsp;(0.32</B></TD>
    <TD align=left width="2%" ><B>)</B> </TD>
    <TD align=left width="1%" ><B>$</B></TD>
    <TD align=right width="10%"><B>&nbsp;0.55</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=justify>For the years ended December 31, 2010 and 2009, 912,001 and
923,900 of potential common shares were excluded from the diluted loss per share
calculation because their effect was anti-dilutive as a result of the Company&#146;s
net loss.</P>
<P align=justify><B>5</B>. <B>INVENTORIES, NET </B></P>
<P align=justify>None. </P>
<P align=justify><B>6</B>. <B>PROPERTY, PLANT AND EQUIPMENT</B> </P>
<P align=justify>Property, plant and equipment from continuing operations
consist of: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="37%"
     colSpan=8><B>December 31,</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2010</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Machinery and equipment </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;562,610 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;562,610 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;562,610 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Furniture and fixtures </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">91,928 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">91,928 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">91,928 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Leasehold improvements </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>1,185,059 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>1,185,059 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>1,185,059 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,839,597 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,839,597 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,839,597 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Less accumulated depreciation and
      amortization </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>(1,839,597</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>(1,838,987</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>(1,837,300</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">&nbsp;610 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">&nbsp;2,297 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=justify>Total depreciation expense amounted to $610, $1,687 and $30,919
for calendar years 2010, 2009 and 2008, respectively.</P>
<P align=justify><B>7</B>. <B>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES </B></P>
<P align=justify>Accounts payable and accrued liabilities consist of the
following:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="36%"
    colSpan=7><B>December 31,</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2010</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2009</B> </TD>
    <TD noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Trade accounts payable and accrued expenses
    </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;674,917 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;378,872 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;409,433 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD align=left  bgColor=#ffffff>Accrued legal and other professional fees </TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%"  bgColor=#ffffff>77,442</TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%"  bgColor=#ffffff>70,935</TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%"  bgColor=#ffffff>117,837 </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD></TR>
  <TR>
    <TD align=left  bgColor=#e6efff>Accrued payroll and related costs </TD>
    <TD align=left width="1%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1">&nbsp;</TD>
    <TD align=right width="10%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1">140,725</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1">&nbsp;</TD>
    <TD align=right width="10%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1">134,702</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1">&nbsp;</TD>
    <TD align=right width="10%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1">
    115,195 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD align=left  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff style="border-top-style: solid; border-top-width: 1; border-bottom-style: double; border-bottom-width: 3">
    $ </TD>
    <TD align=right width="10%"  bgColor=#ffffff style="border-top-style: solid; border-top-width: 1; border-bottom-style: double; border-bottom-width: 3">&nbsp;893,084</TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff style="border-top-style: solid; border-top-width: 1; border-bottom-style: double; border-bottom-width: 3">
    $</TD>
    <TD align=right width="10%"  bgColor=#ffffff style="border-top-style: solid; border-top-width: 1; border-bottom-style: double; border-bottom-width: 3">
    584,509</TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff style="border-top-style: solid; border-top-width: 1; border-bottom-style: double; border-bottom-width: 3">
    $ </TD>
    <TD align=right width="10%"  bgColor=#ffffff style="border-top-style: solid; border-top-width: 1; border-bottom-style: double; border-bottom-width: 3">642,465 </TD>
    <TD align=left width="2%"
  bgColor=#ffffff>&nbsp;</TD></TR></TABLE>
<P align=center>F-16 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_26></A><BR>
<P align=justify><B>8</B>. <B>INCOME TAXES </B></P>
<P align=justify>The provision for income taxes consist of the following: </P>
<P align=justify><B>Year ended December 31, </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2010</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2009</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><U>Current:</U> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#ffffff>Federal </TD>
    <TD align=left width="1%"  bgColor=#ffffff>$</TD>
    <TD align=right width="10%" bgColor=#ffffff>- </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff>$</TD>
    <TD align=right width="10%" bgColor=#ffffff>&nbsp;(198,239</TD>
    <TD align=left width="2%"  bgColor=#ffffff>) </TD>
    <TD align=left width="1%"  bgColor=#ffffff>$</TD>
    <TD align=right width="10%" bgColor=#ffffff>&nbsp;172,186 </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>State </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>1,351 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>1,784 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>7,400 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#ffffff>&nbsp; </TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#ffffff>1,351 </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#ffffff>(196,455</TD>
    <TD align=left width="2%"  bgColor=#ffffff>) </TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#ffffff>179,586 </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><U>Deferred:</U> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#ffffff>Federal </TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#ffffff>- </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#ffffff>- </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#ffffff>- </TD>
    <TD align=left width="2%"  bgColor=#ffffff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>State </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#ffffff>&nbsp; </TD>
    <TD width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD width="10%" bgColor=#ffffff>&nbsp; </TD>
    <TD width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD width="10%" bgColor=#ffffff>&nbsp; </TD>
    <TD width="2%"  bgColor=#ffffff>&nbsp;</TD>
    <TD width="1%"  bgColor=#ffffff>&nbsp;</TD>
    <TD width="10%" bgColor=#ffffff>&nbsp; </TD>
    <TD width="2%"  bgColor=#ffffff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Total </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;1,351 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(196,455</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;179,586 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=justify>The effective income tax rate of the Company differs from the
federal statutory tax rate of 34% due to the following items:</P>
<P align=justify><B>Year ended December 31, </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2010</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2009</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Computed tax expense at statutory rate </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(34.0%</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(34.0%</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>34.0% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Deferred revenues </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(16.9%</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(17.1%</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(9.0%</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Tax benefit of exercised options and
      warrant </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(6.4%</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Stock-based compensation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">42.8% </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">23.9% </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">12.4% </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Tax benefit of NOL </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(14.7%</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Other </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(9.5%</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(1.8%</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(11.9%</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Increase (decrease) in valuation allowance
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>17.6% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>25.8% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>0.0% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Effective tax rate (benefit) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%">-
</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
    width="10%">(3.2%</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="10%">4.4%
    </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=justify>The effective rate reconciliation includes the permanent
differences and changes in valuation allowance for deferred revenues,
stock-based compensation and net operating loss. </P>
<P align=justify><B>Year ended December 31, </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2010</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2009</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%"><B>2008</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Tax Credit carryforward </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;1,027,633 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;1,039,390 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;1,039,390 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Deferred revenues </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">466,981 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">741,714 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,231,287 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Other </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>54,846 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>37,736 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Options </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="10%">
    <p align="right">&nbsp; 939,643</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">406,517 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">815,686 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net operating loss carryforward </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>1,168,277 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>556,504 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="10%"
    bgColor=#e6efff>128,775 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net deferred tax assets before valuation
      allowance </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>3,602,534 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>2,798,971 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>3,252,874 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Valuation allowance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(3,602,534</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(2,798,971</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="10%">(3,252,874</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Net deferred tax asset </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="10%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=center>F-17 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_27></A><BR>
<P align=justify>In assessing the realizability of deferred tax assets, the
Company considers whether it is more likely than not that some portion or all of
the deferred tax assets will not be realized. The ultimate realization of
deferred tax assets is dependent upon the generation of future taxable income
during the periods in which the temporary differences representing net future
deductible amounts become deductible. Based on the Company's uncertainty of
anticipated future taxable income, the Company is keeping a full valuation
allowance for all its deferred tax assets. The Company&#146;s valuation allowance
increased by $0.8 million primarily due to the recognition of change a in
estimate related to incentive stock options and the net operating loss
carryforward. </P>
<P align=justify>At December 31, 2010, we had federal tax return net operating
loss carry forwards of approximately $2.7 million of which $1.9 million will
expire in 2029 and $0.8 million 2030, if not utilized. In addition, we had state
tax return net operating loss carry forwards of approximately $4.9 million
related to New York State, which will expire in 2027 through 2030 if not
utilized. The recorded deferred tax asset amount of $0.9 million for net
operating losses shown in the above table is net of windfall stock compensation
deductions due to the disqualification of certain stock option that were
exercised and sold in 2009, which when realized, will be recorded directly to
additional paid-in capital in accordance with ASC 718-25-09. </P>
<P align=justify>At December 31, 2010, we had orphan drug tax credits of
approximately $1.0 million that can be carried forward and will generally expire
in 2023 through 2029, if not utilized. </P>
<P align=justify>As of December 31, 2010, the Company believes that there are no
significant uncertain tax positions, and no amounts have been recorded for
interest and penalties. The Company does not anticipate any events that would
require it to record a liability related to any uncertain tax position.</P>
<P align=justify><B>9</B>. <B>STOCKHOLDERS&#146; EQUITY </B></P>
<P align=justify><B>Stock Option Plans </B></P>
<P align=justify>In July 1997, the Company's stockholders approved a stock
option plan (the &#147;1997 Plan&#148;) for eligible key employees, directors, independent
agents, and consultants who make a significant contribution toward the Company's
success and development and to attract and retain qualified employees which
expired in July 2007. Under the 1997 Plan, qualified incentive stock options and
non-qualified stock options may be granted to purchase up to an aggregate of
500,000 shares of the Company's common stock, subject to certain anti-dilution
provisions. The exercise price per share of common stock may not be less than
100% (110% for qualified incentive stock options granted to stockholders owning
at least 10% of common shares) of the fair market value of the Company's common
stock on the date of grant. In general, the options vest and become exercisable
in four equal annual installments following the date of grant, although the
Company&#146;s board of directors, at its discretion, may provide for different
vesting schedules. The options expire ten years (five years for qualified
incentive stock options granted to stockholders owning at least 10% of common
shares) after such date. In accordance with terms of the 1997 Plan, no options
were granted ten years after the effective date of the 1997 Plan, or July 2007.
In July 2007, approximately 231,000 stock options expired unissued, and there
are no shares available for grant remaining under the 1997 Plan. As of December
31, 2010 there were 9,000 options outstanding under the 1997 Plan. </P>
<P align=justify>In August 2001, the Company's stockholders approved a stock
option plan (the &#147;2001 Plan&#148;), with terms similar to the 1997 Plan. The 2001
Plan authorizes the granting of awards of up to an aggregate of 750,000 shares
of the Company's common stock, subject to certain anti-dilution provisions. On
December 16, 2003, stockholders approved an amendment to the 2001 Plan, which increased the
number of shares authorized for grant from 750,000 shares to 1,750,000 shares,
an increase of 1,000,000 shares. On June 17, 2009, our stockholders approved an
amendment to the 2001 Plan to extend the term of the 2001 Plan from April 6,
2011 to April 23, 2019 and to authorize an additional 300,000 shares of our
common stock for issuance under the 2001 Plan. A total of 2,050,000 shares of
common stock are now authorized for issuance under the amended 2001 Plan. The
Company filed a Registration Statement on Form S-8 for the 2001 Plan with the
Commission on October 5, 2007 and on July 15, 2009 as amended to register these
securities. As of December 31, 2010 options to purchase 1,337,425 shares of
common stock were outstanding under the 1997 Plan and 2001 Plan, and a total of
269,098 shares available for grant remaining under the 2001 Plan. </P>
<P align=center>F-18 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_28></A>
<P align=justify>The summary of the stock options activity is as follows for
year ended: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>Weighted </B></TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>Average </B></TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>Exercise </B></TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%"><B>Shares </B></TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%"><B>Price </B></TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Outstanding at December 31, 2009 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,464,850 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;7.64 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      colSpan=6><B>2010</B>&nbsp;&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Options granted </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Options exercised </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(118,425</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">5.69 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Options canceled or expired </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>-- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>-- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Outstanding at end of year </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,346,425 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">7.81 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Options exercisable at year end </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,223,925 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>6.62 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Shares available for future grant </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">269,098 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">-- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=justify>The Company did not grant any stock options during 2010. </P>
<P align=justify>The following table summarizes information relating to stock
options by exercise price at December 31, 2010: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD vAlign=bottom align=left><B><U>Option <B>Exercise </B>Price</U></B><B>
      </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="7%"><B>Outstanding </B><B>Shares </B></TD>
    <TD vAlign=bottom align=center width="2%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="7%"><B>Weighted </B><B>Average Life </B><B>(years) </B></TD>
    <TD vAlign=bottom align=center width="2%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="7%"><B>Weighted </B><B>Average </B><B>Exercise </B><B>Price </B></TD>
    <TD vAlign=bottom align=center width="2%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="7%"><B>Exercisable </B><B>Shares </B></TD>
    <TD vAlign=bottom align=center width="2%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=center
    width="7%"><B>Weighted </B><B>Average </B><B>Option </B><B>Price </B></TD>
    <TD vAlign=bottom align=left width="2%" ></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>$0.83-2.00 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>661,925 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>4.45 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>1.00 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>661,925 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>1.00 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>4.00-6.00 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">257,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">6.42 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">4.69 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">249,500 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">4.65 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>13.00-14.00 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>125,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>7.38 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>13.51 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>110,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>13.55 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>17.00-18.99 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">70,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">7.93 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">17.69 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">40,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">17.30 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>19.00-21.00 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>112,500 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>7.75 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>20.57 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>62,500 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>20.23 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>26.00-28.00 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">45,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">8.69 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">26.43 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">45,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">26.43 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>29.00-31.00 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>75,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>8.88 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>29.53 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>55,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>29.64 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">1,346,425 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="7%">5.94
    </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="7%">7.81
    </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">1,223,925 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="7%">6.62
    </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE></DIV>
<P align=justify>We did not grant any stock options during 2010. The
weighted-average grant-date fair value for options granted during 2009 was
$24.43 per share and $16.00 per share in 2008. During the 2010, 2009 and 2008,
$673,375, $380,029 and $255,388 were received from stock options exercised by
employees, respectively. The aggregate intrinsic value of options outstanding
and exercisable as of December 31, 2010 was approximately $23.2 million.
Aggregate intrinsic value represents the total pre-tax intrinsic value, based on
the closing price of our common stock of $25.60 on December 31, 2010, which
would have been received by the option holders had all option holders exercised
their options as of that date. Total unrecognized compensation cost related to
non-vested stock options outstanding as of December 31, 2009 was approximately
$0.7 million which we expect to recognize over a weighted-average period of 1.3
years.</P>
<P align=justify><B>10. COMMITMENTS AND CONTINGENCIES </B></P>
<P align=center>F-19 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_29></A>
<P align=justify><B>Lease Agreements </B></P>
<P align=justify>Our corporate headquarters are currently located at 35 Wilbur
St., Lynbrook, NY 11563. As previously reported, our previous lease for our
headquarters terminated on June 30, 2010. Since June 30, 2010, we have been
leasing the space from Wilbur St. Corp. on a month-to-month basis. On February
28, 2011, we notified Wilbur St. Corp. of our termination of the lease effective
March 31, 2011. We intend to negotiate a new lease for our current space or seek
alternative space in the surrounding area. </P>
<P align=justify>The Company's operations are principally conducted on leased
premises. Future minimum annual rental payments required under non-cancelable
operating leases are zero. </P>
<P align=justify>Rent expense under all operating leases amounted to
approximately $136,500, $136,250 and $150,000 for calendar year 2010, 2009 and
2008.<B> </B></P>
<P align=justify><B>11</B>. <B>RELATED PARTY TRANSACTIONS </B></P>
<P align=justify>On February 1, 2008, the Estate of Edwin H. Wegman (the
&#147;Estate&#148;) sold an aggregate of 344,114 shares of the Company's common stock, par
value $0.001, at a purchase price of $12.00 per share to certain private
investors. The Estate used certain of the proceeds of the transaction to repay
the loan owed to the Company by Edwin H. Wegman, our former Chairman and CEO.
The total loan repayment amount was $1,116,558, which represents the principal
amount of $625,774 owed to the Company and accrued interest through January 31,
2008 of $490,784.</P>
<P align=justify>As previously reported, ABC-NY (together with the Company, the
&#147;Tenant&#148;) and Wilbur St. Corp. (the &#147;Landlord&#148;) were parties to a lease
agreement initially dated as of January 30, 1998 and modified as of June 24,
2009 (the &#147;Lease Agreement&#148;), pursuant to which the Landlord leased to the
Tenant the premises located at 35 Wilbur Street, Lynbrook, NY 11563 (the
&#147;Premises&#148;) until June 30, 2010 and for an annual rental price of $135,000.
Following the expiration of the Lease Agreement, the Tenant has continued to
lease the Premises from the Landlord on a month-to-month basis. As described
above in Note 10, we have notified the Landlord of our termination of the Lease
Agreement effective March 31, 2011. </P>
<P align=justify><B>12</B>. <B>EMPLOYEE BENEFIT PLANS</B> </P>
<P align=justify>ABC-NY has a 401(k) Profit Sharing Plan for employees who meet
minimum age and service requirements. Contributions to the plan by ABC-NY are
discretionary and subject to certain vesting provisions. The Company made no
contributions to this plan for calendar years 2010, 2009 or 2008.</P>
<P align=justify><B>13. SUBSEQUENT EVENTS </B></P>
<P align=justify>On February 28, 2011, Auxilium and Pfizer announced that the
European Commission granted XIAPEX marketing authorization for the treatment of
Dupuytren&#146;s contracture in adult patients with a palpable cord. Auxilium and
Pfizer also announced that XIAPEX &#147;is expected to be available for use in some
European markets later this year&#148;. </P>
<P align=justify>In January 2011, we announced promising results from our study
Chien-802, showing dramatic reductions in canine lipoma following injections
with purified injectable collagenase. These results build upon an earlier dose
escalation study from which we selected the dose for Chien-802.</P>
<P align=justify>In January 2011, we also announced the initiation of a larger
clinical trial, Chien-803, for the same indication. We have voluntarily agreed
to suspend this trial and will not be initiating any new trials using injectable
collagenase in animals or humans pending a resolution of our dispute with
Auxilium concerning our right to conduct clinical trials without the prior
approval of the companies&#146; Joint Development Committee. On February 15, 2011,
Auxilium filed a complaint against us in the Court of Common Pleas in Chester
County, Pennsylvania. The complaint seeks declaratory and injunctive relief, but
not monetary damages. The dispute has been sealed pending further order of the
court. The outcome of the dispute will have no effect on the amounts due to us
from Auxilium for exercised indications (Dupuytren&#146;s contracture, Peyronie&#146;s
disease and Frozen Shoulder). However, if the court rules in a manner that is
detrimental to our interests or interprets our agreement with Auxilium in a way that limits the scope of our rights under that agreement,
we may be precluded from pursuing additional indications and, if Auxilium does
not pursue such additional indications, we may also be precluded from the
opportunity to receive from Auxilium license fees for the rights to, as well as
potential milestone, royalty and other payments with respect to, such additional
indications.</P>
<P align=center>F-20 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_30></A>
<P align=justify><B>14. SELECTED QUARTERLY DATA (Unaudited) </B></P>
<P align=justify>The following table sets forth certain unaudited quarterly data
for each of the four quarters in the years ended December 31, 2010 and 2009. The
data has been derived from the Company's unaudited consolidated financial
statements that, in management's opinion, include all adjustments (consisting of
normal recurring adjustments) necessary for a fair presentation of such
information when read in conjunction with the Consolidated Financial Statements
and Notes thereto. The results of operations for any quarter are not necessarily
indicative of the results of operations for any future period.<B> </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">First </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">Second </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">Third </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">Fourth </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Year ended December 31, 2010 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net revenues </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;2,659,032 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;854,807 </TD>
    <TD align=right width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$ </TD>
    <TD align=right width="10%" >1,004,097 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">1,143,413 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Operating profit (loss) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(271,963</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(936,157</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(501,784</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(323,128</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net income (loss) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(254,180</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(910,232</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(484,297</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">140,169 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Basic earnings per share (1)
    </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(0.04</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(0.15</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(0.08</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;0.02 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Diluted earnings per share (1) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;(0.04</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;(0.15</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;(0.08</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;0.02 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">First </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">Second </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">Third </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="10%">Fourth </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="10%">Quarter </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Year ended December 31, 2009 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="10%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net sales </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;343,473 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;1,221,595 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;836,568 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="10%">&nbsp;754,122 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Operating profit (loss) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(939,370</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(43,082</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(453,237</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="10%" bgColor=#e6efff>(729,219</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net income (loss) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(945,977</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(87,809</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(382,121</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(540,637</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Basic earnings per share (1)
    </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(0.16</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(0.01</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(0.06</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="10%" bgColor=#e6efff>&nbsp;(0.09</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Diluted earnings per share (1) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(0.16</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(0.01</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(0.06</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="10%">(0.09</TD>
    <TD align=left width="2%" >) </TD></TR></TABLE>
<P align=justify>(1) Quarterly income (loss) per share may not equal the annual
reported amounts due to rounding </P>
<P align=center>F-21 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_31></A>
<P align=center><B>EXHIBIT INDEX </B></P>
<P align=justify>The documents listed below are being filed or have previously
been filed on behalf of the Company and are incorporated herein by reference
from the documents indicated and made a part hereof. Exhibits not identified as
previously filed are filed herewith: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B><I>Exhibit</I></B> </TD>
    <TD align=left width="90%"></TD></TR>
  <TR vAlign=top>
    <TD align=left><U><B><I>Number</I></B> </U></TD>
    <TD align=left width="90%"><U><STRONG><EM>Description</EM></STRONG>
  </U></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>3.1 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Registrant&#146;s Certificate of Incorporation, as amended
      (incorporated by reference to Exhibit 3.1 of the Registrant&#146;s Form 10-KSB
      filed with the Commission on March 2, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.2 </TD>
    <TD align=left width="90%">
      <P align=justify>Registrant&#146;s Amended and Restated By-laws (incorporated
      by reference to Exhibit 3.2 of the Registrant&#146;s Form 10-KSB filed with the
      Commission on March 2, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.1 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Lease Modification Agreement dated June 22, 2009 between
      ABC-NY, the Company and Wilbur St. Corp. (incorporated by reference to
      Exhibit 10.1 of the Registrant&#146;s Form 8-K filed with the Commission on
      June 29, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.2 </TD>
    <TD align=left width="90%">
      <P align=justify>Copy of Extension and Modification Agreement, dated July
      1, 2005, between the Company and the Wilbur Street Corporation
      (incorporated by reference to Exhibit 10.5 of the Registrant&#146;s Form 10-KSB
      filed with the Commission on March 2, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.3 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Asset Purchase Agreement between the Company, ABC-NY and
      DFB dated March 3, 2006 (incorporated by reference to Exhibit 2.1 of the
      Registrant&#146;s Form 8-K filed with the Commission on March 9, 2006)
  </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.4 </TD>
    <TD align=left width="90%">
      <P align=justify>Amendment to Asset Purchase Agreement between the
      Company, ABC-NY and DFB dated January 8, 2007 (incorporated by reference
      to Exhibit 10.1 of the Registrant&#146;s Form 8-K filed with the Commission on
      January 12, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.5 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Dupuytren&#146;s License Agreement dated November 21, 2006
      between the Company and the Research Foundation (incorporated by reference
      to Exhibit 10.1 of the Registrant&#146;s Form 8-K filed with the Commission on
      November 28, 2006) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.6 </TD>
    <TD align=left width="90%">
      <P align=justify>Frozen Shoulder License Agreement dated November 21, 2006
      between the Company and the Research Foundation (incorporated by reference
      to Exhibit 10.2 of the Registrant&#146;s Form 8-K filed with the Commission on
      November 28, 2006) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.7 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Form of 1997 Stock Option Plan of Registrant
      (incorporated by reference as Exhibit 4.1 of the Registrant&#146;s Form S-8
      filed with the Commission on September 26, 1997) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.8 </TD>
    <TD align=left width="90%">
      <P align=justify>Amended and Restated 2001 Stock Option Plan of Registrant
      (incorporated by reference to Appendix D of the Registrant&#146;s Schedule14A
      filed with the Commission on April 30, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.9 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Rights Agreement dated as of May 14, 2002 (incorporated
      by reference as Exhibit 1 to the Registrant&#146;s Form 8-A filed with the
      Commission on May 30, 2002) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.10 </TD>
    <TD align=left width="90%">
      <P align=justify>Amendment No. 1 to Rights Agreement, dated June 19, 2003
      (incorporated by reference to Exhibit 10.19 of the Registrant&#146;s Form
      10-KSB filed with the Commission on March 2, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.11 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Amendment No. 2 to Rights Agreement, dated as of February
      3, 2011 (incorporated by reference to Exhibit 4.1 to the Registrant&#146;s
      Current Report on Form 8-K filed with the Securities and Exchange
      Commission on February 4, 2011). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.12 </TD>
    <TD align=left width="90%">
      <P align=justify>Change of Control Agreement, dated June 18, 2007 between
      the Company and Henry Morgan (incorporated by reference to Exhibit 10.21
      of the Registrant&#146;s Form 10-KSB filed with the Commission on September 26,
      2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.13 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Change of Control Agreement, dated June 18, 2007 between
      the Company and Michael Schamroth (incorporated by reference to Exhibit
      10.22 of the Registrant&#146;s Form 10-KSB filed with the Commission on
      September 26, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.14 </TD>
    <TD align=left width="90%">
      <P align=justify>Change of Control Agreement, dated June 18, 2007 between
      the Company and Dr. Paul Gitman (incorporated by reference to Exhibit
      10.23 of the Registrant&#146;s Form 10-KSB filed with the Commission on
      September 26, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.15 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
      <P align=justify>Agreement dated August 27, 2008 (incorporated by
      reference to Exhibit 10.1 of the Registrant&#146;s Form 8-K filed with the Commission
      on September 5, 2008) </P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_32></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.16 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>Amended and Restated
      Development and License Agreement dated December 11, 2008 and effective
      December 17, 2008 between the Company and Auxilium Pharmaceuticals, Inc.
      (incorporated by reference to Exhibit 10.1 of the Registrant&#146;s Form 8-K
      filed with the Commission on December 19, 2008) </TD></TR>
  <TR vAlign=top>
    <TD align=left>10.17 </TD>
    <TD align=left width="90%">Executive Employment Agreement, dated August 5,
      2008 between the Company and Thomas L. Wegman (incorporated by reference
      to Exhibit 10.1 of the Registrant&#146;s Form 8-K filed with the Commission on
      August 8, 2008) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>10.18 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>Change of Control Agreement,
      dated October 1, 2008 between the Company and Dr. Matthew Geller </TD></TR>
  <TR vAlign=top>
    <TD align=left>14 </TD>
    <TD align=left width="90%">Amended and Restated Code of Business Conduct
      and Ethics (incorporated by reference to Exhibit 14.1 of the Registrant&#146;s
      Form 10-KSB filed with the Commission on March 2, 2007) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>21 </TD>
    <TD align=left width="90%" bgColor=#eeeeee>Subsidiaries of the Registrant
      (incorporated by reference to Exhibit 21.1 of the Registrant&#146;s Form 10-KSB
      filed with the Commission on March 2, 2007) </TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="exhibit23.htm">23* </a> </TD>
    <TD align=left width="90%"><a href="exhibit23.htm">Consent of Tabriztchi &amp; Co. CPA, P.C.*
    </a>
  </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit31.htm">31* </a> </TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit31.htm">Certification of Principal
      Executive Officer and Principal Financial Officer pursuant to Section 302
      of the Sarbanes-Oxley Act of 2002* </a> </TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="exhibit32.htm">32* </a> </TD>
    <TD align=left width="90%"><a href="exhibit32.htm">Certification of Principal Executive Officer
      and Principal Financial Officer pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002* </a> </TD></TR></TABLE>
<P align=justify>* filed herewith </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_33></A>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>In accordance with section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant caused this Report on Form 10-K to be
signed on its behalf by the undersigned, thereto duly authorized individual.</P>
<P align=justify>Date: March 14, 2011 </P>
<DIV align=right>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left colSpan=2><B>BIOSPECIFICS TECHNOLOGIES CORP.</B> </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="90%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >By: </TD>
    <TD align=left width="90%"><U>/s/ Thomas L. Wegman&nbsp;&nbsp;&nbsp;&nbsp;
      </U>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >Name: </TD>
    <TD align=left width="90%">Thomas L. Wegman </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left >Title: </TD>
    <TD align=left width="90%">President </TD></TR></TABLE></DIV>
<P align=justify>In accordance with the Securities Exchange Act of 1934, this
Report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B>SIGNATURE</B> </TD>
    <TD align=center width="50%"><B>TITLE</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>/s/ Thomas L. Wegman</U> </TD>
    <TD align=left width="50%">President, Director, and Principal Executive,
      Financial </TD></TR>
  <TR vAlign=top>
    <TD align=left>Name: Thomas L. Wegman </TD>
    <TD align=left width="50%">and Accounting Officer </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 14, 2011 </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>/s/ Dr. Matthew Geller</U> </TD>
    <TD align=left width="50%">Director </TD></TR>
  <TR vAlign=top>
    <TD align=left>Name: Dr. Matthew Geller </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 14, 2011 </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>/s/ Dr. Paul Gitman</U> </TD>
    <TD align=left width="50%">Director </TD></TR>
  <TR vAlign=top>
    <TD align=left>Name: Dr. Paul Gitman </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 14, 2011 </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>/s/ Henry G. Morgan</U> </TD>
    <TD align=left width="50%">Director </TD></TR>
  <TR vAlign=top>
    <TD align=left>Name: Henry G. Morgan </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 14, 2011 </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>/s/ Michael Schamroth</U> </TD>
    <TD align=left width="50%">Director </TD></TR>
  <TR vAlign=top>
    <TD align=left>Name: Michael Schamroth </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 14, 2011 </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>/s/ Dr. Mark Wegman</U> </TD>
    <TD align=left width="50%">Director </TD></TR>
  <TR vAlign=top>
    <TD align=left>Name: Dr. Mark Wegman </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 14, 2011 </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>/s/ Toby Wegman</U> </TD>
    <TD align=left width="50%">Director </TD></TR>
  <TR vAlign=top>
    <TD align=left>Name: Toby Wegman </TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 14, 2011 </TD>
    <TD align=left width="50%">&nbsp; </TD></TR></TABLE><HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
